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Reducing the Burden of Bacterial Meningitis in the
African Meningitis Belt After MenAfriVac
Laura V. Cooper
The African meningitis belt - a semi-arid region stretching from Senegal to Ethiopia -
experiences the highest incidence of bacterial meningitis in the world, characterised by seasonal
fluctuations in endemic disease, localized outbreaks, and multiennial epidemics. MenAfriVac, a
serogroup A meningococcal conjugate vaccine, was introduced in mass campaigns in 2010 and
has significantly reduced carriage and incidence of group A disease across the meningitis belt.
However, other meningococcal serogroups and Streptococcus pneumoniae continue to cause
outbreaks of meningitis in the region. A new pentavalent meningococcal conjugate vaccine
protecting against serogroups A, C, W, Y, and X is in development and promises to help
eliminate outbreaks of meningococcal meningitis by 2030. However, questions remain as to how
best to respond to outbreaks of pneumococcal meningitis and non-A meningococcal meningitis
and how to use the pentavalent meningococcal conjugate vaccine when it becomes available.
This thesis aims to evaluate the remaining challenges to control of bacterial meningitis in the
African meningitis belt and assess the relative effectiveness and efficiency of various responses.
The first research chapter describes patterns in bacterial meningitis incidence before and
after the introduction of MenAfriVac and compares outbreaks where NmA, NmC, NmW,
and S. pneumoniae are predominant. The second chapter describes in detail an outbreak of
pneumococcal meningitis in Ghana and models the potential impact of reactive vaccination
using pneumococcal conjugate vaccine. In the third chapter I present a systematic review and
meta-analysis of meningococcal carriage patterns by age and season in the African meningitis
belt and propose ways in which it might inform the use of the pentavalent meningococcal
conjugate vaccine. In the fourth chapter, I analyse the results of a longitudinal household study
to identify behavioural and environmental risk factors for meningococcal carriage acquisition.
The final chapter examines the spatio-temporal spread of the novel NmC strain which emerged
in Nigeria in 2013, estimates the impact of reactive vaccination campaigns that occurred in the
region between 2015 and 2017, and models the effects of alternative outbreak response strategies,
including targeting neighbouring districts.
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Chapter 1
Aims and rationale
The African meningitis belt is a semi-arid region of sub-Saharan Africa stretching from
Senegal in the west to Ethiopia in east and falling between 4 and 16 degrees north latitude,
characterized by high incidence and recurrent epidemics of bacterial meningitis.1 For decades,
group A Neisseria meningitidis (or meningococci) were the predominant cause of meningitis in
the African meningitis belt. The introduction of a group A meningococcal conjugate vaccine,
MenAfriVac, in mass vaccination campaigns in countries across the meningitis belt has almost
eliminated the burden of group A meningococcal meningitis and reduced all-cause meningitis by
57%.2 Many countries are planning to introduce or have already introduced the vaccine into
their routine infant vaccination programs. With adequate coverage, routine infant vaccination
can ensure long-term reductions in group A meningococcal meningitis incidence.3 However, the
years following the introduction of MenAfriVac have seen significant increases in the incidence
of non-group-A meningococcal meningitis.2 Of particular note are the re-emergence of group C,
which caused the largest group C epidemic ever observed in 2017, and the persistence of groups
W and X. Outbreaks of meningitis caused by Streptococcus pneumoniae (or pneumococci) are
also of concern.
A thermostable pentavalent vaccine protecting against meningococcal serogroups A, C, W,
Y, and X is currently in development by the Serum Institute of India, which hopes to submit
the vaccine to the World Health Organization (WHO) for pre-qualification by 2023.4 Gavi,
the Vaccine Alliance has approved, in principle, some degree of financial support for this new
vaccine. If delivered widely enough, this multivalent vaccine has the potential to nearly eliminate
epidemics of meningococcal meningitis. A variety of scenarios including restricting use of the
pentavalent vaccine to higher-risk countries and introducing the pentavalent only in routine
infant immunisation are being considered to limit the extent of Gavi’s investment.
In 2017, experts from governments, global health organisations, academia, and the private
sector gathered to draft a global roadmap to defeat meningitis by 2030.5 The resulting plan
focused on the four organisms responsible for most bacterial meningitis - Neisseria meningitidis,
Streptococcus pneumoniae, Haemophilus influenzae type b, and Streptococcus agalacticae - with
three broad aims to be achieved by 2030: eliminate meningitis epidemics, substantially reduce
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overall cases and deaths from vaccine-preventable meningitis, and provide high quality care for
survivors with sequelae.6 In the African meningitis belt in particular, achieving this goal requires
the use of distinct short- and long-term strategies. Meningococcal meningitis outbreaks will
continue to occur at least until the pentavalent meningococcal conjugate vaccine (NmCV-5) is
available for use, and possibly for longer if widespread use is unaffordable. Use of H. influenzae
b (Hib) conjugate vaccine in infants has reduced Hib meningitis dramatically7,8 and in European
countries with high (≥ 90%) infant coverage, pneumococcal conjugate vaccine (PCV) has had
significant direct and indirect effects on invasive pneumococcal disease in as little as five years.9
The introduction of group C meningococcal conjugate vaccine in Spain, the United Kingdom, and
Canada demonstrated significant indirect effects within just one year, but all of these countries
used catch-up campaigns for older children in addition to routine infant immunisation.10–12 It is
likely that routine infant PCV and NmCV-5 will eventually have the same effects in the African
meningitis belt - but how long it will take to establish herd immunity for these bacteria remains
unclear. Epidemiological research can inform choices about short-term responses to meningitis
outbreaks and long-term strategies for establishing and maintaining protection.
This thesis addresses both short- and long-term issues. In the short-term, the focus is
on responding to outbreaks of meningococcal and pneumococcal meningitis, including testing
alternative warning systems, use of conjugate vaccines in reactive responses, and informing
stockpile management. The long-term aims contribute to the use of and understanding the impact
of MenAfriVac and NmCV-5. These issues are addressed over five research chapters. Chapter 3
describes patterns in bacterial meningitis before and after the introduction of MenAfriVac
and compares outbreaks in which NmA, NmC, NmW, and S. pneumoniae are predominant.
Chapter 4 describes an outbreak of pneumococcal meningitis in Ghana and models the impact
of reactive vaccination using a pneumococcal conjugate vaccine. In Chapter 5 I present a
systematic review and meta-analysis of meningococcal carriage patterns by age and season in
the African meningitis belt and propose ways in which it might inform the use of the pentavalent
meningococcal conjugate vaccine. In Chapter 6, I analyse the results of a longitudinal household
study of meningococcal carriage acquisition and identify behavioural and environmental risk
factors for acquisition. Chapter 7 examines the spatio-temporal spread of the novel NmC strain
which emerged in Nigeria in 2013, estimates the impact of reactive vaccination campaigns
that occurred in the region between 2015 and 2017, and compares new strategies for outbreak
response. In Chapter 8 I review my findings and discuss how this research can be used to inform
bacterial meningitis control in the African meningitis belt.
Chapter 2
Introduction
2.1 Human and microbe
Meningitis refers to the inflammation of the meninges, the membranes surrounding the
brain and central nervous system. One of the most serious causes of this inflammation is
bacterial infection. Two of the most common causes of bacterial meningitis today are Neisseria
meningitidis and Streptococcus pneumoniae, with Haemophilus influenzae type b making up
a sizeable burden in the pre-vaccine era.7 All three of these species are human commensals
that primarily inhabit the nasopharynx and are transmitted between hosts via respiratory
secretions. An individual may host the bacteria in his or her nasopharynx transiently or over
sustained periods, a phenomenon known as carriage. The duration of carriage varies from
days to months, and depends on the characteristics of the colonising strain, the host’s mucosal
immune environment, and the presence of other bacteria in the nasopharynx. The limited data
available on meningococcal carriage in Africa indicate an average duration of carriage for group
A meningococci of about one month and other meningococci about three months.13–16 A more
comprehensive study of pneumococcal carriage in children in Kenya estimates average durations
ranging from 28 to 124 days, varying by serotype.17 There is considerable diversity in carriage
duration across settings and individuals, and in reality carriage may be chronic, intermittent, or
transient.15,18
S. pneumoniae belongs to the phylum Firmicutes and is Gram-positive. H. influenzae and
N. meningitidis belong to the phylum Proteobacteria and are Gram-negative. In the absence
of resistance, penicillin, ampicillin, and chloramphenicol are effective antibiotic treatments for
meningitis caused by S. pneumoniae, H. influenzae and N. meningitidis. A systematic review
of studies of antibacterial resistance in West Africa found low levels (< 20%) of penicillin and
chloramphenicol resistance in S. pneumoniae, H. influenzae and N. meningitidis isolates.19
Because the bacteria are susceptible to drying and cannot survive for long periods outside of
the nasopharynx, transmission between hosts requires close contact for the exchange of saliva or
upper respiratory secretions. Many meningococci and pneumococci are encased in protective
outer capsules that help to slow drying and aid in transmission. Meningococci are classified
20 Introduction
into serogroups depending on the biochemical makeup of the polysaccharides embedded in these
capsules. There are twelve serogroups, but only six regularly cause invasive disease: A, B, C, W,
Y, and X. Pneumococci are similarly classified into serotypes, of which there are more than 90,
and H. influenzae are classified into six serotypes, with type b most commonly causing disease.
The capsule is the main virulence factor and the most immunogenic part of these bacteria, and
may be lost permanently or temporarily by deletion or down-regulation of the capsule locus
- thus helping to evade the host’s immune system. Meningococci which have lost the capsule
locus entirely are referred to as capsule-null and very rarely cause invasive disease.
Although they are primarily commensals, these species of bacteria may also be characterised
as accidental or opportunistic pathogens. In rare cases, the bacteria may penetrate the mucosal
lining of the nasopharynx and pass into the cerebrospinal fluid (CSF), resulting in meningitis, or
into the blood, resulting in sepsis. When invasive disease does occur, it is thought to occur soon
after acquisition.20 S. pneumoniae and H. influenzae are also important causes of pneumonia.
Instances of invasion of normally sterile sites of the body, called invasive disease, do not aid in
the transmission of bacteria between hosts and as such are not thought to be evolutionarily
beneficial. Nonetheless, strains may acquire virulence traits through mutation or horizontal
transfer and relatively hypervirulent strains have been shown to persist and cause outbreaks for
years.21,22
2.2 Epidemiology
Meningococcal carriage prevalence in the African meningitis belt is highly variable, with
observations ranging from 0 to 35%.23 The age distribution of meningococcal carriers in high-
income countries peaks around 19 years of age.24 Chapter 5 describes in detail patterns of
meningococcal carriage by age in the meningitis belt. Pneumococcal carriage is most prevalent
in children under five, and common across all age groups, with 63% of under five year olds and
28% of over fifteen year olds in sub-Saharan Africa estimated to be carriers.25 The duration
of carriage for both meningococci and pneumococci appears to decrease with age.14,17 For S.
pneumoniae, this has been shown to be linked to the development of both serotype-specific and
serotype-independent natural immunity.26,27
Meningococcal disease incidence and serogroup distribution vary widely from region to
region.28,29 The African meningitis belt has the highest incidence of bacterial meningitis of
any region and is the only place where irregular and recurrent epidemics of meningococcal
disease are still observed.1,30,31 Meningitis in this region is highly seasonal, with the majority of
cases occurring during the dry season, predominantly in the first five months of the year.32–34
Epidemics tend to start in the middle of the dry season, which lasts from October to April,
and end with the onset of the rainy season, which usually starts in May.35,36 One proposed
explanation for this striking seasonality is an increased risk of invasive disease in the dry
season, due to mucosal damage from environmental factors such as low absolute humidity and
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dust.31,37,38 This risk is sometimes measured as the ratio of meningitis cases to carriers in the
same population. An alternative hypothesis suggested by mathematical modelling is that higher
rates of carriage transmission during the dry season contribute to regular seasonality, and
combine with longer-term fluctuations in population immunity to produce irregular interannual
epidemics.39 Although a review of carriage in the meningitis belt published in 2007 found no
evidence to support a seasonal effect on carriage,23 more recent studies have found a higher
prevalence of carriage in the dry season.40,41 I will return to this question in Chapter 5.
Meningococcal meningitis, which is the most epidemic-prone of the three major causes, is also
characterised by unique long-term trends.42 Mueller and Gessner propose an explanatory model
for meningitis with three distinct dry-season patterns: hyperendemicity, localised epidemics,
and epidemic waves.43 During the rainy season, a weekly incidence of less than 1 case per 100
000 persons is usual - a rate comparable to that observed in most other regions globally.43 In
the hyperendemic pattern, incidence increases by a factor of about 10 to 100, driven, according
to Mueller and Gessner, by an increase in invasiveness caused by the dusty, dry weather. This
occurs in most districts during the dry season. In some communities, incidence may be further
increased 10- to 100-fold – an increase the authors attribute to an increase in carriage prevalence.
Localised epidemics may form a wave affecting multiple regions, with incidence 3- to 10-fold
higher than during seasons with only localised epidemics.43 These epidemic waves occur with
irregular periodicity, resulting in peaks at the national level every 7 to 12 years.44 These epidemic
waves may last for multiple years, but incidence always returns to endemic levels during the
intervening rainy seasons.43
It seems likely that the meningococcus was brought to Africa by European colonisers, with
the earliest documented outbreak among soldiers in Algiers in 1840. From here, it may have
spread via the Egyptian army to Sudan, and from Sudan to West and Central Africa via the
Hajj.31 The first proven meningococcal outbreak in the general population, confirmed by the
observation of diplococci in the CSF of cases, occurred in northern Nigeria in 1905 and caused
thousands of deaths.31 Since at least the 1940s and up until the introduction of a conjugate
polysaccharide vaccine in 2010, serogroup A has been the predominant cause of bacterial
meningitis in the African meningitis belt, causing major epidemics most recently in 1996-1997
and 2009.28 Meningococcal serogroups C, W, and X have also demonstrated their potential
for causing epidemics. In the 1970s and 1980s there were reports of epidemic serogroup C
meningococcal disease in Guinea, Nigeria, and Burkina Faso.45 Sporadic cases of serogroup
W and X occurred in the 1990s in Niger, Mali, the Gambia, Cameroon, and Chad.28 A large
outbreak of serogroup X followed an epidemic and subsequent decline of serogroup A disease in
northern Ghana in 2000, and another occurred in 2006 in Niger.28,46 A serogroup W epidemic
occurred in Burkina Faso in 2002 and 2003, and in 2012.28 Epidemics of group Y or B have not
been observed in the African meningitis belt, although sporadic cases do occur.30 A novel strain
of serogroup C caused an outbreak in Northern Nigeria in 2013, the first since 1979.47 This
strain continues to circulate, and has caused outbreaks in Nigeria, Niger, Burkina Faso, and
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Mali as of 2019. S. pneumoniae has not caused documented widespread epidemics of meningitis,
but accounts for about one fourth of confirmed cases of bacterial meningitis reported to the
World Health Organization (WHO) meningitis belt surveillance system since 2003.34
Since the 1980s, the reference method for categorising strains of N. meningitidis was
multilocus enzyme electrophoresis, which identifies clusters of closely related strains by indirectly
assigning alleles based on their electrophoretic mobility. The application of multilocus enzyme
electrophoresis (MLEE) revealed greater genetic diversity in N. meningitis than other bacterial
species.48 It also revealed that successive epidemics waves of serogroup A meningitis in the
African meningitis belt between 1960 and 2000 were caused by three distinct clonal complexes,
named subgroups I, IV-1, and III.49 In the late 1990s a new method for classifying meningococcal
strains was developed called multi-locus sequence typing, which grouped strains based on the
alleles identified by sequencing seven important housekeeping genes.50 Application of this method
to a set of 357 isolates from patients with invasive disease from countries in the meningitis belt
between 1988 and 2003 identified three sequence types (STs) that caused the majority (92%) of
outbreaks and endemic disease: serogroup A ST-5 and the closely related ST-7 and serogroup
W ST-11.51 Serogroup A ST-5 was previously identified by MLEE as subgroup III; subgroups I
and IV-1 (now ST-1 and ST4, respectively) are rarely identified since 1988.51 More recently,
researchers have identified a novel serogroup A sequence type, ST-2859, which is closely related
to ST-5 and ST-7 and caused the 2006 epidemic in Burkina Faso.49 By 2010, ST-7 and ST-2859
appeared to have completely replaced ST-5.52,53 In 2014, Funk and colleagues identified a novel
sequence type 10217 associated with the NmC outbreaks in Northern Nigeria.47 Brynildsrud
and colleagues hypothesise that a related unencapsulated strain horizontally acquired a group
C capsule and other virulence genes at some time between 2007 and 2011, becoming invasive
and causing the NmC outbreaks beginning in 2013.54 The authors identify a strain isolated
from a carrier in Burkina Faso in 2012 as the closest carriage relative of the outbreak strain
present in the publicly available N. meningitidis genome library, but this analysis is limited
by the low number of carriage isolates available in the library. Whole-genome sequencing of
invasive NmC isolates from Nigeria, Niger, Burkina Faso, and Mali 2013-2016 revealed a new
sequence type closely related to ST-10217, ST-12446, circulating in Mali in 2016.55 In general,
molecular studies of N. meningitidis have focused on isolates from invasive disease, as these
are readily available. Molecular studies of carriage isolates have generally found a high level of
non-groupable meningococci in carriers, with very low or no carriage of known virulent types.56,57
Bacterial meningitis has a fast onset: as many as 84% of deaths occur within the first
24 hours of illness.58 The case-fatality ratio (CFR) reported for meningococcal meningitis is
usually around 10% in the African meningitis belt, a rate not different from that found in
industrialised countries.31 However, detailed community studies suggest that the true CFR
may be significantly higher because individuals may die before reaching a health care facility.58
Pneumococcal meningitis has a higher CFR, with observations ranging from 17% to 53%.21,32,59–65
Recent data from the Burkinabe case-based surveillance system shows a crude CFR of 9.7% for
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meningococcal meningitis (95% CI 8.3-11%) and 23% for pneumococcal meningitis (95% CI
22-25%).33
Meningococcal disease in the African meningitis belt tends to be more evenly distributed
across age groups than in high-income, temperate countries, but higher incidence is still observed
in individuals under 20 years of age, while disease is uncommon in adults over 30 years.30
Recent surveillance data from Burkina Faso show about one-third of confirmed meningococcal
meningitis in children under 5 and about one-half in 5- to 14-year-olds, with few cases in older
children and adults (see Table 2.1).33 By contrast, nearly one-third of pneumococcal meningitis
cases occurred in individuals 15 years and older, roughly equal to the share in under fives. The
large majority of H. influenzae meningitis cases occur in children under five.
Table 2.1 Confirmed bacterial meningitis cases by age and etiology in Burkina Faso, 2011 – 2015.33
Confirmed meningitis cases
Cause Under 5 years 5-14 years 15 plus years Total
H. influenzae b 77 (69%) 31 (28%) 3 (3%) 111
N. meningitidis 621 (34%) 889 (49%) 298 (16%) 1808
S. pneumoniae 690 (27%) 1090 (42%) 801 (31%) 2581
In the years 1990 to 2017, the Institute for Health Metrics and Evaluation (IHME) estimates
that meningococcal, pneumococcal and H. influenzae b meningitis caused on average 73 000
deaths and 600 000 cases per year across the African meningitis belt, accounting for about 1.6%
of total deaths and 0.4% of years lived with disability.66 It should be noted that S. pneumoniae
causes pneumonia more frequently than meningitis, with on average 260 000 deaths due to
pneumococcal pneumonia annually in the region over the same time period (1990-2017). In
recent years (2013-2017), the burden of bacterial meningitis has decreased somewhat, with 55
000 deaths and 560 000 cases estimated annually. Nonetheless, these estimates place meningitis
among the top ten causes of years of life lost and death in sub-Saharan Africa.66
The IHME estimates that N. meningitidis, S. pneumoniae, and H. influenzaeb cause a
roughly equal share of cases, with a somewhat larger share of deaths due to S. pneumoniae.
However, these estimates are dubious when compared to data on confirmed cases reported by
national ministries of health: of more than 15 000 confirmed cases reported between 2004 and
2013, roughly 4% were H. influenzaeb, 26% were S. pneumoniae, and 67% were N. meningitidis.34
The IHME model relied heavily on verbal autopsy data for the African meningitis belt region,
which would not give information on the etiology of meningitis. It is possible that their estimates
of the breakdown of meningitis deaths by etiology are reliant on data from other regions, where
N. meningitidis does not predominate.
2.3 Control and policy
Twenty-six countries have some territory in the meningitis belt: Benin, Burkina Faso, Burundi,
Cameroon, the Central African Republic, Chad, Cote d’Ivoire, the Democratic Republic of the
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Congo, Eritrea, Ethiopia, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Mali, Mauritania,
Niger, Nigeria, Rwanda, Senegal, South Sudan, Sudan, Togo, Uganda, and Tanzania. PCV has
been introduced in infant immunisation in 23 of these 26 countries.67 Guinea and South Sudan
have not yet introduced PCV and Chad plans to introduce the vaccine in 2021. Hib conjugate
vaccine has been in use in all countries since 2014.
MenAfriVac (routine) PCV (routine)
Hib (routine) MenAfriVac (mass)
























Fig. 2.1 Map showing the timing of actual and planned (post-2018, shown as crosses) introduction of conjugate
vaccines to prevent bacterial meningitis. Source: WHO Immunization, Vaccines and Biologicals website.67
For years, the approach to reducing morbidity and mortality due to meningococcal meningitis
has been reactive mass administration of meningococcal polysaccharide vaccines in districts
experiencing epidemics. Because polysaccharide vaccination has low immunogenicity in infants,
induces only short-lived immunity, and does not protect against carriage, it is not a lasting
control measure. In response to group A epidemics in the meningitis belt, the Meningitis
Vaccine Project (MVP), a partnership between the WHO and the Program for Appropriate
Technology in Health (PATH), was established in 2001 with the aim of eliminating epidemic
group A meningitis through the development, testing, licensure, and introduction of a group A
meningococcal conjugate vaccine that would be affordable in Africa.68
The vaccine, MenAfriVac, uses group A meningococcal polysaccharide with tetanus toxoid
protein as a carrier. Protein-polysaccharide conjugate vaccines induce T-cell dependent immune
response, allowing for memory response priming, antibody maturation, inducement of protective
antibodies in young children and infants, and reduction of nasopharyngeal carriage.69 The




































Hib  (routine infant)
MenAfriVac  (routine infant)
MenAfriVac (mass)




Fig. 2.2 Timing of introduction of conjugate vaccines to prevent bacterial meningitis (proportion of 26 meningitis
belt countries), and third-dose coverage estimates for PCV and Hib vaccine for infant cohorts. Source: WHO
Immunization, Vaccines and Biologicals website.67
reduction of carriage reduces transmission of the bacteria and allows for the development of
herd immunity, whereby unvaccinated individuals are protected by reduced transmission. Herd
immunity is largely responsible for the high impact of the meningococcal group C conjugate
vaccine in the United Kingdom and may also be key to MenAfriVac’s success in the meningitis
belt.70
MenAfriVac was pre-qualified by the WHO and first introduced in mass vaccination campaigns
for individuals between the ages of 1 and 29 years across the meningitis belt starting in 2010.
As of 2018, 23 countries had introduced MenAfriVac in mass campaigns (Kenya, Sudan, and
Uganda did not undertake mass campaigns).67 MenAfriVac is now included in the WHO
Extended Programme of Immunisation for infants between 9 and 18 months and 9 countries
have introduced MenAfriVac in routine infant immunisation (Burkina Faso, Central African
Republic, Cote d’Ivoire, Ghana, Gambia, Mali, Niger, Sudan, Chad) (see Figures 2.2 and 2.1).
A further nine countries plan to introduce MenAfriVac into infant schedules in the coming years
(Benin, Cameroon, Eritrea, Ethiopia, Guinea, Kenya, Nigeria, Senegal, Togo).
Vaccination has significantly reduced the prevalence of serogroup A nasopharyngeal carriage
and incidence of group A meningitis in short-term studies.71,72 In Burkina Faso, this reduction in
carriage has persisted for at least two years following vaccination.73 A study of surveillance data
between 2010 and 2015 found that mass MenAfriVac campaigns have decreased the incidence of
suspected cases of meningitis by 57% and confirmed cases of NmA meningitis by 99%.2 The
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vaccine has continued to be effective, with only 19 confirmed cases of group A meningitis across
Benin, Burkina Faso, Chad, Cote d’Ivoire, Ghana, the Gambia, Mali, Niger, Nigeria and Togo
since vaccination was implemented (as of November 2019).72,74
However, other meningococcal serogroups continue to circulate and cause disease in the
region, in particular serogroups W, X, and C. Although previously an infrequent cause of disease
in the African meningitis belt, a new serogroup C strain emerged in Nigeria in 2013, spread to
Niger in 2015, and in 2017 caused the largest serogroup C outbreak ever observed in the African
meningitis belt.75 The strain has now spread to Burkina Faso, where it caused outbreaks in
2019. Group W has continued to cause outbreaks, most significantly in Ghana in 2016, in Togo
in 2016, 2017, and 2019, and in Chad in 2019.
Vaccine for outbreak response is often either unaffordable or in short supply, as pharmaceutical
companies phase out production of polysaccharide vaccines and transition towards increased
production of conjugate vaccines for the Western market. In 2018, the International Coordinating
Group (ICG) on Vaccine Provision for Epidemic Meningitis, which coordinates the provision of
vaccines for reactive vaccination campaigns in response to meningococcal outbreaks, held 3.5
million doses of C-containing meningococcal vaccine, 1.5 million doses short of the 5 million
required to respond adequately in 5 of 6 epidemic years, and 7.1 million doses short of the 10.6
million needed to respond in most worst-case scenarios.76,77
In 2008, the United Kingdom Department for International Development partnered with
PATH and the Serum Institute of India to develop an affordable and thermostable pentavalent
meningococcal conjugate vaccine for Africa, protecting against serogroups A, C, W, Y, and X.
The vaccine is currently in stage III trials in Mali and the Gambia for use in 2- to 29-year-olds.78,79
The partners hope to submit the vaccine to the WHO for pre-approval by 2023.4 The 2018
Gavi Vaccine Investment Strategy approved, in principle, financial support for this vaccine.80 If
delivered widely enough, this multivalent vaccine has the potential to nearly eliminate epidemics
of meningococcal meningitis. Modelling work is ongoing in assessing the cost-effectiveness of
routine infant pentavalent vaccination in combination with reactive or preventative vaccination
campaigns in the wider population.81,82 A variety of scenarios including restricting use of the
pentavalent vaccine to higher-risk countries and introducing the pentavalent only in routine
infant immunisation are being considered to limit the size of Gavi’s investment.83
In 2017, experts from governments, global health organisations, public health bodies,
academia, private sector and civil society gathered to create a roadmap with the aim of
eliminating meningitis epidemics, reducing cases and deaths from vaccine-preventable menin-
gitis, and providing high quality care for survivors with sequelae by 2030, focusing on the
four organisms responsible for most bacterial meningitis - N. meningitidis, S. pneumoniae,
H. influenzaeb, and S. agalacticae.5,6 Specific gaps and research priorities identified in the
roadmap process include optimising strategies for outbreak prevention and response, including
a better understanding of pneumococcal outbreaks, and finding an optimum schedule for the N.
meningitidis pentavalent vaccine NmCV-5.This thesis focuses primarily on meningitis caused by
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N. meningitidis and S. pneumoniae, with very brief mention of H. influenzae. It is useful to
consider them together because all three of these organisms occupy similar ecological niches,
but important to recognise that they have different potential to cause meningitis in individuals
and to cause epidemics.
The following sections address some more technical aspects of relevance to this thesis. I
begin with an overview of different types of models for meningococcal transmission which are
used in Chapters 4 and 7. I then review the epidemiology of pneumococcal meningitis in the
African meningitis belt, with relevance to Chapter 4, and summarise the findings of studies
of climactic and environmental risk factors for meningococcal meningitis outbreaks in Africa,
which serve as a starting point for the analyses in Chapter 3 and 7 and underpin investigations
of the seasonality of carriage in Chapters 6 and 5.
2.4 Modelling meningococcal meningitis in the African meningitis
belt
Mathematical models describe systems using mathematical concepts. Models provide a
means of experimentation where it would be unethical or unfeasible to do so in reality. As
such, they are useful both for informing decisions about public health and disease control - for
example, the best age to give a vaccine in a national immunisation scheme - and for testing
scientific hypotheses about processes that may be difficult to observe - for example, the role of
seasonality in disease transmission.84 It is generally accepted that a model should be as simple
as possible while still accurately answering the question at hand and the information available.85
As the aim of this thesis is primarily to test hypotheses relevant to the control of bacterial
meningitis in resource-poor settings where information may be limited, the models used are
fairly simple.
2.4.1 Models of reactive vaccination for meningococcal meningitis outbreaks
Reactive vaccination policy in the African meningitis belt has evolved in response to changes
in disease burden and continuing insights from research. The first epidemic definition for
meningococcal meningitis was recommended by the WHO in 1995 on the basis of analysis by
Moore and colleagues of surveillance data from Burkina Faso.86 Under these guidelines, an
epidemic threshold was triggered where a district recorded 15 suspected cases of meningitis per
100 000 population per week average over two consecutive weeks. In districts neighbouring a
district which had already triggered the epidemic threshold, the threshold was lowered to 5
cases per 100 000 per week.87 This was updated in 2000 to recommend a lower threshold of 10
suspected cases per 100 000 per week for high risk districts and to emphasise the importance of
surveillance at a district level, as outbreaks of meningitis tend to occur at a fine spatial scale
and can be missed when surveillance is carried out more coarsely.88 A recommendation was
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also made for vaccination of districts in alert (exceeding incidence of 5 suspected cases per
100 000 per week) and neighbouring an epidemic district. With the introduction of group A
meningococcal conjugate vaccine in the meningitis belt in 2010 and subsequent reduction in
the burden of group A meningococcal meningitis, these thresholds were re-evaluated, focusing
on NmW outbreaks.89 This research informed the next iteration of WHO guidelines, which
maintained the epidemic threshold of 10 suspected cases per 100 000 per week but emphasised
the importance of surveillance in populations smaller than 100 000 persons, shortening the delay
between triggering of the incidence threshold and intervention, lowered the alert threshold to
3 suspected cases per 100 000 per week, and relaxed the recommendation for vaccination in
neighbouring districts to allow for more flexibility.90
The principle behind the policy is the use of weekly incidence thresholds to predict high
cumulative seasonal incidence. The weekly threshold is triggered as the outbreak grows, giving
an early warning sign and allowing local health authorities to carry out preventative measures,
including mass vaccination. If the weekly incidence threshold is set low, it will give earlier
warnings, but also will warn more often in cases where an outbreak does not actually occur. If
the threshold is set high, it will warn later, giving less time to respond, but is more predictive
of an outbreak. The optimal threshold is generally determined on the basis of its sensitivity and
specificity, or by maximising the potential cases averted per dose of vaccine used.
An early method developed by Pinner and colleagues to estimate the cases averted by
a vaccination campaign treated a localised outbreak of meningitis as a temporally varying
environmental exposure, defining the observed incidence, I, in a partially-vaccinated population
as
It = IV,tpt + IN,t(1 − pt)
where IV,t is the incidence in the vaccinated population, IN,t is the incidence in the non-
vaccinated population, and pt is the proportion of individuals vaccinated at time t.91 Making
the assumption
IV = (1 − σ)IN





thus giving an estimate of incidence in the absence of vaccination. This method ignores
transmission during the outbreak and assumes that all cases are the result of carriers progressing
to invasive disease.
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for each age class, a, and each week, t.92 Woods and Kaninda also added to the Pinner





It is important to note that σ must be individual vaccine efficacy against all causes of
meningitis, such that in a district with an epidemic in which half the cases are caused by NmA
and half by NmW, modelling a reactive campaign using NmW vaccine, the usual vaccine efficacy
must be reduced by one half. In practice, many early studies assume that all suspected cases
are due to the focal pathogen (usually NmA).
Ferrari and colleagues added an upper bound to their estimates of vaccine impact by fitting
a dynamic time-series SIR model to the observed incidence.95 Under this model, no cases in the
epidemic are the result of asymptomatic carriers progressing to invasive disease and vaccination
prevents onward transmission. By contrast, under the Pinner-type model all cases are the
result of asymptomatic carriers progressing to invasive disease and vaccination has no effect
on transmission (under the assumption that transmission does not occur during the epidemic).
It is not clear how much increased transmission during the epidemic contributes to incidence
of invasive disease and to what extent cases are simply triggered by environmental effects like
increased temperature and dust that increase the risk of invasive disease in existing carriers.
These two models represent two extremes in potential models of the outbreak process.
Estimates of the proportion of cases averted by reactive vaccination campaigns varies widely,
in part because of differing assumptions of vaccine efficacy and in part because meningitis
outbreaks are variable (see Table 2.2 for a summary of studies of reactive vaccination). Those
that progress slowly after triggering the epidemic threshold allow more time for the vaccine to
take effect; in contrast, some epidemics have all but finished by the time the vaccine is delivered.
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Table 2.2 Studies modelling the impact of reactive vaccination for meningitis outbreaks. All the studies use a variant of the static Pinner model. The study by
Ferrari and colleagues compares this to the dynamic time-series SIR model.
Study Setting Serogroup Coverage Vaccine
efficacy
Delay Impact findings
Pinner 199291 Nairobi, Kenya 1989 A Variable
by ward
87% None Cases reduced by “at least” 20%
Kaninda 200093 Togo 1990-1997 A 85% 85% 1 week seroconversion,
2 weeks operational
65% of cases in epidemic districts
prevented
Woods 200094 One district in Ghana 1997 A 72% 85% 2 weeks 23% of cases prevented
Parent du Chatelet
200192
One district in Senegal 1997 A 77% 85% Until weekly incidence
of 60 per 100 000
49% of cases prevented
Leake 200296 One district in Burkina Faso
1997
A 86% 85% 2 weeks seroconversion,
3 weeks operational
59% of cases prevented
Ferrari 201495 Katsina State, Nigeria 2009 A Variable
by ward
85% Variable by ward 4-12% of cases in state prevented
Trotter 201589 136 district-years across belt W Effective coverage of 75% 2 weeks seroconversion,
4 weeks operational
75% of cases during epidemic period
prevented
Mainassara 201597 3 regions of Niger 2002-2011 A 80% 80% 3 weeks 4% of all cases in 3 regions
prevented
Mainassara 201798 Dosso Region, Niger 2015 C 80% 80% 3 weeks 2% of all cases in region prevented
(only 1 district vaccinated)
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A study using a Pinner-type model to simulate reactive vaccination in three regions of Niger
between 2002 and 2012 found that reactive vaccination was most effective (most cases prevented)
when surveillance was performed at the subdistrict level and vaccination at the district level and
most efficient (most cases prevented per dose) when surveillance and vaccination were performed
at the subdistrict level.97 While reducing the delay between triggering epidemic threshold and
vaccination from four to one week roughly doubled efficiency and effectiveness, these gains were
not equal in magnitude to those associated with switching from district-level to subdistrict-level
surveillance.
Another study using the same methods examined vaccine response strategies against group
C meningitis in Dosso, a region of Niger with high group C meningitis incidence in 2015.98
Efficiency was again highest for subdistrict-level surveillance and vaccination and effectiveness
highest for subdistrict-level surveillance and district-level vaccination. Reducing delay from four
weeks to one again improved efficiency and effectiveness of district-level vaccination, but not as
much as switching to subdistrict-level surveillance. Weekly incidence thresholds of 9 and 10
suspected cases per 100 000 at the district level were optimal for detection of annual incidence
greater than the 95th and 97th percentiles, respectively. This finding reinforced the current
threshold of 10 cases per 100 000 per week.
Trotter and colleagues assessed reactive vaccination for group W epidemics across the
meningitis belt using a data set of weekly suspected case counts by district linked to requests to
the ICG for group W polysaccharide vaccine to identify likely group W outbreaks.89 As with
Mainassara’s assessment, shortening response time is more effective than lowering the epidemic
threshold.
Trotter and colleagues found much higher efficacy overall for reactive vaccination for group
W (27 cases per 100 000 doses with a threshold of 10 cases per 100 000 per week and delay of
four weeks) than Mainassara’s findings for group C (fewer than 2 cases per 100 000 doses with
equivalent assumptions) and simulating group A elimination (no cases prevented). However the
group C and simulated post-group A elimination datasets were small (three epidemic signals
compared to 49 for the group W dataset), encompassing only parts of Niger and only the year
2015 for group C.
Unfortunately, it is difficult to directly compare the findings of these various studies because
they do not use a standardised set of values for coverage, efficacy, and delays. However, the
internal comparisons drawn within a given framework are sound - for example, the findings by
Mainassara regarding optimal spatial scale. Modelling consistently indicates that timeliness is
crucial to maximising the impact of an outbreak response. The studies by Trotter and Kaninda
reflect the largest datasets of the group and indicate that a high proportion of cases in epidemic
districts are prevented by reactive vaccination.
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2.4.2 Dynamic models of meningitis
A variety of model structures have been used to study the dynamics of meningococcal disease
and vaccination, but most are compartmental SIR models in which the “infected” compartment
tracks individuals who are carrying the bacteria.99 To distinguish from invasive disease, these
compartments are sometimes labeled “C” for carriage, and compartments for individuals with
meningitis labeled “I”. However, because of the very low prevalence of invasive disease relative
to carriage, the role of the “I” compartment in transmission dynamics can often be ignored. The
remaining underlying dynamics of carriage transmission follow the same fundamental dynamics
of any disease system that can be approximated by an SIR model, allowing for parallels with
other systems for which more sophisticated models have already been developed.
Some meningitis models include invasive disease explicitly as a state whereas others model
incidence of disease solely as a function of carriage prevalence. Both systems have advantages.
Including invasive disease as a state represents the infectious and the susceptible populations
more accurately. However, as the duration of invasive disease is short relative to the duration of
carriage (typically one week compared to one to three months) and the intensity of the illness is
such that individuals are often confined to bed during this time, the contribution of diseased
individuals to the force of infection may be negligible. Excluding compartments for invasive
disease reduces the number of states in the model, allowing for faster and easier computation
and simulation.
Natural immunity induced by carriage is another prominent source of diversity and uncertainty
in modelling approaches. Some models assume no natural immunity from carriage100 whereas
others assume durations as long as 11 years.3 Some studies have even used two tiers of immunity,
each increasing in duration with age, essentially proposing that the first instance of carriage
induces some modest protection against reacquisition, which can then be further boosted to a
higher level if an individual is reinfected before protection wanes.101 This structure is drawn in
Table 2.3, with S1 indicating immunologically naive persons, C1 indicating carriage by naive
persons, S2 indicating persons with moderate immunity, C2 indicating carriage by moderately
immune persons, S3 indicating persons with high immunity, and C3 indicating carriage by highly
immune persons. Individuals in S3 are less likely to acquire carriage than individuals in S2 and
individuals in S2 are less likely to acquire carriage than individuals in S1. Carriers in C3 are
less likely to experience invasive disease (progress to I) than carriers in C2, and likewise for
C2 compared to C1. Another model structure assumes a shorter duration of immunity from
carriage (individuals moving from C1 to R1) than invasive disease (individuals moving from C2
to I to R2) .81
One modelling study that attempted to infer the average duration of natural immunity by
maximum likelihood using an SCIRS model and surveillance data from Burkina Faso found
an inter-quartile range of 0.87 to 5 years.102 Such a wide range does not inspire confidence,
less so when considering that the plausible range explored was 0.13 to 5 years. There is no
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known serological correlate of immunological protection against carriage acquisition, which
makes it difficult to critically evaluate.103 It is generally believed that some degree of natural
mucosal immunity develops over the course of an individual’s lifetime through exposure to
N. meningitidis and other commensal Neisseria species, including Neisseria lactamica. There
is strong evidence that N. lactamica may out-compete and exclude N. meningitidis from the
nasopharynx. Considering the high prevalence of carriage of N. lactamica in infants, this may
explain the low prevalence of meningococcal carriage in infants.104 However, few authors have
included N. lactamica co-infection in their modelling frameworks as it is generally more expedient
to assume low transmission among infants.
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Table 2.3 Dynamic models for meningococcal meningitis transmission in the African meningitis belt.
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Most published models of meningococcal meningitis, including all those designed for the
meningitis belt, have considered transmission of a single strain, though in reality a variety of
serogroups coexist in a community. The primary target for immunity is the polysaccharide
capsule which determines the serogroup classification, but some limited cross-immunity may
arise from common sub-capsular antigens. Aggregation of strains in models may bias predictions
about vaccine effects: a study of two stochastic models of meningococcal conjugate vaccination,
one with two strains (C and other Neisseria species) and one with four strains (C, B, N.
lactamica and other) found that the two-strain model tended to predict faster reductions in
vaccine-type disease and little to no strain replacement compared to the four-strain model.107
The four-strain model also displayed evidence of multiple attractors, resulting in sustained
oscillations in serogroup prevalence even in the absence of vaccination pressure. The authors
speculate that this is because prevalence is spread more thinly across four serogroups than two,
so competitive effects are enhanced. Despite the important epidemiological consequences of
antigenic diversity, the lack of strain- or serogroup-specific data has been a significant obstacle
to the development of more accurate multi-strain models.
Most models of meningitis in the African meningitis belt make use of a sinusoidal function
to introduce seasonality in transmission and progression to invasive disease, with a number
including a further stochastic term drawn from a uniform distribution to force greater inter-
annual variability in the size of epidemics.3,101 This annual term is often likened to the impact
of climactic drivers on incidence. While it is true that large-scale inter-annual variation in
meningitis incidence is likely driven by climactic variation, national- and district-level variation
must necessarily further depend on differences in the serogroups present and levels of immunity,
neither of which are captured by single-population single-strain models.
Two models have attempted to capture spatial heterogeneity in meningitis by using a meta-
population structure. Irving made use of a lattice framework approximating the population of
Burkina Faso of around 3 500 homogeneously mixing patches of 5 arc-minutes square, showing
that a relatively simple model with constant seasonal forcing could reproduce the complex
behaviour observed in the meningitis belt - localised outbreaks occurring in different populations
every year and sometimes extending to become widespread epidemic waves.105 Yaesoubi and
colleagues developed a 55-patch model in which each patch represented one homogeneously-
mixing district of Burkina Faso, using a gravity model to describe the rate of contact between
individuals in different districts.81
Although this thesis makes limited direct use of dynamic modelling, it is important to discuss
the key findings and limitations of earlier studies as these guide later chapters. Dynamic models
of meningitis in Africa have been limited by a lack of age- and serogroup-specific data. I attempt
to address this gap with respect to disease incidence in Chapter 3 and carriage prevalence
in Chapter 5. Chapters 3 and 7 capture some aspects of spatial heterogeneity in meningitis
incidence. These data could be used to inform mixing assumptions in spatial dynamic models.
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2.5 Pneumococcal meningitis
Since 1999, 14 studies studies have been published reporting on passive surveillance (in-
dividuals attending health facilities) of pneumococcal meningitis in countries of the African
meningitis belt: two studies in Niger, one in Nigeria, one in Mali, five in Burkina Faso, two in
Ghana, four in Togo, and one in Ethiopia. Study dates range from 1981 to 2016, many spanning
multiple years and in populations of various sizes.21,32,59–65,108–112 In two studies, 10- or 13-valent
pneumococcal conjugate vaccine (PCV) had been recently introduced into national routine
infant immunisation programs (see Table 2.4).
Eight studies reported the serotype distribution of isolates, seven in populations with no PCV
use (Table B.3, Figure 2.3). PCV13 covers the majority of strains that have historically caused
pneumococcal meningitis in the African meningitis belt and a high proportion of meningitis is
caused by a single serotype, ST1. Seventy percent of isolates were PCV13 vaccine-types; 45%
were serotype 1. Kwambana-Adams et al. 2016 reports a higher proportion of isolates belonging
to serotype 1 (67% overall) than other studies.21
Unlike for meningococcal meningitis, there is no consistent definition for an outbreak or
epidemic of pneumococcal meningitis. Only three studies specifically report outbreaks or non-
endemic patterns of disease: Kwambana-Adams and colleagues report a single outbreak over one
dry season in a single region of Ghana.21 Data from this outbreak are used to model the impact
of reactive vaccination in Chapter 4. Leimkugel et al. report an outbreak continuing over three
years, 2000 to 2003, in a single region in Ghana.61 The authors cite seasonality, broad host age
range, and clonality of the strains isolated as evidence of a single outbreak rather than seasonal
changes in endemic disease. Traore and colleagues describe an “epidemic pattern similar to that
of N. meningitidis meningitis” in a region including three districts in Burkina Faso and three
districts in Togo over a four-year period.62
Across all 14 studies, the confirmation rate of suspected bacterial meningitis cases ranged
from 24-48%, with S. pneumoniae isolated from between 10 and 77% of confirmed cases. There
is no consistent difference between studies characterising pneumococcal meningitis incidence as
“outbreak” or “epidemic” behaviour and those reporting on endemic incidence.
All but three studies find seasonal trends in pneumococcal meningitis, most reporting that
incidence peaks between February and March.32,59–63,65,108,110–112 Leimkugel notes that the peak
in pneumococcal meningitis cases appears to precede the peak in meningococcal meningitis cases
each year by 1-2 months.61 A wavelet analysis by Paireau and colleagues shows a consistent
trend, with pneumococcal meningitis incidence peaking in mid-February and meningococcal






Table 2.4 Studies of pneumococcal meningitis in the African meningitis belt, published 1999 to 2017. ¶ Proportion (and number) of bacterial cases confirmed S.
pneumoniae. *Proportion of suspected cases confirmed for any bacteria. **Average cumulative annual incidence of confirmed pneumococcal meningitis per 100 000
population.






Campagne 199959 National Hospital of Niamey, Niger (nearly all suspected
meningitis cases in Niamey)
1981-1996 10% (n=613) § 42% 14
Emele 2000112 Usman Danfodio University Teaching Hospital in Sokoto, Nigeria 1987-1992 18% (n=53) 26% <1
Campbell 200460 Hopital Gabriel Toure, (nearly all pediatric admissions in)
Bamako, Mali
2002-2003 (n=47) 7
Leimkugel 200561 Kassena Nankana, Bongo, and Builsa Districts, and Bolgatanga
Regional Hospital, Ghana
1998-2003 43% (n=117) 17
Traore 200962 † Regional Hospital of Bobo-Dioulasso, Burkina Faso; three
hospitals in Dapaong, Sokode, and Soutouboua in Togo
2002-2006 42% (n=463) 41% 14
Mueller 201263 Four health districts in and around Bobo-Dioulasso, Burkina Faso 2007-2009 35% (n=159) 47% 9
Karou 2012110 Regional Hospital of Dapaong, Tone District, Togo 2007-2010 27% (n=68) 48% 8
Gessner 2012111 Regional Hospital of Bobo-Dioulasso, Burkina Faso; four referral
hospitals in Dapaong, Kara, Sokode, and Soutouboua in Togo
2007-2009 (n=282) 8
Collard 2013109 Niger, principally Niamey, Tillabery and Dosso 2003-2011 13% (n=1010) 42% 2
Chaibou 2014108 Ouagadougou Yalgado Ouedragogo Teaching Hospital, Burkina
Faso
2007-2011 (n=455) <1
Mihret 201664 ‡ Three referral hospitals in Ethiopia 2012-2013 39% (n=18) 33% -
Kambire 201632 Burkina Faso, nationwide bacterial meningitis surveillance system 2011-2013 53% (n=1528) 24% 6
Kwambana-Adams
201621 #
All hospitals in Brong-Ahafo Region, Ghana 2015-2016 77% (n=104) 24% 9
Moisi 201765 All six health facilities in Tone and Cinkasse Districts, Togo 2010-2013 59% (n=78) 34% 7
§Also presents data from 11 non-epidemic years, where S. pneumoniae responsible for 21% of confirmed cases. †Links to Yaro 2006. ‡PCV10 in routine
immunisation since 2011. # PCV13 in routine immunisation since 2012.
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Six studies reported age-specific annual incidence of confirmed pneumococcal meningitis,
all in populations where PCV was not in use at the time (Table B.4, Figure 2.3). In all of the
studies, incidence is greatest in infants. Many studies show an additional peak in older children
and adults, but the precise age and magnitude of this peak is variable. Variation in incidence
could come from difficulties in estimating the catchment area of the health facilities where
these studies are being carried out or in differences in the frequency of taking and testing CSF






























































































































































































































































Proportion of confirmed cases Proportion of confirmed cases (adjusted) Incidence of confirmed cases
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Fig. 2.3 Case-fatality ratio, proportion of pneumococcal meningitis cases caused by serotype 1 and PCV13 vaccine-type serotypes, proportion of all pneumococcal
meningitis cases (adjusted by proportion of population in age group), and incidence of pneumococcal meningitis by age group and study. Vertical error bars
indicate binomial 95% confidence intervals for case-fatality ratio and proportion of cases due to ST1 and PCV13 types; horizontal error bars indicate minimum and
maximum age of reported age group. Studies describing outbreaks or epidemic patterns shown in blue.
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Eight studies reported the age distribution of confirmed cases of pneumococcal meningitis
(Table B.1, Figure 2.3). Although case distribution varies significantly from study to study,
seven of eight report more than 60% of confirmed cases in individuals 5 years and older and
more than 25% of confirmed cases in individuals 15 years and older. The data from the recent
Brong-Ahafo outbreak shows a particularly strong peak in older age groups, however it is not
markedly different from other distributions from situations not described as outbreaks. By
contrast, the distribution of cases by age reported in Traore et al. 2009 is uniform despite a
description in the discussion of “epidemic” patterns.62
Nine studies reported case-fatality ratios (CFR) or provided necessary data for the calculation
of CFR for confirmed pneumococcal meningitis (Table B.2, Figure 2.3). Reported age-specific
CFRs range from 9% to 62%, with no obvious variation by age. Overall CFRs ranged from 17%
to 53%. More recent studies generally show lower overall CFR; the highest CFRs were reported
in association with the data from 1981 to 1996.
Overall, there is no clear distinction between epidemic and endemic patterns of pneumococcal
meningitis in the African meningitis belt. PCV13 covers the most serotypes that cause pneumo-
coccal meningitis in the African meningitis belt, in particular ST1. A substantial burden of
disease falls on older children and adults, and CFRs appear higher than those for meningococcal
meningitis, with no clear variation in fatality by age.
2.6 Environmental correlates and risk factors for meningitis out-
breaks
The climate in the African meningitis belt is primarily bimodal and tropical, characterised
by a dry season from October to April, and a wet season from May to September. In the
middle of the dry season, January to March, dry, hot winds called the Harmattan blow from
the northeast to the southwest, carrying dust from the Sahara desert. In the wet season,
monsoon winds bring rain (mostly between July and September) and high humidity from the
Gulf of Guinea.36 Meningitis incidence in the region is strongly seasonal, and the influence of
climate on meningitis dynamics has been studied extensively. Quantitative studies generally fall
into two categories: explanatory studies which use all available data and attempt to explain
or describe the normal seasonal behaviour of meningitis,114–116 and predictive studies which
restrict predictor variables to those measured in the time before an outbreak and try to explain
what characterises particularly high-incidence years or district-years.117,118 Table 2.5 provides
a brief summary of quantitative studies of risk factors for meningitis outbreaks and their
findings. Elevated incidence of meningitis has been linked with high temperatures,38,115,116,119
low humidity,38,115,116,119–121 dust,36,38,115,116,119,120,122–124 low rainfall,37,114,116,119–122 land cover,120
population density,120 wind speed and direction,116,118,123,125 and sunshine hours.119 Many studies
are set in Niger and Burkina Faso, as both have most of their territory inside the meningitis
belt and experience the highest incidence of meningitis. Because climate variables describe
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large-scale trends, climate-based models tend to be more successful at higher spatial aggregation
and less good at explaining variation at the district and subdistrict level.126 Only one study has
examined the relationship between carriage and climate explicitly, although some other studies
have examined seasonal trends in carriage.127 Non-climactic risk factors, including outbreaks
in neighbouring communities, connectivity, and population density, are less well studied, with
early cases (October through December), population density, presence of primary roads, and
cases in neighbouring communities sometimes being associated with increased risk.121,123,124,128
The next chapter examines patterns of suspected cases of meningitis and tests for associations
between the occurrence of early cases, cases in neighbouring communities, and district-level
outbreaks in a broad range of countries across the meningitis belt.
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Table 2.5 Studies of risk factors for meningitis outbreaks.









Correlation Positive correlation with temperature (0.63) & dust
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Rainfall Correlation Significant negative correlation between cases &
rainfall (R = −0.27)

























Increased rainfall in January & August & dust in
April linked to fewer cases, increased dust in October










Higher humidity linked to acquisition of
non-groupable meningococcus (OR 2.1), no significant
relationship for NmA, W, Y, X
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December (Niger) correlated with incidence; predicts
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All found to be significant, with temperature (+) &
humidity (-) contributing the most; rain (-) & previous
cases (+) the least (Kendall’s correlation 0.64)
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Both national- & district-level incidence predicted
using November-December wind speed & early cases;
October-December dust also predictive at district








Dust, early cases, humidity,
neighbouring cases, primary
roads, rainfall, temperature,
wind speed & direction
Logistic
regression
High relative humidity in November-June & early
rains (March) protective; neighbour having at least
one case (OR 2.4), primary road crossing the area
(OR 1.7), & cases between 1 October & 31 December














Models can predict exceeding epidemic threshold with
specificity 71-80% & sensitivity 48-66% three weeks in
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Wind speed & direction is the best predictor on its
own, a model with wind speed, relative humidity, &
dust correlated almost as well as model using all









Dust, early cases Logistic
regression
Weak association between early cases & elevated
incidence (OR 1.1); high dust associated with elevated




Trends in bacterial meningitis in the African
meningitis belt 2005-2017
3.1 Introduction
This chapter brings together three data sources – district-level administrative maps, weekly
district-level syndromic surveillance, and national laboratory confirmation – to provide a broad
overview of bacterial meningitis in the African meningitis over the last decade. The weekly
district-level surveillance data set was made available to me through collaboration with Katya
Fernandez and Olivier Ronveaux at WHO Geneva and the data set is collated and maintained
by Clement Lingani at the WHO Inter-country Support Team for West Africa.
In the 2013 MenAfriVac investment case, the 26 African meningitis belt countries were
classified as follows:
• Core countries (n=7): Burkina Faso, Chad, Ethiopia, Mali, Niger, Sudan, and 26 northern
states of Nigeria;
• Bordering countries with hyperendemic zones (n=12): Benin, Cameroon, Central African
Republic, Cote d’Ivoire, Democratic Republic of the Congo, The Gambia, Ghana, Kenya,
Togo, Senegal, Uganda and the remaining states of Nigeria;
• Other at-risk countries without hyperendemic zones (n=7): Burundi, Eritrea, Guinea,
Guinea-Bissau, Mauritania, Rwanda, and Tanzania.
These categories have helped national ministries of health and international organizations
to prioritize the most at-risk populations to receive MenAfriVac earlier. However, they are
mostly based on geography, and do not necessarily reflect the burden of disease. To allow for the
development of country-specific models for NmA vaccination, Karachaliou and Trotter proposed
an updated classification based on historical reports reviewed by Molesworth120 and surveillance
data presented by Lingani and colleagues:34,129
• High incidence countries, with average annual incidence of 45-50/100,000 and outbreaks
every 5-6 years (n=2): Burkina Faso and Niger;
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• Medium incidence countries, with average annual incidence of 15-20/100,000 and outbreaks
every 10-15 years (n=9): Mali, Nigeria, Chad, Sudan, Ethiopia, Cameroon, Gambia, Ghana,
and Togo;
• Low incidence countries, with average annual incidence of less than 5/100,000 (n=15):
Senegal, Mauritania, Cote d’Ivoire, Benin, CAR, Eritrea, South Sudan, Guinea, Guinea-
Bissau, DRC, Burundi, Kenya, Rwanda, Uganda, and Tanzania.
These categories are primarily used to estimate the cases and deaths averted by MenAfriVac
as part of the Vaccine Impact Modelling Consortium (VIMC). The investment case presented to
Gavi in 2018 for the pentavalent meningococcal conjugate vaccine proposed using the multivalent
vaccine in high and medium incidence countries only.83
The aims of this chapter are: i) to use the data described above to examine the frequency of
alert and epidemic signals, the frequency and magnitude of outbreaks, and the proportion of
suspected cases which are laboratory tested and confirmed; ii) to characterise how the former
vary across countries, over time, and by predominant etiology; iii) to validate or propose new
risk categories for non-NmA meningitis.
3.2 Methods
I use surveillance data from 2004 to 2017 on suspected cases of meningitis from the enhanced
district-level surveillance system.34 A suspected case is defined as any person with sudden
onset of fever (>38.5°C rectal or 38.0°C axillary) and any one of the following: neck stiffness,
flaccid neck (infants), bulging fontanelle (infants), convulsion, or other meningeal signs. Weekly
district-level counts of suspected cases are collated nationally and then reported to the WHO
Inter-country Support Team (WHO-IST) for West Africa. I use the district-level population sizes
reported by each country to WHO-IST, which are updated annually. I compare the country-wide
sum of these population sizes to the total population estimated in the United Nations (UN) 2017
Revision of World Population Prospects, available online at https://population.un.org/wpp/, to
give an estimate of national surveillance coverage, a measure of the proportion of the population
under surveillance for suspected bacterial meningitis.
Epidemic and alert incidence thresholds are consistent with current WHO guidelines, with
alert defined as more than 3 suspected cases per 100,000 population per week or more than 2
cases total per week for districts with less than 30,000 population, and epidemic defined as more
than 10 suspected cases per 100,000 population per week or more than 5 cases total per week
or a doubling of cases in a two-week period for districts with less than 30,000 population.90
Cumulative district incidence of 100 cases per 100,000 population annually (roughly the 97.5th
percentile of cumulative annual incidence in the data set) is defined as a local outbreak (Table 3.1).
Early cases are defined as any suspected case reported in the final 12 weeks of the preceding
year, roughly October to December, as consistent with previous studies.124
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Table 3.1 Incidence thresholds used to define alert and epidemic signals and localised outbreaks. *For districts
with population less than 30,000.
Event Definition
Alert signal More than 3 suspected cases per 100,000 population per week
*More than 3 suspected cases per week
Epidemic signal More than 10 suspected cases per 100,000 population per week
*More than 5 suspected cases per week or a doubling of cases in a two-week period
Local outbreak More than 100 suspected cases per 100,000 population annually
I use national-level annual data on confirmed cases of bacterial meningitis. Cerebrospinal
fluid (CSF) samples are tested by national reference laboratories using PCR, culture, or latex
agglutination and these results are collated by WHO-IST.130 From 2005 to 2009, the meningitis
bulletin reported the overall number of CSF samples taken, the number of samples contaminated
and negative (no bacteria), and the number of isolates of NmA, NmW, other Nm, S. pneumoniae,
H. influenzae b, and “other pathogens”. In 2010, the bulletin began reporting isolates of NmB,
NmC, NmX, and NmY separately.
Because fine-grained data on etiology is lacking, to identify characteristic outbreaks of
particular etiology I use incidence data from only those country-years in which I can be
reasonably confident that all outbreaks are caused by a single agent. I select country-years where
a particular agent represents significantly more than 50% of bacterial cases (as determined by
binomial test). I also show the country-years where a particular agent represents significantly
more than 75% of bacterial cases. I make an exception for the years 2013, 2016, and 2017 in
Nigeria, where little data is reported to WHO but evidence from the literature suggests that
NmC is predominant.47,54,131
As meningococcal immunity is thought to be largely serogroup-specific, I then also use these
classifications to characterise pairs of country-years as “concordant” or “non-condordant” to
identify years where the predominant cause of meningitis is the same or different from that in
the previous year.
The data are generally described, noting differences by predominant etiology, year, and
country. Trends by country are compared to data from Molesworth and colleagues’ review
and to the classifications proposed by Karachaliou and colleagues and used in the Gavi 2018
investment strategy.129
I then perform a series of mixed-effects logistic regressions, modelling the probability of
crossing the epidemic threshold and the probability of a local outbreak (as defined by cumulative
annual incidence threshold given in Table 3.1) as a function of the following risk factors:
occurrence of cases early in the hyperendemic season, incidence exceeding the alert or epidemic
threshold in the district in the previous year (focal status), and incidence exceeding alert or
epidemic threshold in neighbouring districts in the previous year (neighbour status), adjusting
for country as a fixed effect and district as a random effect. These analyses are performed on
the full data set, in effect treating all suspected cases as equivalent, and then repeated for NmA-
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and NmC-predominant and concordant district-years. There were insufficient data to consider
NmW circulation.
Linking the surveillance data and the map data presented two challenges: first, district names
change in spelling from year to year and between data sources, and second, new administrative
divisions are sometimes established. This causes difficulties in tracking individual districts’
epidemiological history and in situating districts in space. I deal with these challenges first
by correcting errors related to Unicode parsing, common abbreviations, and differences in
punctuation, spacing, and capitalisation. Then, in order to capture as many variations in location
name as possible, I use maps from five different data sources for primary (i.e. province), secondary
(i.e. district), and tertiary (i.e. subdistrict) administrative boundaries: the Database of Global
Administrative Areas, the United Nations Office for the Coordination of Humanitarian Affairs
(accessed via the Humanitarian Data Exchange at https://data.humdata.org/), MenAfriNet,
and two WHO maps, one of the full meningitis belt and an alternative version of the Nigerian
administrative boundaries. I match districts by name between the surveillance data set and the
maps, first by exact matching, and then by hand to identify districts with alternative spellings
or names.
Finally, I preserve original geographies where they can be identified. For example, Niger’s
capital Niamey was originally divided into three districts, Niamey I, II, and III. As the population
grew, it became necessary to further divide Niamey I and II in half, resulting in five districts,
Niamey I through V. I maintain the original divisions in order to track the epidemiological
history of these populations accurately.
3.3 Results
3.3.1 Coverage and linkage
Most country-years had surveillance coverage above 90% (see Figure 3.1). A few notable
exceptions included Uganda in 2016, and Ethiopia in 2012, 2013, and 2015, where only one or
two districts reported suspected cases. Surveillance coverage in the Democratic Republic of the
Congo (DRC) declined sharply from 2015. Guinea in 2015, 2016, and 2017, and Ghana in 2006
reported much larger populations surveilled than the UN-estimated national population counts.
As of 2017, surveillance coverage was above 90% in all countries but Mauritania, Uganda, and
DRC.
There were 26,764 unique district-years of suspected case data representing meningitis
incidence in 23 countries of the African meningitis belt from 2004 to 2017 to be geolocated.
Before cleaning, 10,080 of these (38%) could be matched by name to the shapefile (see Figure 3.2).
After cleaning and hand-matching, 25,477 (95%) could be matched by name to the shapefile.
The majority of district-years which could not be located were in the DRC (502) and Sudan
(328).
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Fig. 3.1 Population reported in surveillance data set compared to UN national population estimates by year.
Coverage higher than 100% is possible because the numerator comes from country estimates and the denominator
from UN estimates.
The merged shapefile initially contained district data from five different map sources, giving
13,284 geographic shapes with unique names from 23 countries to which to link the surveillance
data. 3,672 of these were linked to an entry in the surveillance data set.
3.3.2 Trends by predominant etiology
There was no clear majority etiology for meningitis in most country-years (see Table 3.2). I
identified 16 country-years where NmA was predominant, 8 where NmC was predominant, 7
where NmW was predominant, and 22 where S. pneumoniae was predominant (see Figure 3.3).
In 2009 in DRC, other Nm was the predominant category of isolates, but because of reporting
practices described above, these isolates could have been NmB, NmC, NmX, or NmY. Bacteria
other than S. pneumoniae, N. meningitidis, and H. influenzae b were predominant in four
district-years. There is, on average, a lower proportion of cases lab tested in country-years where
NmA is predominant, most likely because the quality of laboratory surveillance has improved
over time. For country-years where NmC, NmW, and Spn are predominant, more than 50% of
cases were lab tested. Bacteria were isolated from between 26% and 41% of tested cases, and
more than 67% of positive isolates belonged to the majority group for each etiology.
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Fig. 3.2 Proportion of geolocated district-years before and after data cleaning and hand-matching.
Table 3.2 Summary of surveillance data by predominant etiology (95% CI ≥ 50% of all bacterial isolates). Tested
refers to the proportion of suspected cases that were tested; confirmed refers to the proportion of tested cases
that were confirmed bacterial meningitis, and majority etiology group refers to the proportion of confirmed cases






Tested Confirmed In majority
etiology group
NmA 16 1 282 8% 41% 87%
NmC 8 3 654 58% 34% 71%
NmW 7 359 72% 33% 67%
Other Nm 1 382 1% 33% 100%
Spn 22 1 253 55% 33% 68%
Other bacteria 4 471 44% 26% 85%
No majority 103 13 838 18% 26% ...



















Fig. 3.3 Predominant cause of bacterial meningitis by country and year. Deeper tones indicate 95% CI ≥ 75% of
all bacterial isolates; lighter tones indicate 95% CI ≥ 50% of all bacterial isolates. Asterisk shows exception for





Fig. 3.4 Cumulative annual district-level incidence of suspected meningitis cases by dominant etiology.
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There was a high rate of localised outbreaks during the periods identified where NmA
was predominant. Incidence exceeded the alert threshold in nearly half of all district-years
where NmA was predominant, and exceeded the epidemic threshold in more than one quarter
(see Figure 3.5). By contrast, incidence exceeded the epidemic threshold in less than 10% of
district-years for any other etiology. However, when comparing district-years in which incidence
exceeded the epidemic threshold, the distributions of cumulative annual incidence are similar,
with medians ranging from 74 to 127 cases per 100,000 for NmA, NmC, NmW, and Spn. All


















































Fig. 3.5 (a) Number of districts per country-year triggering alert signal, epidemic signal, and outbreak thresholds,
stratified by predominant etiology. (b) Cumulative annual incidence of suspected meningitis per 100,000
population in districts exceeding (blue) and not exceeding (orange) epidemic threshold. Box plot shows median
and inter-quartile range.
3.3.3 Trends by country
District-level annual incidence of suspected cases of meningitis varied widely between
countries, with the highest median annual incidence in Burkina Faso, CAR, DRC, Niger, and
Togo, and median of less than one suspected case reported per 100,000 population per year
in Benin, Cote d’Ivoire, Ethiopia, the Gambia, Ghana, Guinea, Kenya, Mauritania, Nigeria,
South Sudan, Sudan, Tanzania, and Uganda (see Table 3.3). Incidence in districts triggering
the epidemic threshold is less skewed but still variable, ranging from median 43 to 171 cases per
100,000. Burkina Faso, Niger, and Chad have the greatest proportion of district-years exceeding
the epidemic and outbreak thresholds.
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Fig. 3.6 Cumulative annual incidence in districts triggering epidemic signal by etiology.
Nigeria and Ethiopia report the highest rate of confirmation among cases that were tested,
but also the lowest rate of lab testing, with just 1% of cases being tested between 2005 and
2017. Senegal and Sudan report testing more CSF than suspected cases overall. After these two
countries, the highest rate of lab testing is in Togo, the Gambia, and Mali, with 89%, 76%, and
61%, respectively. Although DRC reports relatively high incidence of suspected cases, rates of
testing and confirmation are low, with 2% of cases tested and 11% of tested cases confirmed.
No lab confirmation data are shared for Kenya, Tanzania, and Uganda.
In recent years (2015-2017), all reporting countries tested more than 50% of suspected
cases except for DRC, Ethiopia, Nigeria, Cameroon, South Sudan, and the Gambia. Benin,
CAR, Senegal, and Togo reported more CSF samples tested at a national level than suspected
cases occurring at district level. The reason for this is unclear. More than half of all countries
confirmed 11 to 35% of cases, with the highest confirmation rates in Niger and Burkina Faso (38
and 36% respectively). Fewer than 10% of tested cases were confirmed in South Sudan, Senegal,





Table 3.3 Summary of surveillance data by country. Outbreak defined as exceeding annual epidemic cumulative incidence threshold (100 cases per 100,000).
Confirmed cases include all samples where bacterial pathogens are isolated. Annual incidence given in suspected cases per 100,000 population.
Country Years Cases Proportion of district-years Median annual incidence Proportion of cases
Outbreak Epidemic signal Alert signal Overall Epidemic signal Confirmed Tested
Benin 13 7 710 2% 2% 11% 0 171 36% 56%
Burkina Faso 13 85 600 11% 16% 49% 25 120 35% 22%
Cameroon 11 11 300 1% 2% 14% 1 62 21% 14%
CAR 12 4 070 0% 2% 18% 5 45 23% 47%
Chad 12 19 400 4% 6% 20% 1 122 39% 9%
Cote d’Ivoire 13 4 590 <0.5% 1% 5% 0 74 12% 58%
DRC 13 82 500 2% 4% 32% 7 89 11% 2%
Ethiopia 6 4 120 0% <0.5% 3% 0 43 81% 1%
Gambia 6 840 0% 2% 12% 0 54 10% 76%
Ghana 12 8 980 1% 2% 10% 0 75 29% 54%
Guinea 8 2 630 0% 0% 4% 0 ... 19% 40%
Kenya 2 318 0% 0% 2% 0 ... ... ...
Mali 13 8 160 0% 1% 6% 1 57 19% 61%
Mauritania 6 58 0% 0% 2% 0 ... 31% 45%
Niger 13 42 500 6% 10% 27% 5 109 39% 57%
Nigeria 11 88 300 2% 4% 9% 0 81 58% 1%
Senegal 5 1 220 0% <0.5% 1% 1 13 6% 115%
South Sudan 6 590 0% <0.5% 2% 0 77 39% 5%
Sudan 4 324 0% 0% <0.5% 0 ... 10% 112%
Tanzania 1 3 0% 0% 0% 0 ... ... ...
Togo 13 6 950 2% 3% 18% 3 120 21% 89%
Uganda 2 129 0% 0% 0% 0 ... ... ...
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3.3.4 Comparison to other data sources
The data from the Molesworth review are given in the form of median, minimum, and
maximum cumulative annual incidence per 100,000 population. In Figure 3.7, these data are
compared to those from the data analysed here. It is important to note that these sources
represent different time periods (2005-2017 versus 1980-1999). The range between minimum
and maximum incidence is generally very wide. These overlap in almost every case except
for DRC (median 16, range 11-18 versus median 2, range 0-6 cases per 100,000), where the
WHO-AFRO database reports consistently higher incidence than Molesworth. The ranges are
also non-overlapping for Sudan (median 0.3, range 0.1-0.5 versus median 3, range 1-140 cases per
100,000) but this can be explained by the separate reporting of South Sudan in the more recent
WHO-AFRO database (median 0.8, range 0.3-3). Median national-level incidence estimates are
correlated (Pearson’s correlation 0.71, p-value < 0.001). The median incidence values tend to be
higher in Molesworth than in this analysis, with a linear relationship between the WHO-AFRO






100 200 300 400 500
























Fig. 3.7 Median (points) and range (error bar) of annual incidence by country from Molesworth 2003 and the
database analysed here. Note the scales of the x- and y-axis, which are scaled by the square root.
3.3.5 Incidence before and after MenAfriVac introduction
The impact of MenAfriVac on meningitis incidence is apparent. The classifications proposed
by Karachaliou and Trotter are mostly consistent with the ranking of countries by median
annual incidence pre-MenAfriVac introduction (introduced in Section 3.1). DRC and CAR rank
higher despite being classed as low-incidence; Ghana and Sudan rank low but are classed as
medium-incidence countries (Figure 3.8a). The rank by median incidence post-MenAfriVac
is markedly different: Benin, DRC, and CAR all rank high although they are classed as low
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incidence countries for NmA (Figure 3.8b). Importantly, meningitis incidence does not appear























































































































































































































Fig. 3.8 (a) Annual incidence before MenAfriVac introduction, ranked by median value. Median incidence from
Molesworth 2003 shown for reference as black crosses. Colours indicate classification by Karachaliou and Trotter.
(b) Annual incidence after MenAfriVac introduction, ranked by median value before introduction.
Fig. 3.9 Map showing maximum cumulative annual incidence of suspected cases by district for (a) the period
before completion of MenAfriVac mass campaigns and (b) the period after completion of MenAfriVac mass
campaigns.
3.3.6 Trends over time
The population under surveillance has increased more than five-fold from 2005 to 2017.
The number of districts exceeding outbreak and epidemic thresholds peaked sharply in 2009
and has otherwise remained fairly steady (14-38 outbreaks per year)(Figure 3.10). Similarly,
cumulative incidence peaked in 2009 and has remained less than 10 cases per 100,000 since
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2010 (Table 3.4). The intensity of incidence in districts triggering the epidemic threshold has
not decreased substantially, ranging from 85 to 171 cases per 100,000. A high proportion of
the total suspected cases occurs in districts triggering the epidemic threshold, although this
varies from year to year, ranging from 15% in 2014 to 76% in 2009. The proportion of cases
being confirmed by laboratory tests has increased, particularly in recent years, whereas the










































Fig. 3.10 a) District-level epidemic signals, alert signals, and outbreaks by year. b) District-level alert signals
and total districts reporting by year. c) Suspected, tested, and confirmed cases of bacterial meningitis by year.
Table 3.4 Summary of surveillance data by year. CSF=cerebrospinal fluid samples. Outbreak defined as exceeding
annual epidemic cumulative incidence threshold (100 cases per 100,000). Positive CSF include all samples where
bacterial pathogens are isolated. Population given in millions. Cumulative incidence given in suspected cases per
100,000 population.










2005 125 3% 24% 12 164 23% 40% 13%
2006 134 6% 24% 22 171 63% 32% 22%
2007 237 5% 19% 15 159 63% 43% 7%
2008 238 7% 26% 14 85 44% 43% 10%
2009 270 15% 35% 32 143 76% 47% 7%
2010 307 3% 21% 9 94 23% 38% 14%
2011 324 2% 13% 7 140 37% 36% 23%
2012 370 3% 15% 7 124 34% 27% 26%
2013 390 2% 10% 5 104 19% 18% 28%
2014 513 1% 9% 4 85 15% 26% 23%
2015 433 2% 8% 5 146 48% 31% 47%
2016 562 2% 7% 3 112 27% 27% 59%
2017 685 2% 6% 4 89 41% 25% 43%
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3.3.7 Risk factors for outbreaks
Table 3.5 shows the full risk factor analysis for exceeding the epidemic incidence threshold.
The occurrence of early cases is not a significant risk factor for exceeding the epidemic incidence
threshold for NmA, NmC, or all suspected cases. Considering all suspected cases, both previous
year focal status and previous year neighbour status are predictors of exceeding the epidemic
incidence threshold in the current year, with no significant difference between exceeding the
alert threshold and exceeding the epidemic threshold, and no significant difference between
neighbour status and focal status.
There is substantially less data available for NmA- and NmC-specifc analyses, with only
district-years from Niger (2008-2009), Burkina Faso (2006-2007, 2007-2008), and Chad (2011-
2012) making up the NmA-specific data set and only district-years from Nigeria (2013-2014,
2014-2015, 2015-2016, 2016-2017) and Niger (2015-2016, 2016-2017) making up the NmC-specific
data set. For NmA, no significant incidence-based risk factors could be identified. For NmC,
both focal epidemic status and neighbour alert or epidemic status in previous year are significant
predictors of epidemic risk (OR 3.2 for focal, 8.0 and 12 for neighbour).
Similar risk factors are found for exceeding the cumulative annual incidence threshold of 100
cases per 100,000 population, although substantially fewer districts exceeded the cumulative
annual incidence threshold than exceeded the weekly epidemic incidence threshold (Table 3.6).
The presence of early cases are not a significant risk factor for exceeding the annual cumulative
incidence threshold for NmA, NmC, or all suspected cases. For NmA, only exceeding the alert
threshold in the previous year is a significant risk factor for outbreak, and its effect is weak (OR
2.6 95% CI 1.1-6.0). For NmC and all suspected cases, both focal alert or epidemic status and





Table 3.5 Risk factors for exceeding weekly epidemic threshold by predominant serogroup. OR = odds ratio. 95% CI = 95% confidence interval.
Group A Group C All suspected cases
Factor Number of
districts
OR (95% CI) Number of
districts
OR (95% CI) Number of
districts
OR (95% CI)
Status in previous year
No alert 25/145 1.0 44/2702 1.0 352/15984 1.0
Alert 34/66 1.9 (0.9-4.2) 4/44 1.9 (0.49-5.7) 211/2187 2.6 (2.1-3.2)
Epidemic 45/97 1.1 (0.48-2.5) 8/31 3.2 (1.1-9.2) 135/686 3.5 (2.7-4.6)
Neighbour status in previous year
No alert 8/72 1.0 28/2540 1.0 199/12349 1.0
Alert 16/67 0.82 (0.28-2.5) 12/139 8.0 (3.8-16) 270/4707 2.9 (2.4-3.6)
Epidemic 80/169 1.5 (0.5-4.5) 16/98 12 (4.9-26) 229/1801 3.3 (2.6-4.3)
Early cases (Oct-Dec of previous year)
No 78/234 1.0 46/2617 1.0 556/16386 1.0
Yes 26/74 1.1 (0.56-2.0) 10/160 2.2 (0.96-4.7) 142/2471 1.2 (0.97-1.4)
Country
Niger 23/40 1.00 6/85 1.0
Burkina Faso 54/94 0.78 (0.30-2.0)
Chad 26/116 0.22 (0.096-0.47)
Mali 0/58





Table 3.6 Risk factors for exceeding annual epidemic cumulative incidence threshold (100 cases per 100,000) by predominant serogroup. OR = odds ratio. 95% CI
= 95% confidence interval.
Group A Group C All suspected cases
Factor Number of
districts
OR (95% CI) Number of
districts
OR (95% CI) Number of
districts
OR (95% CI)
Status in previous year
No alert 14/145 1.0 10/2702 1.0 150/15984 1.0
Alert 27/66 2.6 (1.1-6.0) 3/44 6.0 (1.1-26) 133/2187 3.3 (2.5-4.3)
Epidemic 34/97 1.4 (0.59-3.6) 4/31 6.7 (1.3-32) 94/686 5.2 (3.7-7.3)
Neighbour status in previous year
No alert 4/72 1.0 5/2540 1.0 81/12349 1.0
Alert 10/67 1.0 (0.29-4.4) 6/139 18 (4.9-65) 152/4707 3.1 (2.3-4.2)
Epidemic 61/169 2.0 (0.59-3.6) 6/98 12 (2.5-57) 144/1801 3.5 (2.5-5.0)
Early cases (Oct-Dec of previous year)
No 56/234 1.0 14/2617 1.0 300/16386 1.0
Yes 19/74 1.1 (0.55-2.1) 3/160 1.5 (0.31-5.5) 77/2471 1.1 (0.81-1.4)
Country
Niger 15/40 1.00 3/85 1.0
Burkina Faso 41/94 0.85 (0.32-2.2)
Chad 19/116 0.31 (0.13-0.72)
Mali 0/58
Nigeria 14/2692 1.4 (0.37-7.2)
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3.4 Discussion
District-level syndromic surveillance has expanded over the past two decades to cover nearly
the entire population of the meningitis belt. This study was able to link the majority of
district-years in the surveillance data set to physical locations. This geolocated data set could
be used in further studies. The total population under surveillance has increased over time as
more countries have joined the surveillance network, and the rate of laboratory testing of cases
has also increased, whereas the rate of confirmation has decreased.
The highest rate of district-level outbreaks was seen in country-years where NmA was
the dominant cause of meningitis, followed by NmW, then NmC, and finally Spn. However,
when outbreaks did occur, they were of comparable size regardless of etiology. Though N.
meningitidis has historically been recognised as the sole cause of seasonal meningitis outbreaks
in the African meningitis belt, numerous studies have identified outbreaks of meningitis with
similar high incidence, seasonality, and age distribution where S. pneumoniae is the causative
agent.21,61,132,133 The following chapter assesses the potential efficiency and impact of responding
to localised outbreaks of pneumococcal meningitis with reactive vaccination.
Average annual incidence was highly variable between countries, and less variable considering
only district-years that trigger the epidemic threshold. The highest overall incidence of meningitis
is found in Niger, Burkina Faso, and Chad, countries which lie entirely or almost entirely within
the meningitis belt.
Considering the full data set of suspected cases, elevated incidence in previous years is
a significant risk factor for epidemic signals and outbreaks, both within a given district and
between neighbouring districts. This trend was also true where NmC was predominant, but
could not be shown for NmA. It is possible that elevated risk in neighbouring districts was
demonstrated for NmC outbreaks because it is a novel strain that has only recently emerged
and is spreading geographically, whereas NmA was established and widespread. However, given
that the same trends were shown in the full data set considering all suspected cases, it seems
more likely that there were too few district-years in NmA-predominant settings to draw any
significant conclusions. Early cases occurring between October and December of the previous
year were not a significant risk factor for epidemic signals or outbreaks.
These findings contrast with previous findings linking early cases with higher risk of outbreaks:
one study of confirmed group A meningitis in Niger between 2004 and 2010 and one of suspected
cases in Niger between 1986 and 2006.121,123 One additional study found significantly elevated
odds with low magnitude (OR 1.14 95% CI 1.06-1.21).124
While many studies have examined climactic risk factors for meningitis outbreaks, few studies
have addressed incidence-based factors. A study in Niger found that subdistricts with a higher
percentage of neighbours with confirmed NmA cases had a higher risk of cases that same year
(incidence rate ratio 2.37, 95% CI 2.08-2.70).121 One analysis of reactive vaccination campaigns
in Ethiopia speculated that, due to the wave-like spread of outbreaks and the delays involved in
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organising a reactive response, it may be advantageous to target neighbouring communities.134
The potential of targeting neighbouring districts in reactive vaccination responses is examined
further in Chapter 7.
The question of which countries should prioritise introduction of the pentavalent vaccine
is a difficult but very important one. On the basis of median national incidence in the post-
MenAfriVac era, the classification of Benin, CAR, and DRC as low risk might need to be
reconsidered. There are data quality concerns about DRC that would merit further research,
including high but unusually low-variance incidence, low laboratory testing and confirmation
rates, and unusually variable reported population sizes. One possible criterion for risk could
be having any district-year with cumulative annual incidence greater than 100 suspected cases
per 100,000 post-MenAfriVac mass campaign completion. This would include Benin, Burkina
Faso, Cameroon, Chad, the DRC, Ghana, Niger, Nigeria, and Togo. As is made clear by this
chapter, risk for outbreaks is highly heterogeneous within countries. Southern regions of Nigeria,
Benin, Ghana, and Togo, for example, report low incidence of meningitis and outbreaks in these
regions are rare.
Another approach might be to consider all countries which have a confirmed non-A meningo-
coccal outbreak. A brief literature search and review of the WHO Weekly Epidemiological
Record suggests that this would include Benin, Burkina Faso, Chad, Cote d’Ivoire, the Gambia,
Ghana, Niger, Nigeria, and Togo,135–138 and possibly also Guinea (480 suspected NmW cases in
2013), Kenya (74 suspected NmW or X cases in 2006), Sudan (28 suspected NmW cases in 2006),
and Uganda (37 suspected NmW or X cases in 2006), depending on outbreak definition.139–141
Unfortunately the population and case numbers for outbreaks are not reported, so specific
incidence-based definitions cannot be evaluated. Seven countries – Benin, Burkina Faso, Chad,
Ghana, Niger, Nigeria, and Togo – fulfil both criteria: any district-year with high suspected
cumulative annual incidence post-MenAfriVac mass campaign completion and a confirmed non-A
outbreak reported in the literature.
Confidence in this analysis is limited by the underlying assumption that national laboratory
confirmation is uniformly representative of all districts and that causes of meningitis outbreaks
are homogeneous within countries. This assumption is unrealistic. The choice to place the
threshold for predominance at 50% minimum may be too lenient, resulting in localised outbreaks
of uncommon serogroups being misattributed. For example, outbreaks caused by both NmW
and Spn were observed in Ghana in 2016.21,142 The analysis is also based on the assumption that
localised outbreaks are largely caused by a single serogroup. This assumption is consistent with
the current understanding of what is necessary to produce an outbreak as opposed to an endemic
seasonal increase in incidence (low population immunity, which is largely serogroup-specific,
allows for a rapid increase in transmission) and is backed up by studies in outbreak settings.126,143
Taken together, these methods should capture most large outbreaks in countries with decent
laboratory confirmation, but are not comprehensive.
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In most country-years (103 of 195), no single predominant etiology for meningitis could be
identified. However, more than 100 districts across 27 country-years reported enough suspected
cases of meningitis to exceed the definitional threshold for a bacterial meningitis outbreak. This
suggests that multiple serogroups of meningococci or pneumococci coexist simultaneously and
at least cause sporadic cases. It is not uncommon for multiple pathogens to cause separate
outbreaks in different regions of a single country.21,142 However, the extent to which “mixed”
outbreaks occur - i.e. a single outbreak in a relatively small community (on the scale of a district)
caused simultaneously by two pathogens - is debated.143 Expanded case-based surveillance could
help to answer this question.144 The limited national-level data available now is insufficient to
explore heterogeneity within smaller communities.
All the suspected cases in the database used in this chapter are identified based on a specific
set of symptoms which are typical of meningitis: fever, neck stiffness, convulsion, headache,
nausea, vomiting, photophobia.34 The decision to report a case of suspected meningitis is made
by the local health care professional, and no data on specific symptoms are included in the
available data. Surveillance of invasive meningococcal disease in the African meningitis belt has
historically focused on signs of meningitis: data on the frequency of alternative presentations,
including meningococcemia, arthritis, cutaneous vasculitis, conjunctivitis, and gastrointestinal
symptoms, are lacking. In the United States and Europe, about 40-50% of cases present as
meningitis. There is some limited evidence that this proportion is higher in the meningitis
belt.145 Presentation may depend on serogroup, with serogroup A manifesting more frequently
as meningitis and serogroups C, W, and X as non-meningeal disease.145–147 This narrow case
definition may result in cases of meningococcal disease being missed, particularly in time periods
and regions where non-group-A meningococci are prevalent.
Coverage of MenAfriVac mass campaigns has generally been high, with estimates greater
than 89% in 12 of 14 countries (Benin,Burkina Faso, Central African Republic, the Gambia,
Ghana, Guinea, Mali, Niger, Senegal, Sudan, Togo, and Uganda).148 Despite lower coverage
estimates in Cameroon (74%) and Nigeria (70%), the impact of MenAfriVac on incidence of
suspected meningitis in these regions is still dramatic.
Stratifying by country, year, or etiology can be misleading if other factors are not considered.
For example, NmC outbreaks appear more uncommon when measured as the percentage of
districts reaching the outbreak threshold because NmC emerged in Nigeria, a large country with
many districts and only half of its territory lying within the meningitis belt. Over time, more
countries have joined the surveillance system, many of which only have a proportion of their
territory inside the meningitis belt. This can create the illusion that the incidence of meningitis
has decreased more dramatically in recent years than it actually has.
The past decade has been a dynamic period for bacterial meningitis in Africa. The introduc-
tion of MenAfriVac has resulted in decreased incidence of suspected cases and outbreaks and has
galvanised investment in national meningitis surveillance systems. This analysis is the largest
study of meningitis in Africa at the district level. Although it is limited by the inadequacies of
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the data produced by an aggregated syndromic surveillance system with limited microbiological
confirmation, it represents a good starting point for thinking about what has changed since the
introduction of MenAfriVac and what challenges still remain. NmA caused outbreaks more
frequently in the pre-MenAfriVac era than do NmC, W, or S. pneumoniae, but the intensity of
outbreaks where and when they do occur appears to be the same, whether caused by NmA, C,
W, or S. pneumoniae.

Chapter 4
Modelling reactive vaccination for pneumococ-
cal meningitis outbreaks in the African menin-
gitis belt
The immediate impetus for this work was a request from the Ghana Health Service to
the WHO Department of Pandemic and Epidemic Diseases for assistance in responding to
an outbreak of bacterial meningitis that met the incidence-based criteria for a meningococcal
epidemic but appeared to be caused by a pneumococcal strain. It was undertaken in collaboration
with James Stuart from the London School of Hygiene & Tropical Medicine, Olivier Ronveaux
and Katya Fernandez from the Department of Pandemic and Epidemic Diseases at the World
Health Organization,Charles Okot from the World Health Organization Country Office Ghana,
Franklin Asiedu-Bekoe from the Brong-Ahafo Regional Health Directorate, and my supervisor
Caroline Trotter. A version of this work is in published in Vaccine (see Appendix A). Charles
Okot and Franklin Asiedu-Bekoe provided access to the surveillance data used in this analysis.
Olivier Ronveaux and Katya Fernandez provided policy guidance to inform the conceptualisation.
Caroline Trotter and James Stuart provided guidance in the structuring and interpretation of
results. I performed the data curation, model design, formal analysis, implementation of the
code, and prepared the original draft. All authors participated in review and editing of the final
manuscript.
4.1 Introduction
With the decrease in group A meningococcal disease and increase in surveillance quality
that has accompanied the rollout of the group A conjugate vaccine, MenAfriVac, it has become
increasingly clear that pneumococcal meningitis represents a substantial proportion of the
burden of bacterial meningitis in the African meningitis belt. A growing body of evidence
indicates the ability of S. pneumoniae to cause outbreaks of meningitis characterised by strong
seasonality, broad host range, and clonality.21,61,62
68 Reactive pneumococcal vaccination
The introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into Ghana’s routine
immunisation programme in 2013 has significantly decreased the burden of invasive pneumococcal
disease in children under five, but appears to have not yet been able to induce herd immunity in
the broader population.149 An outbreak of predominantly serotype 1 pneumococcal meningitis
in the Brong-Ahafo region of Northern Ghana in late 2015 and early 2016 demonstrated the
ongoing vulnerability of older age groups and the clear potential of S. pneumoniae to cause
outbreaks of meningitis in the African meningitis belt.21
Under the current WHO guidelines for meningococcal meningitis outbreaks, an epidemic
response is triggered when districts exceed an incidence threshold of 10 suspected cases per
100,000 population.34 As part of this response, countries may apply to the International Coordi-
nating Group (ICG) on Vaccine Provision for Epidemic Meningitis Control for meningococcal
vaccine to deliver in mass campaigns in affected districts. The aim of this chapter is to explore
whether a similar mechanism may be appropriate for responding to outbreaks of pneumococcal
meningitis. First, I calculate the sensitivity and specificity of different incidence thresholds
for predicting high cumulative incidence of suspected pneumococcal meningitis. Then, using a
static model like the ones described in Section 2.4.1, I estimate the potential impact of a mass
vaccination response to the 2015-2016 pneumococcal meningitis outbreak in Brong-Ahafo. I then
reflect on the generalisability of these results and whether the protocols currently recommended
by the WHO in response to meningococcal outbreaks should be expanded to include pneumo-
coccal outbreaks as well. I have further reviewed surveillance studies of the epidemiology of
pneumococcal meningitis in the meningitis belt in order to contextualise the following analysis,
which relies on data from a single outbreak (see Section 2.5).
4.2 Methods
Line list data on suspected cases of meningitis reported in the Brong-Ahafo Region between
2 December 2015 (week 49, 2015) and 11 April 2016 (week 15, 2016) was obtained from the
Ghana Health Service via the WHO. I determined the sensitivity and specificity of a range of
incidence thresholds (10, 7, 5, and 3 suspected cases per 100,000 per week) for predicting a
range of sizes of outbreaks (20, 40, 60, 80, and 100 cumulative cases per 100,000) in order to
choose the optimal threshold for triggering reactive vaccination.
As a variety of laboratory tests were used for case confirmation, likely etiology was inferred
according to Table 4.1. In a large proportion of cases (60%), etiology could not be determined.
For this reason, cases of pneumococcal meningitis were modelled as
CSpn,i = CS,i(1 − pn)ν
where CS,i is the number of suspected cases reported in week i, pn is the proportion of CSF
samples in the district testing negative, and ν is the proportion of all confirmed cases in the
district caused by S. pneumoniae.
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Table 4.1 Classification of case etiology.
Classification Criteria
Spn Any test (Pastorex, culture or PCR) indicating Spn or positive gram stain
Nm Any test (Pastorex, culture or PCR) indicating Nm or negative gram stain
Negative Two or more tests (Pastorex, culture, PCR or gram stain) failing to indicate bacteria in CSF
Indeterminate Any sample not fulfilling any of the above 3 criteria
I then modelled reactive vaccination of 5- to 29-year-olds building on methods developed in
an earlier paper,89 using a threshold of 10 suspected cases per 100,000 per week, the threshold
which I found had the highest specificity. Five- to 29-year-olds were targeted because this would
effectively extend coverage to all individuals under 30 years of age (individuals under 5 are
eligible for three doses of PCV13 under the new vaccine schedule in Ghana). The following
additional assumptions were made: i) 5- to 29-year-olds represent 52% of the population;150
ii) the case fatality ratio for pneumococcal meningitis cases is 23%, as reported for confirmed
pneumococcal meningitis cases in this data set; iii) 70% of confirmed cases of pneumococcal
meningitis occurred in the 5- to 29-year age group; iv) 84% of cases of pneumococcal meningitis
were caused by PCV13 vaccine-type serotypes;21 v) 5% vaccine wastage.
In a clinical trial, 10- to 18-year-old children having never received a pneumococcal vaccine
were given PCV13 and their opsonic pneumococcal activity (OPA) titres against each vaccine
serotype tested one month post-vaccination. The lowest seroconversion rate was 94.5% for
ST5 (95% CI 90.2 - 97.3).151 On this basis, I made the additional assumption that reactive
vaccination (a single dose of PCV13) would protect at least 90% of individuals 5 to 29 years of
age against PCV13 vaccine-type serotypes, giving two weeks for immunological protection to
take effect.
In the model, I calculate the cases of pneumococcal meningitis averted by vaccination
(Caverted) as a function of the modeled cases over time (CSpn,i), the proportion of cases occurring
in the 5- to 29-year age group (a), the proportion of cases caused by PCV13 vaccine-type
serotypes (σ), the individual efficacy of a single dose of PCV13 (ϵ), the week the incidence
threshold is exceeded (it), the delay to implementing a campaign (d), vaccine wastage (w), and





The number of deaths averted is calculated as the product of the case fatality ratio (CFR)
and the total cases averted.
The number of doses of vaccine (D) is calculated as
D = αP
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where α is the proportion of the population between 5 and 29 years of age, and P is the
total population size of the districts where vaccination occurs.
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Fig. 4.1 Negative predictive value (NPV), positive predictive value (PPV), sensitivity, and specificity of various
incidence thresholds (3, 5, 7, and 10 suspected cases per 100,000 per week) for predicting a range of sizes of
outbreaks.
I determined the cases averted, deaths averted, number needed to vaccinate to prevent a
case (NNV) and number needed to vaccinate to prevent a death (NNVD) for three scenarios:
where vaccination occurs immediately, two, or four weeks after crossing the epidemic threshold
(delay of zero, two or four weeks, respectively). In the base case, a delay of 2 weeks is assumed.
As a sensitivity analysis, I repeated the modelling process 10,000 times, resampling following
parameters: ρ, ν, a , ϵ, σ, w, α, and CFR (shown in Table 7.4).
Table 4.2 Variables included in sensitivity analysis.
Variable Meaning Base Distribution
ρ Proportion of CSF samples testing negative Variable Binomial
ν Proportion of confirmed cases caused by S. pneumoniae Variable Binomial
a Proportion of cases in 5- to 29-year age group 71% Binomial(p=0.71, size=119)
ϵ Individual efficacy of PCV13 90% Uniform(80%, 100%)
σ Proportion of cases caused by PCV13 serotypes 84% Binomial(p=0.84, size=49)
w Vaccine wastage 5% Uniform(0%, 10%)
α Proportion of population in 5- to 29-year age group 52% Uniform(40%, 60%)
CFR Case fatality ratio 23% Binomial(p=0.23, size=168)
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4.3 Results
Twenty of the 27 districts of the Brong-Ahafo Region were represented in the line list. Nine of
these had cumulative incidence greater than 20 suspected cases per 100,000; five had cumulative
incidence greater than 40 per 100,000; four had cumulative incidence greater than 80 per 100,000,
and three had cumulative incidence greater than 100 per 100,000 (see Figure 4.1). For predicting
larger epidemics of 60 cases per 100,000 and greater, all thresholds had a sensitivity and negative
predictive value of 100%, but a threshold of 10 per 100,000 had the highest positive predictive
values and specificity.
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Fig. 4.2 Incidence of suspected, modelled likely, and confirmed pneumococcal meningitis in five districts crossing
the epidemic threshold of 10 cases per 100,000. Transparent ribbon shows 2.5th and 97.5th percentile of
bootstrapped modelled pneumococcal meningitis incidence.
In six districts (Jaman North, Nkoranza South, Sene West, Tain, Techiman North, and
Wenchi), suspected meningitis incidence exceeded the epidemic threshold of 10 cases per 100,000
per week. In three of six of these, cumulative incidence exceeded 100 cases per 100,000 (see
Figure 4.2). One district, Sene West, was excluded from the reactive vaccination simulation as
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the majority of confirmed cases were caused by NmW. Another district, Jaman North, had a
particularly low confirmation rate (132 of 178 samples of cerebrospinal fluid tested negative for
any pathogens by two or more laboratory tests) but was still included in the analysis as the
majority of cases that were confirmed were caused by S. pneumoniae (39 of 46).
Vaccinating individuals between 5 and 29 years of age in the five eligible districts would have
required approximately 284,000 doses of vaccine. Figure 4.3 shows modelled incidence with and
without reactive vaccination with delays of 0, 2, and 4 weeks. If the campaign were implemented
within two weeks of exceeding the epidemic incidence threshold, 59 cases of an estimated 328
likely pneumococcal meningitis cases occurring in the five eligible districts during the epidemic
period would have been prevented as a result of direct protection from vaccination, placing the
number needed to vaccinate to prevent a case at 4 830 (see Table 4.3). A delay of four weeks
roughly halves the number of cases prevented, whereas immediate action roughly doubles it.






































Fig. 4.3 Incidence of modelled pneumococcal meningitis with and without reactive vaccination with a delay of 0,
2 and 4 weeks. Transparent ribbon shows 2.5th and 97.5th percentile of bootstrapped modelled incidence.
4.4 Discussion 73
Table 4.3 Cases and deaths prevented by direct protection from reactive vaccination with different times to
implementation. Numbers in parentheses show 2.5th and 97.5th percentiles of sensitivity analysis.
Delay Cases Proportion of cases Deaths NNV NNVD
0 106 (88 - 140) 32% (27 - 41%) 25 (18 - 36) 2670 (1560 - 2980) 11500 (6150 - 14500)
2 59 (48 - 79) 18% (15 - 23%) 14 (10 - 20) 4830 (2780 - 5390) 20800 (11000 - 26400)
4 28 (22 - 38) 9% (7 - 11%) 7 (4 - 10) 10100 (5840 - 11800) 43300 (23300 - 57400)
4.4 Discussion
An incidence threshold of 10 cases per 100,000 per week seems most appropriate given the
limited data available. This threshold would also have been triggered in four of five previous
likely outbreaks of pneumococcal meningitis (Solenzo, Burkina Faso, 2009; Goundi, Chad, 2009;
Karangasso Vigue, Burkina Faso, 2011; Pama, Burkina Faso, 2011) and is consistent with the
current meningococcal outbreak threshold.34 Chapter 3 demonstrated that S. pneumoniae is an
important cause of outbreaks and sporadic cases of bacterial meningitis in the African meningitis
belt. S. pneumoniae predominated in 22 country-years, more than any other cause. In these
years, 17 districts exceeded the weekly incidence threshold of 10 suspected cases per 100,000,
and 9 of these exceeded cumulative incidence of 100 cases per 100,000. No attempt was made
to evaluate different microbiological criteria for defining a pneumococcal outbreak. In this case,
a simple majority of confirmed cases was required. There is still a need for improved laboratory
confirmation of suspected cases of pneumococcal meningitis. This would allow for evaluation of
more specific microbiological criteria.
The number needed to vaccinate to prevent a case (NNV) is within the range of previous
estimates for reactive meningococcal campaigns (3,700 to 11,600 for 2 to 4 week lag).89 This
analysis suggests that reactive vaccination for pneumococcal meningitis outbreaks may be as ef-
fective as current practice for meningococcal meningitis outbreaks. Although the number needed
to vaccinate to prevent a death (NNVD) has not been estimated for reactive meningococcal
campaigns, the NNVD for pneumococcal outbreaks is likely lower given the high case-fatality
rates typically associated with pneumococcal meningitis.152
It is not clear how quickly immune response would build up after PCV13 in the targeted
age groups, however, a clinical trial of naive 10- to 18-year-olds showed high (>90%) serum
bactericidal activity one month post-vaccination.151 The model presented here only estimates
cases prevented as a result of direct protection from the vaccine. A conjugate vaccine will
have additional indirect benefits, decreasing carriage and transmission of vaccine-type serotypes
where it is used. A dynamic SIR-type model could provide an upper estimate of the impact of
reactive vaccination with a conjugate vaccine. Ferrari and colleagues compared two models, a
Pinner-type model like the one used here that assumes that all cases in the epidemic are the
result of asymptomatic carriers progressing to invasive disease and a dynamic time-series SIR
model that assumes all cases are the result of carriage transmission.95 They found that under the
SIR model more than twice as many cases were prevented by vaccine. It is not clear how much
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increased transmission during the epidemic contributes to incidence of invasive disease and to
what extent cases are simply triggered by environmental effects like increased temperature and
dust that increase the risk of invasive disease in existing carriers. These two models represent
two extremes in potential models of the outbreak process. Perhaps more importantly, mass
PCV vaccination would have a very large impact on the burden of pneumococcal pneumonia
and meningitis in following years.
Serotype 1 was predominant in this outbreak. Seven other studies in the meningitis belt have
reported serotype distribution of pneumococcal meningitis cases, all in populations with no PCV
use.32,60,62,65,109,111,153 Overall, 45% were serotype 1. Kwambana-Adams and colleagues report a
higher proportion of isolates belonging to serotype 1 (67%) in the outbreak described here than
in other studies.21 Among the other studies, there are no marked differences between settings
described as “epidemic” or “outbreak” and endemic settings. There are no appropriate data
available to support or contradict the hypothesis that outbreaks of pneumococcal meningitis
tend to be caused by a single serotype because most serotyping data is published as aggregate
data over many years.
This model may be more conservative than the model used to evaluate reactive meningococcal
vaccination, which had access to less detailed microbiological and age-specific data because
of its broad scope.89 Whereas the meningococcal outbreak model assumed all cases occurred
in individuals under 30, this model assumes that only 70% of cases occur in the targeted age
group. The meningococcal model also assumed that 79% of suspected cases were caused by N.
meningitidis W, whereas this one estimates that on average only 49% of suspected cases during
the outbreak were caused by S. pneumoniae. For these reasons, this analysis may underestimate
the impact of reactive vaccination for pneumococcal outbreaks relative to meningococcal.
The very high suspected incidence in Jaman North was due to an error in reporting that
resulted in a large number of probable malaria cases being reported as suspected meningitis
(personal communication, WHO). I decided to keep the district in the analysis because there
was still a high number of confirmed pneumococcal meningitis cases and the modelling methods
adjust for this inaccuracy in reporting.
This analysis assumes no under-reporting in order to maintain consistency with previous
studies and because there is already a large amount of uncertainty in the model of likely
pneumococcal meningitis cases. However, a study from Northern Nigeria suggests that under-
reporting of suspected cases is substantial and variable by ward.95
The predictions of this model are dependent on the age distribution of cases, the proportion
of cases caused by S. pneumoniae, and the shape of the epidemic curve over time. For example,
in this outbreak, 14% of suspected cases occurred within four weeks of triggering epidemic
response – in other words, 14% of suspected cases would be missed by a response with a lag of
two weeks. More suspected cases occurred in the first four weeks of past suspected pneumococcal
meningitis outbreaks: 18% in Goundi, Chad in 2009, 28% in Karangasso Vigue, Burkina Faso in
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2011, 21% in Pama, Burkina Faso in 2011 and 38% in Solenzo, Burkina Faso in 2009.34 Reactive
vaccination would have had lower impact in these outbreaks.
Our estimates, based on data from the Brong-Ahafo outbreak, suggest that reactive vaccina-
tion for pneumococcal meningitis would have prevented fewer cases per dose of vaccine than
previous estimates for meningococcal meningitis reactive vaccination, a routine practice in the
African meningitis belt. As the size and duration of outbreaks are likely to vary by country
and by year, data from future outbreaks are needed to refine these estimates. Nonetheless, this
analysis shows that in this particular case, reactive vaccination for pneumococcal meningitis is
about as effective as reactive vaccination for meningococcal meningitis, something that is done
every year in the African meningitis belt.
It is clear that any reactive response must be timely in order for it to be effective. A
particular challenge for timeliness is microbiological confirmation of a reasonable number of
cases and serotyping of pneumococcal isolates to determine whether the outbreak is caused by a
vaccine-type strain. In the case of Brong-Ahafo, resources for serotyping were limited and no
districts had confirmed the serotype of any samples at the time that incidence exceeded the
epidemic threshold. On the positive side, PCV may be more readily available than the vaccines
used in reactive meningococcal campaigns because it is used in many meningitis belt countries
as part of the routine immunisation programme.
This chapter helps to address some of the knowledge gaps identified in the Meningitis 2030
Roadmap around pneumococcal outbreaks and assesses the utility of reactive vaccination in
achieving the two aims of eliminating meningitis epidemics and substantially reducing cases
and deaths from vaccine-preventable meningitis.6 Even with an instantaneous response, reactive
vaccination in this situation would only have prevented 32% of pneumococcal meningitis cases
and deaths, and a reactive strategy cannot, by definition, eliminate outbreaks of pneumococcal
meningitis.
Reactive vaccination is not a substitute for figuring out how best to achieve indirect protection
of older age groups by routine vaccination, and if implemented, should not direct resources away
from routine vaccination. A WHO expert committee is now considering whether a different
routine vaccination schedule with a booster at 18 months (2 + 1) would be more appropriate for
this setting.149 It has been shown in high-income countries that routine immunisation with PCV
provides indirect protection to older children and adults and that this is accelerated with the use
of catch-up campaigns. There is less evidence regarding the scale of indirect effects from PCVs
in African countries. Pneumococcal meningitis affects a broader age range of individuals in the
African meningitis belt than in high-income countries. There is also evidence that climactic
conditions particular to the meningitis belt increase the risk of invasive pneumococcal disease.38
The only country to show indirect benefit without a catch up campaign in older children
(South Africa) used a 2 + 1 schedule.154 This chapter only considers reactive vaccination as
a short-term response to meningitis outbreaks in older age groups not protected by routine
vaccination. Finally, it is important to consider that meningitis accounts for only about 1% of
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severe cases of pneumococcal disease and 12% of deaths due to pneumococcal infection.8 The
optimal vaccination schedule should take into account the overall burden of disease, including
pneumonia.
Chapter 5
Meningococcal carriage prevalence in the African
meningitis belt by age: a systematic review and
meta-analysis
This work was undertaken in collaboration with Paul A. Kristiansen, Hannah Christensen,
Andromachi Karachaliou, and Caroline L. Trotter. Paul Kristiansen shared data from carriage
studies undertaken in Burkina Faso. Andromachi Karachaliou duplicated the systematic review
and data entry. Hannah Christensen provided guidance on the statistical methodology used in
the meta-analysis. A version of this work excluding sections 5.3.2.1, 5.3.2.2, and 5.3.2.3 has been
published in Epidemiology and Infection (see Appendix A). I led the systematic review, data
analysis, and drafting of the manuscript. All authors contributed to editing the final manuscript.
I would like to further acknowledge Nicole Basta, Judith Mueller, Ryan Novak, Gerd Pluschke,
and Pratima Raghunathan for information on previously published work included in this meta-
analysis, and the MenAfriCar Consortium for providing additional unpublished data. I also
thank Brian Greenwood for his thoughtful comments on the manuscript.
5.1 Introduction
Most transmission of Neisseria meningitidis occurs amongst carriers, therefore targeting
carriers is the only way to generate herd protection. Experience with conjugate vaccines
has shown that with the correct age-specific strategy, such indirect effects make a profound
contribution to disease control.70 To this end, it is important to understand the distribution
of meningococcal carriage to allow for efficient targeting of individuals who account for the
most transmission. The age distribution of meningococcal carriers in high income countries has
been described and synthesised; this showed that prevalence peaks around 19 years of age.24
Patterns of carriage are however known to differ in the African meningitis belt, a region that
experiences the highest burden of meningococcal disease in the world. Here, meningococcal
carriage is a relatively common occurrence compared to invasive disease, although population
overall prevalence is highly variable, ranging from 0% to 30%.23,24 Although the distribution of
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carriage prevalence by age also appears more variable in the African meningitis belt than in
high-income countries, some studies have shown that carriage is most prevalent in children.23
Studies of meningococcal carriage in the African meningitis belt have identified a number
of risk factors apart from age. A multi-site cross-sectional study found increased odds of
meningococcal carriage in rural areas versus urban, and higher prevalence in males.40 Household
crowding and pollution from tobacco and indoor kitchen facilities also increased the odds of
carriage significantly.40 The association between respiratory infection and meningococcal carriage
remains unclear, but some studies indicate a positive relationship between carriage acquisition
and symptoms of respiratory disease, like sore throat or rhinitis.127 Localised epidemics of
meningococcal meningitis occur frequently in the belt, but there is no clear relationship between
epidemic status and the prevalence of carriage. One study found higher rates of serogroup
W carriage in a district experiencing a group W epidemic compared to a neighbouring non-
epidemic district, prompting speculation that it may be dominance of a strain rather than
overall prevalence that links carriage and epidemics.155
Season may complicate the relationship between age and carriage. Meningitis epidemics in the
meningitis belt occur in the dry season and mathematical models of meningococcal transmission
dynamics currently require substantial seasonal forcing of transmission to reproduce the observed
patterns of disease.39 One carriage study found higher odds of carriage of capsular meningococci
during the dry season;40 this has not been demonstrated consistently but is compatible with the
idea that the capsule protects the bacterium from drying during aerosol transmission. Carriage
of unencapsulated strains does not appear to have any association with season.40
Previous reviews of the literature on meningococcal carriage in Africa have not been system-
atic in nature and have not examined age-specific patterns in any quantitative way. The aim of
this chapter is to conduct a systematic literature review of meningococcal carriage prevalence
by age and season in the African meningitis belt and to synthesize these data in order to inform
future vaccination strategies.
5.2 Methods
5.2.1 Search and study selection
This chapter was prepared in accordance with the meta-analysis of observational studies
in epidemiology (MOOSE) and preferred reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines.156,157 The literature searches were performed by one author
(LVC) in January 2017 and updated in September 2017. PubMed, Web of Science, the Cochrane
Library, and the grey literature were searched for papers reporting carriage of N. meningitidis
in defined age groups in locations within the African meningitis belt, using the following search
terms: “(“Neisseria meningitidis” OR “N meningitidis” OR meningitis OR meningococcal OR
meningococci OR meningococcus OR meningitidis) AND (carriage OR carrier OR carriers)
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AND (Africa OR “meningitis belt” OR Gambia OR Senegal OR Guinea-Bissau OR Mauritania
OR Guinea OR Ghana OR “Burkina Faso” OR “Upper Volta” OR “Cote d’Ivoire” OR “Ivory
Coast” OR Togo OR Benin OR Nigeria OR Niger OR Chad OR Tchad OR Cameroon OR
“Central African Republic” OR Sudan OR “South Sudan” OR Eritrea OR Ethiopia OR Uganda
OR Kenya OR “Democratic Republic of Congo” OR Zaire)”.
Studies were eligible for inclusion if they reported pharyngeal carriage of all meningococcal
serogroups in defined age groups in generalisable populations in the African meningitis belt.
Longitudinal, cross-sectional, and serial cross-sectional study designs were included. Studies
reporting carriage rates among household contacts of Hajjis or other known carriers were
excluded. Studies in both English and French were included in the systematic review. Two
studies in Russian were excluded because abstracts could not be obtained. The reference lists of
included papers were hand-searched to identify any papers that were missed by the electronic
search. Details of the search process are given in Figure 5.1.
5.2.2 Data extraction and classification
Authors were contacted for additional information if studies reported age groups wider than
10 years and the median age was not reported or if the time period of the study was not reported.
Where carriage prevalence was reported in age groups of range 10 years or less, the midpoint
age was used. For open-ended age groups, the midpoint was calculated with an upper age
limit of 60 years. Using additional data from the African Meningococcal Carriage Consortium
cross-sectional studies, the oldest age group previously reported as 30 plus years was divided
into two groups, 30 to 44 years and 45 plus years.
For papers that included results from several populations or studies, data were extracted
only for observations meeting the inclusion criteria. Extracted data included the study location,
time period, design, any mention of an outbreak or epidemic of meningitis coinciding with the
study period, whether the study occurred before or after the MenAfriVac mass campaigns in the
study region, use of random sampling, laboratory used to culture the pharyngeal swabs, time
between sampling and plating, age range of the individuals, median age of individuals in each
age group, number of individuals swabbed, and the number of individuals positive for capsulated
meningococcal carriage. Capsule-null isolates were excluded from our definition of capsulated
meningococcal carriage, but isolates characterised as non-determinate or non-groupable were
included.
Studies were assigned to the dry or rainy season on the basis of the month in which the
study took place, defining the dry season as December to June and the rainy season as July to
November. Disaggregated data from the studies by Kristiansen and colleagues in Burkina Faso
and Ethiopia were used to divide prevalence estimates from these studies into dry and rainy
season measures. Studies were classified as having used random sampling if this was specifically
reported; otherwise “no” was recorded. Data were extracted independently by LVC and AK,
and differences were checked by CLT.
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5.2.3 Data analysis
For the meta-analysis, data from age groups wider than 20 years were excluded. For
longitudinal studies, only the first observation in the time series was used to avoid over-
representing a particular population in the meta-analysis.
A natural cubic spline (a piecewise cubic polynomial function with linear tails) was used to
model group median age.24,158 The basis matrix for the spline was generated using the “ns()”
function in the R core package “splines”. Boundary knots (points in the spline below and above
which the function is defined to be linear) in the spline were placed at zero and thirty years
because of the low density of sampling in older age groups. The number of internal knots was
selected by comparing the Akaike information criterion (AIC) of models with two and three
internal knots, placing knots at appropriate quantiles (inner tertiles for two knots, inner quartiles
for three knots. Optimal placement of these knots was determined by evaluating the AIC of
models with every possible combination of knots drawn from the set of ages equidistant from
every consecutive observed age between zero and 30 years. Internal knots placed at 9.25, 9.75,
and 28.5 years of age gave the best model fit.
Season and outbreak status were modelled as a three-tiered fixed effect and a nested
interaction term of location and year of swabbing as random effects. I used a fixed effects term
for season and outbreak status because I wanted to estimate the overall impact of season across
the whole data set and because I wanted to be able to test whether the groups were significantly
different by comparing confidence intervals. I used random effects terms for location and year
because there were more than ten different locations and years in the data set and these were
factors for which only a subset of all possible levels had been observed. Physical laboratory
was tested as a proxy for differences in ambient temperature, growth medium, swab type, and
other unreported factors which might affect the likelihood of isolating meningococci from a
sample, but this did not improve model fit. Other factors that were considered but did not
improve model fit included mass group A conjugate vaccination, country, decade, latitude, time
to plating, and study.
I started with a simple logistic regression because this is the traditional model for analysing
prevalence data. However, when I found that a low proportion of observations fell within the
bootstrapped 95% CI, I investigated three additional models which are commonly used to capture
overdispersion: an observation-level random effects model, a beta-binomial or hierarchical model,
and a zero-inflated binomial model.159 The simple logistic regression captured more of the
variability in the data than the observation-level random effects model and provided a better fit
than the beta-binomial and zero-inflated binomial models, so I kept a logistic structure for the
final model.
All candidate models allow overall carriage prevalence to vary but constrain the distribution
of prevalence by age to be the same across all years and locations.
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Models were fit using the lme4, spaMM and glmmADMB packages in R.160–163 All of these
packages use maximum likelihood methods to fit different families of regressions (binomial,
beta-binomial, zero-inflated binomial). To generate confidence intervals for the model predictions
and random effects, 10 000 iterations of bootstrapping with replacement were performed, and
bias-corrected 95% confidence intervals were calculated.164 Profile confidence intervals for fixed
effects parameters were calculated using the “lme4” package.160 Goodness of fit was measured
by AIC and by performing leave-one-out cross-validation, whereby the model is refit on the
full data set excluding a single observation and this new model is used to predict prevalence in
the excluded observation. This prediction is then compared to the true value. To check the
results of the spline model, I identified the age group with the highest carriage prevalence for
each study measuring carriage in more than one age group and performed a one-way proportion
test between this peak value and prevalence in all other age groups. To adjust for repeated
significance testing, a p-value cut-off of 0.0005 was used, yielding an overall confidence of greater
than 95%.
For the visual presentation of the fixed effects portion of the model, the observed carriage
prevalence (Pobserved) was adjusted to account for the random effects in the full model as follows:
Padjusted = exp(log(Pobserved) − σLocation − σLocation−year), where σLocation and σLocation−year are
the random effects intercepts for location and year for a given observation.
To estimate the proportion of carriers that would be targeted in a mass vaccination campaign
covering four age groups (0 to 15 years, 0 to 17 years, 0 to 19 years, and 0 to 29 years) I assumed a
population structure consistent with that of Niger in 2017 and used the fitted estimate of carriage
prevalence for the rainy season (although results are consistent across seasons).150 Uncertainty
in this estimate was measured by simulating 100,000 draws from a uniform distribution with
boundaries at the 2.5th and 97.5th percentile of the fitted prevalence, using these draws as the
rates for a random binomial draw with population size corresponding to each single year age
cohort in Niger 2017, and then taking the 2.5th and 97.5th percentiles of the proportion covered
to yield a 95% confidence interval.
5.2.4 Assessment of study quality and heterogeneity
The role of study design was assessed by comparing a model with and without sampling
procedure (random vs. non-random) and with and without time to plating of swabs as fixed
effect variables.
Ten of 16 studies included in the meta-analysis reported carriage in more than two age
groups (the minimum number of points required to fit a spline). To investigate the heterogeneity
between these 10 studies in trends related to age and season, the final mixed effects model was
fit using subsets of the overall data from each study. The overall model is a mixed effects model
with random effects for location and year and some studies encompassed multiple locations or
years, so three different approaches were compared for the individual study fits. First, mixed
effects models were fit where appropriate (where more than one location or year is reported),
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using the best fit knots from the overall analysis. Second, fixed effects only models were fit
for all studies, again using the best fit knots from the overall analysis. Third, mixed effects
models were fit where appropriate but with internal knots at the 25%, 50%, and 75% percentiles
of median age for each data subset, hereafter referred to as “free knot” fits. Table 5.1 gives a
summary of the model construction for each study. In order to make fair comparisons, a fixed
effects model was fit on the overall data set.
Table 5.1 Summary of model construction for individual study fits.
Fixed effects Random effects
Model Age Season Location Location-year
Overall *** *** *** ***
Barnes 2016165 *** ***
Burian 1974166 ***
Forgor 2005167 ***
Kristiansen 201141 *** *** ***
Kristiansen 2013168 *** *** *** ***
Kristiansen 201473 *** ***
Leimkugel 2007169 ***
MenAfriCar 201540 *** *** *** ***
Mueller 2011170 ***
Trotter 2013171 ***
The odds ratios from these models for the dry versus rainy season measures were compared to
assess heterogeneity in season effects across studies. For the season heterogeneity analysis, four
studies reported carriage in both dry and rainy seasons and could thus be included: MenAfriCar
2015, Kristiansen 2011 and 2013, and Barnes 2016.40,41,165,168 No studies reported carriage
during both outbreak and non-outbreak periods, so heterogeneity with this respect could not
be assessed. I also compared the curve of carriage prevalence by age for each study and the
proportion of carriers under 16, 18, 20, and 30 years of age to show between-study variability
in age patterns. Finally, for both season- and age-related trends I compared the impact of
including random effects terms for location and location-year for those studies where more than
one location or year is reported (Kristiansen 2011, Kristiansen 2013, Kristiansen 2014, and
MenAfriCar 2015).41,73,165,168
5.2.5 Site-specific analysis
In order to validate some of the authors’ claims about the season and the urban or rural
character of study sites, I used global gridded data on population density to capture urbanicity
and data on precipitation and relative and specific humidity to capture seasonality. Geographic
areas of relevance were defined for each study using the following methods: where a map of
study site is given, this is digitised and the full extent taken; where latitude and longitude are
given, the study site is assumed to occupy a 2 kilometre radius circle around the study centre;
where only a place name is given, the GeoNames API is used to obtain coordinates for the
location and then a 2 kilometre radius circle is assumed as above.
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Data on population density are taken from the WorldPop Africa Continental Population
Datasets and give the estimated number of people per square kilometre for timepoints between
2000 and 2020 at five-year intervals.172,173 I use precipitation data from the National Oceanic and
Atmospheric Administration (NOAA) Precipitation Reconstruction over Land (PREC/L) and
the Climate Prediction Center Merged Analysis of Precipitation (CMAP) datasets and specific
humidity data from the National Centers for Atmospheric Prediction and the National Center for
Atmospheric Research (NCEP/NCAR) Reanalysis dataset.174–176 All three datasets are publicly
available and are provided by the NOAA on their website at https://www.esrl.noaa.gov/psd/.
Table 5.2 provides detailed information on the resolution, range, and units of the three gridded
datasets used in these analyses. For the climate analysis, I take the mean value of these measures
over the relevant time period reported for swabbing and over the area included in the study
locations. In the case of population density, I choose the measure at the closest point in time to
when swabbing is reported.
I then coded each of these variables categorically, using the median value for a cutoff to
distinguish low and high, and included these variables as fixed effects in a logistic regression,
adjusting separately for presence or absence of reported outbreak. I additionally compared
author reporting of urban versus rural sites with the mean population density given by WorldPop
for these sites and fit two log-normal density distributions to urban and rural observations to
determine a population density cutoff for urbanicity consistent with the literature. I then used
this cutoff to classify sites where the authors had not described the urban or rural character
of the sites and included this as a categorical variable in the logistic regression for carriage
prevalence.
I checked our season definition - studies assigned to the dry or rainy season on the basis of the
month in which the study took place, defining the dry season as December to June and the rainy
season as July to November - against average monthly rainfall and specific humidity anomalies
for the period 1981 to 2010 in each site (Figure C.3, Table 5.2) and against average rainfall and
humidity during swabbing periods (Figure 5.7) using publicly available data from the NOAA
described above. In a sensitivity analysis, I excluded data from four sites with non-characteristic
rainfall patterns. These sites all fell on the edges of the meningitis belt: Butajira, Ethiopia
(2 sub-sites), Arba Minch, Ethiopia (4 sub-sites), and Kpalkpalgbeni, Brong-Ahafo District,
Ghana.
5.2.6 Serogroup-specific analysis
As nearly all studies presented data on the serogroups or genogroups of carriage isolates, I
wished to analyse separately trends in carriage of NmA, NmW, NmX, and NmY by age and
season. I excluded NmB, NmC, and capsule-null from this type of analysis as these were very
rarely reported. I fitted the same logistic regression with a cubic spline of age, fixed effect of
season, and random effects from location and location-year that I used to model carriage of any
capsulated meningococci to data on carriage of NmA, NmW, NmX, and NmY and compared
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Table 5.2 Summary of gridded data.












































the central estimates from these models to one another and to the findings from the overall
model.
I also fitted a logistic regression with a cubic spline of age, fixed effect of season, and random
effects from location with an additional fixed effect of whether the study occurred before or
after mass introduction of MenAfriVac in the study location to assess the impact of group
A conjugate vaccination on NmA carriage. I dropped the location-year random effects term
because this resulted in singularities in the data because the MenAfriVac introduction term is
necessarily time-dependent.
5.3 Results
Twenty-three relevant articles were identified that reported unique studies of carriage by
age in generalisable populations in the African meningitis belt representing eight countries:
Burkina Faso, Chad, Ethiopia, Ghana, the Gambia, Mali, Nigeria, and Niger. Eleven were cross-
sectional studies; five serial cross-sectional, four longitudinal, and three were vaccine trials (two
polysaccharide and one conjugate vaccine). Twelve of 23 articles did not report randomisation in
participant selection. Sixteen studies were eligible for inclusion in the meta-analysis (Table C.1).
Seven of these sixteen did not report random sampling. Eighteen of 23 studies in the systematic
review and 15 of 16 eligible for inclusion in the meta-analysis reported information on the
serogroups or genogroups of the carriage isolates (Table 5.4). See Figure 5.1 and Tables C.2 and
C.3 for further details of search and reasons for exclusion.
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Fig. 5.1 Selection of studies on meningococcal carriage prevalence for systematic review and meta-analysis.
5.3.1 Systematic review
5.3.1.1 Longitudinal studies
Longitudinal studies reported high variation in carriage rates over time (1-35%), but no
significant differences in carriage prevalence between age groups.169,177–179 Prevalence recorded
around the time of meningococcal outbreaks was generally high in recent studies (2000s and
2010s), with two studies showing particularly high rates in ages 5 to 29 years (16-38%, Ta-
ble C.3).167,170,180 Two early studies (1970s) during a group A meningococcal outbreak found
lower rates of carriage (2-5%).181,182
5.3.1.2 Studies of seasonal change
Most studies which specified beginning and ending months for dry and rainy seasons placed
the beginning of the dry season between November and January and the beginning of the rainy
season between April and July. One study additionally defined a Harmattan season (October
to January) between the rainy and dry seasons.183 Early studies documented the variability
of carriage prevalence in the African meningitis belt but found little support for consistent
differences in prevalence by season. A year-long study in Burkina Faso found a wide variation in
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carriage rates but no significant changes associated with the onset of the rainy season.179 Two
other studies found similarly variable results with no obvious seasonal patterns.13,183 One study
in rural northern Nigeria displayed highly stable prevalence over the year, with carriage ranging
from 2.1% to 2.7% at four sampling intervals.13 These early studies may have been limited by
their relatively short duration or small sample sizes.
An eight-year longitudinal study of a cohort (n≈300) in Northern Ghana measured carriage
twice annually, in April (late dry season) and November (late rainy season). Although this
was not noted in associated publications, the average carriage rate in November (4.4%) was
substantially lower than that in April (7.9%).169 This was the first study to produce evidence
supporting the hypothesis that carriage prevalence increases during the dry season.
A multi-site serial cross-sectional study in Burkina Faso measuring carriage four times
annually in 2009 and 2011 found significantly higher carriage prevalence in dry season surveys
than in rainy.41,168 Finally, a serial cross-sectional study across seven countries of the meningitis
belt found significantly elevated odds of carriage during the dry season as compared with the
rainy (adjusted OR 1.54, 95% CI 1.37-1.75).40
5.3.1.3 Laboratory methods
All studies relied on culture for the initial identification of meningococcal isolates. Between
one and ten colonies were selected for further testing, most commonly serogrouping. Fourteen
of 23 studies (all published after 2000) reported using molecular methods for confirmation and
further characterisation of culture isolates. There was no clear difference in prevalence in studies
which used molecular methods versus those which did not.
5.3.2 Meta-analysis
Data from 16 papers, comprising 114,331 individual swabs, were available for quantitative
data synthesis.
The four model variants tested did not vary greatly in their parameter estimates and goodness
of fit (Table C.4). The logistic regression model was selected because the greatest proportion
of observations fell within the 95% confidence interval of bootstrapped predictions and the
leave-one-out cross-validation correlation was greatest for this model. This best-fitting model
had season as a fixed effect and location and year as random effects.
The fixed effects parameters of the final model are shown in Table 5.3. The model suggests
that meningococcal carriage prevalence in the African meningitis belt increases rapidly in
childhood, peaks at 10 years of age (1.9% in the rainy season, 95% CI 1.9-2.5%), and gradually
declines after this point (Figure 5.2). In a country with the same population structure as Niger,
our model estimates that 58% of carriers are under the age of 16 and 84% are under the age of
30 (Table 5.5). Odds of carriage were significantly increased for studies taking place during the
dry season (1.5 95% CI 1.4-1.7) as compared with the rainy season, and further increased for
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Fig. 5.2 Observed carriage prevalence measures and model predictions. Top panel: Circles show the data points
included in the meta-analysis, with the larger circles representing a larger sample size. Solid line shows model
predictions including random effects. Shaded ribbon shows 95% bias-corrected confidence intervals. Bottom
panel: Circles show the data points included in the meta-analysis, with carriage prevalence adjusted for random
effects intercept. Solid line shows model predictions excluding random effects. Shaded ribbon shows 95%
bias-corrected confidence intervals. Dry season predictions shown in red; rainy season in blue; outbreak in green.
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studies taking place during outbreaks (OR 6.7 95% CI 1.6-29), though the uncertainty in the
latter estimate is high as limited data on carriage during outbreaks are available. No other risk
factors were found to significantly impact the odds of carriage. Predicted carriage prevalence by
age is shown in Figure 5.2.
One-way proportion testing between peak reported carriage prevalence and prevalence in all
other age groups confirmed age-related trends, with four of 13 studies showing a peak in age
groups containing 10 years of age (the peak age identified by the spline regression model) and
the remaining nine showing no significant difference between peak prevalence and the prevalence
in the age group containing 10 years of age (Table C.5).
Predicted carriage prevalence was not significantly different when excluding data from sites
that were climactic outliers (Table 5.3, Figure C.2). Location and year contributed to substantial
variation in overall carriage rates. Random effects intercepts are given in Tables C.6 and C.7.
Figure C.1 shows model predictions including random effects. The variance for the location-year
interaction intercept was greater than that for the location intercept (1.02 versus 0.55). Neither
location nor year alone was a consistent determinant of the location-year intercept (Table C.7).
No years showed consistently low or high prevalence at all locations and no locations showed
consistently low or high prevalence at all years.
Shown in Figure 5.3, leave-one-out cross-validation predicted values were moderately cor-
related with true values (Pearson’s ρ 0.89). However, the median percent error for non-zero
values was substantial, 34%. The model performed poorly at predicting observations of 0%
carriage. More than half of all observations were outside the 95% confidence intervals for the
model predictions (64%).
Table 5.3 Fixed effects parameters. Predicted odds ratios and profile confidence intervals and median bootstrapped
odds ratios and 95% bootstrapped confidence intervals for fixed effects parameters from fit on full data set and
on data set excluding climactic outliers.











Spline I 3.4 (2.9-4.1) 3.5 (2.5-4.6) 3.6 (3-4.4) 3.7 (2.6-4.9)
Spline II 2 (1.6-2.4) 2 (1.5-2.9) 1.8 (1.4-2.2) 1.8 (1.3-2.6)
Spline III 5.2 (3.7-7.2) 4.9 (3-9.6) 4.9 (3.5-7.1) 4.7 (2.8-9.7)
Spline IV 0.79 (0.71-0.87) 0.79 (0.66-0.93) 0.7 (0.63-0.79) 0.71 (0.59-0.83)
Season
Rainy 1 1 1 1
Dry 1.5 (1.4-1.7) 1.5 (1.3-1.8) 1.6 (1.5-1.8) 1.6 (1.3-1.9)
Outbreak 6.7 (1.6-29) 7.9 (3.9-8.3) 4.9 (0.81-31) 5.7 (1.3-6.4)
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Fig. 5.3 Observed carriage prevalence and model predictions by leave-one-out cross-validation. A) Distribution
of model predictions for true zero observations. B) True prevalence and prevalence predicted by leave-one-out
cross-validation. Note the discontinuous scale to emphasize zero observations.
5.3.2.1 Study heterogeneity
Almost every study showed a significantly higher prevalence of carriage during the dry
season, but the magnitude of this effect ranged from OR 1.17 to 1.86 (see Table 5.6). One study,
MenAfriCar 2015, showed a strong opposite effect when fit with a mixed effects model (OR 0.51,
95% CI 0.28-0.86) but the trend was consistent with the others when fit with a fixed effects
model (OR 1.47, 95% CI 1.29-1.68). The fixed effects fit OR is very similar to that reported in
an earlier logistic regression analysis that took into account other risk factors.40 The prevalence
of carriage in the MenAfriCar study is lower in the 2010 dry season than in the 2010 rainy
season: 0.2% compared to 1.5% (see Table 5.7). In 2012, the prevalence of carriage is higher in
the dry season (2.9%) than in the rainy season (0%), but the sample size in the rainy season is
particularly small (n=304). The overall prevalence of carriage 2010-2012 is higher in the dry
season (2.4%) than in the rainy season (1.5%). Knot placement in the cubic spline did not make
a difference in the estimates of odds of carriage between the dry and rainy seasons.
The age spline model was fit to the 10 studies with three or more age groups reported. Even
where the knot placement was the same for each, the shape of the spline varied widely, especially
in studies with small sample size (Figure 5.4). The mixed effects and fixed effects models gave
similar estimates except in the cases where a large number of locations and years were sampled,
i.e. for MenAfriCar 2015 and for the overall fit. In these cases, the central model predictions
were substantially higher for the fixed effects only models than for the mixed effects models.
Notable differences in the shape of the curve of carriage by age were found for Forgor 2005,
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Table 5.4 Studies reporting serogroup distribution of N. meningitidis isolated from carriers in the African
meningitis belt. **Excluded from meta-analysis. *Climactic outliers excluded from meta-analysis in sensitivity
analysis. #Two group E and five group B carriers also reported. †Percentages do not sum to 100 because full
serogroup data not reported.
Study Year Prevalence of
carriage
Serogroup distribution
A C W X Y NG
Burian 1974166 1970 144/2569 (5.6%) 19% 1% ... 9% 4% 56%
Sanborn 1972184** † 1971 179/311 (57.6%) 52% ... ... ... ... ...
Blakebrough 1980181† 1977 7/130 (5.4%) 43% ... ... ... ... ...
Blakebrough 1983182† 1978 4/168 (2.4%) 50% ... ... ... ... ...
Leimkugel 2007169 1998 14/300 (4.7%) 57% ... 7% 0% 29% 7%
Raghunathan 2006155** 2002 203/899 (22.6%) 0% 1% 65% 6% ... 28%
Amadou-Hamidou 2006177 2003 38/287 (13.2%) 0% ... 34% ... 11% 55%
Forgor 2005167*† 2003 48/299 (16.1%) ... ... 71% ... ... ...
Yaro 2007178 2003 16/456 (3.5%) ... ... 50% 0% 0% 50%
Mueller 2011170 2006 129/615 (21%) 74% ... ... ... 26% ...
Sie 2008180** † 2006 24/180 (13%) 92% ... ... ... ... ...
Trotter 2013171 2008 12/1037 (1.2%) ... ... 25% 8% 42% 25%
Kristiansen 201141 2009 809/20326 (4%) 10% 0% 9% 11% 56% 13%
Kristiansen 2013168 2010 1643/25520 (6.4%) 0% 0% 6% 75% 13% 5%
MenAfriCar 201540* 2010 896/48405 (1.9%) 5% 3% 69% 2% 7% 11%
Kristiansen 201473 2012 390/4964 (7.9%) 0% 6% 87% 8% 3% 2%
Manigart 2016185# 2013 33/999 (3.3%) 0% 6% 33% 0% 9% 30%
Barnes 2016165* 2014 492/7479 (6.6%) 0% 1% 6% 14% 2% 76%
All meta-analysis 1970-2014 4703/114331 (4.1%) 5% 1% 26% 31% 17% 17%
Pre-MenAfriVac 1970-2014 2637/73202 (3.6%) 10% 2% 25% 9% 23% 27%
Post-MenAfriVac 2010-2012 2066/41129 (5.0%) <1% <1% 27% 59% 9% 4%
Table 5.5 Proportion of carriers under 60 years of age directly targeted by vaccination of different age groups.
Age group Proportion of carriers (95% CI)
Under 16 years 58% (57-60%)
Under 18 years 64% (63-65%)
Under 20 years 69% (62-74%)
Under 30 years 84% (82-84%)
Table 5.6 Odds ratios and 95% profile confidence intervals for carriage in dry season as compared to rainy season
for individual studies and overall data set using fixed effects models, mixed effects models (fixed and random
effects), and models with free internal knots for the cubic spline of age.
Model Fixed effects OR (95% CI) Mixed effects OR (95% CI) Free knots OR (95% CI)
Overall 1.23 (1.16-1.30) 1.55 (1.42-1.69) 1.55 (1.42-1.69)
Barnes 2016165 1.36 (1.11-1.66) ... 1.35 (1.11-1.66)
Kristiansen 201141 1.46 (1.27-1.69) 1.46 (1.27-1.69) 1.46 (1.26-1.69)
Kristiansen 2013168 1.17 (1.05-1.29) 1.86 (1.64-2.12) 1.86 (1.64-2.12)
MenAfriCar 201540 1.47 (1.29-1.68) 0.51 (0.28-0.86) 0.51 (0.28-0.86)
Trotter 2013, Mueller 2011, Kristiansen 2011, Kristiansen 2013, and MenAfriCar 2015 when
the model type was varied. For Forgor 2005 the fit is essentially degenerate using the best fit
knots, predicting carriage prevalence higher than 100% for some age groups. The same is true
for Trotter 2013 using the free knots. Although very low carriage prevalence was observed in
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Table 5.7 Meningococcal carriage prevalence in the MenAfriCar study40 by year and season.
Prevalence
Year Rainy Dry
2010 1.5% (n=13106) 0.2% (n=3882)
2011 1.6% (n=15910) -
2012 0.0% (n=304) 2.9% (n=15203)
Overall 1.5% (n=29320) 2.4% (n=19085)
Trotter 2013 and very high carriage prevalence was observed in Forgor 2005, both studies are
characterised by multiple sharp increases and decreases in carriage prevalence as you move
through age cohorts, which makes it difficult to fit a model of this relatively inflexible type.
Mueller 2011 Trotter 2013 Overall
Kristiansen 2013 Kristiansen 2014 Leimkugel 2007 MenAfriCar 2015
Barnes 2016 Burian 1974 Forgor 2005 Kristiansen 2011
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Fig. 5.4 Individual study model fits (lines) and prevalence observations (points). Rainy season predictions shown
in red; dry season in green; outbreak periods in blue.
Barnes 2016 and Kristiansen 2011 shows prevalence peaking around 20 years of age, whereas
Kristiansen 2013 and 2014 and MenAfriCar 2015 show peaks around 10 years. The overall
model shows a peak at 10.0 years with the mixed effects model, 9.2 years with the fixed effects
model, and 7.8 years with the free knots mixed effects model.
Taking each study fit independently, the estimates for the proportion of carriers which would
be targeted by vaccination of all individuals under 16 years of age ranged from 45% to 78%, for
under 18 years 45% to 84%, for under 20 years 46% to 89%, and for under 30 years 60% to 99%
(Figure 5.5).


























































































































































Fig. 5.5 Proportion of carriers under 16, 18, 20, and 30 years of age by model type. Black points indicate overall
meta-analysis estimate; coloured points and box plots indicate individual study estimates. Green and triangles
indicate fixed effects only model; red and circles indicate mixed effects model; blue and squares indicate free
knots model.
5.3.2.2 Site-specific analysis
In general, authors’ descriptions of sites as urban or rural were consistent with higher and
lower population density, respectively (see Figure 5.6). The log-normal mixture model fitted to
population density data placed the cutoff for urbanicity at greater than 1000 persons per square
kilometre (95% CI 470 - 3400). Urbanicity did not account for any significant differences in
carriage prevalence, either defined as the authors reported or defined using global gridded data




























































Fig. 5.6 Population density by site description and probability density function (log-normal) of population
density for sites described as urban and rural. Solid line shows central cut-off and dotted lines show upper and
lower bounds of cut-off.
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Our season definition placing the dry season between December and June was generally
consistent with rainfall and humidity patterns (Figure 5.7). Annual rainfall and humidity cycles
are not synchronised. Most sites show similar in climactic patterns, with three to four months
of heavy rains in June to September and a prolonged absence of rain from October to May,
punctuated by low humidity between November and April. 26 of 40 sites show negative humidity
anomalies between November and April, placing the onset of the dry season in November. 20 of
40 sites show positive rainfall anomalies between June and September, placing the onset of the
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Fig. 5.7 Mean daily rainfall and mean specific humidity by assigned season (Rainy season: December to June;
dry season: January to May).
Odds of carriage were increased by similar magnitude during the dry season when using
rainfall and specific humidity measures as proxy for season with an odds ratio of 1.7 (95% CI
1.6-1.9) for both low rainfall and low humidity periods (Table 5.8). Rainfall gave a better fit
by AIC, so this is presented in the formal comparison of season definition in Table 5.9. This
comparison found similar results to the original model which used a uniform season definition
with odds ratios of 1.5 (95% CI 1.4-1.7) compared to 1.7 (95% CI 1.6-1.9) for dry season measures
and 6.7 (95% CI 1.6-29) compared to 7.3 (95% CI 1.6-35) for outbreak measures, and profile
confidence intervals for these parameters overlapping in every case.
5.3.2.3 Serogroup-specific analysis
The seasonal fixed effects parameters of the serogroup-specific models are shown in Table 5.11.
Consistent with the main model of all capsulated meningococcal carriage, the four serogroup-
specific models for prevalence of NmA, NmW, NmX, and NmY suggest that meningococcal
carriage prevalence increases rapidly in childhood and peaks between 8 and 14 years of age, and
gradually declines after this point with the exception of a possible increase in NmY carriage in
older adults (Figure 5.8). The models predicted the earliest peak for NmA (8 years), followed
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Table 5.8 Single variable and multi-variable risk factor analysis for carriage of capsulated meningococcal carriage
with age and outbreak setting included as a priori variables.
Factor Single variable analysis Multi-variable model
Odds ratio (95% profile CI) Odds ratio (95% profile CI)
Natural cubic spline of age
Spline I 3.4 (2.9-4.1)
Spline II 2.0 (1.6-2.4)
Spline III 5.1 (3.7-7.1)





More than 1 mm daily 1.0 1.0
Less than 1 mm daily 1.7 (1.6-1.9) 1.7 (1.6-1.9)
Specific humidity
More than 16g per kg 1.0
Less than 16g per kg 1.7 (1.5-1.8)
Population density (median cutoff)
Fewer than 300 persons per km2 1.0
More than 300 persons per km2 0.72 (0.32-1.7)
Population density (mixture model)
Rural 1.0
Urban 0.73 (0.32-1.8)
Table 5.9 Comparison of fixed effects parameters for model of meningococcal carriage prevalence using uniform
dry season definition (December to June) and rainfall-dependent definition (less than 1mm average rainfall
during swabbing period).
Factor With uniform season definition With climactic indicators
Odds ratio (95% CI) Odds ratio (95% CI)
Natural cubic spline of age
Spline I 3.4 (2.9-4.1) 3.4 (2.9-4.0)
Spline II 2.0 (1.6-2.4) 2.0 (1.6-2.4)
Spline III 5.2 (3.7-7.2) 5.1 (3.7-7.1)
Spline IV 0.79 (0.71-0.87) 0.78 (0.70-0.86)
Season
Rainy 1.0 1.0
Dry 1.5 (1.4-1.7) 1.7 (1.6-1.9)
Outbreak 6.7 (1.6-29) 7.3 (1.6-35)
by NmX (9.5 years), NmW (10 years), and the latest peak for NmY (14 years). Consistent with
this, in a country with the same population structure as Niger, the models estimate that more
than 61% of NmA, NmW, and NmX carriers are under the age of 16 compared to just 47% of
NmY carriers (Table 5.10). I found the lowest overall prevalence for NmA, peaking at less than
0.002% during the rainy season, and the highest overall prevalence for NmW (0.6% during the
rainy season).
Odds of carriage were significantly increased during the dry season for NmA (OR 1.9 95%
CI 1.2-3.0), NmX (OR 2.1 95% CI 1.8-2.4), and NmY (OR 1.4 95% CI 1.2-1.7), but not for
NmW (OR 0.87 95% CI 0.66-1.1) and further significantly increased during outbreaks for NmA
5.3 Results 95
Rainy Dry Outbreak







































Fig. 5.8 Observed carriage prevalence and model predictions by serogroup and season. Circles show the data
points included in the sub-analysis, with carriage prevalence adjusted for random effects intercept. Solid line
shows model predictions excluding random effects. NmA shown in red; NmW in green; NmX in blue; NmY in
purple.
Table 5.10 Target age for vaccination: proportion of carriers of NmA, NmW, NmX, and NmY under 60 years of
age directly targeted by vaccination of different age groups.
Serogroup
Age group NmA NmW NmY NmX
Under 16 61% 64% 47% 63%
Under 18 66% 70% 52% 68%
Under 20 70% 74% 57% 72%
Under 30 84% 86% 73% 82%
(OR 2700 95% CI 28-2.9x106) but not for NmW (OR 41 95% CI 0.87-2200) (Table 5.11). No
data on carriage during outbreaks caused by NmX or NmY were included in the meta-analysis,
so outbreak trends for these serogroups could not be assessed.
Table 5.11 Odds of carriage for dry and outbreak measures as compared to rainy season measures for the
serogroup-specific fits.
Odds ratio (95% profile CI)
Serogroup Dry season Outbreak
NmA 1.9 (1.2-3.0) 2700 (28-2.9×106)
NmW 0.87 (0.66-1.1) 41 (0.87-2200)
NmY 1.4 (1.2-1.7)
NmX 2.1 (1.8-2.4)
The introduction of MenAfriVac decreased the odds of NmA carriage by a factor of 0.01
(95% CI 0.002-0.03) (Table 5.12). The addition of the vaccination fixed effect did not have a
significant impact on the other fixed effects terms (age, season) in the model.
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Table 5.12 Impact of MenAfriVac introduction on carriage of NmA, adjusting for age and season as fixed effects
and location as a random effect.
Factor NmA carriers (Proportion of total subjects) Odds ratio (95% profile CI)
MenAfriVac introduced
No 252/70326 (0.36%) 1
Yes 2/41129 (0.0049%) 0.010 (0.0017-0.033)
Season
Rainy 72/63278 (0.11%) 1
Dry 82/47264 (0.17%) 1.9 (1.2-2.9)
Outbreak 100/913 (11%) 1800 (8.8-3.6×107)
5.4 Discussion
Meningococcal carriage rates in the African meningitis belt were significantly higher in
individuals aged 5 to 19 than in age groups outside this range. A logistic regression showed that
carriage prevalence increases from a minimum in infants to a broad peak in children centred at age
10 (1.94% in the rainy season, 95% CI 1.87-2.47%), then gradually decreases in later adolescence
and adulthood. The trends in prevalence by age captured by the model are broadly consistent
with contact studies in the sub-Saharan Africa, which find the highest intensity of contacts in
5- to 15-year-olds, especially close physical contacts and contacts with individuals outside of
the household.186 In the context of future strategies for use of the pentavalent meningococcal
conjugate vaccine, this work shows that a substantial proportion of meningococcal carriers
could be targeted while lowering the upper threshold for vaccination from 29 years of age to
17 or 19 years of age. However, 17% of carriers in the data that informed the model carried
non-groupable strains, which would not be targeted by a pentavalent vaccine but are also
unlikely to be hypervirulent.187
The dry season in the African meningitis belt is characterised by low humidity, high
temperatures, increased wind speed, and high levels of airborne dust.43,125 I found that the
odds of carriage were significantly increased during the dry season and further increased
during outbreaks, all of which occurred during the dry season. This finding is consistent with
mathematical modelling which has shown that seasonal forcing in transmissibility of carriage is
necessary to reproduce the extreme variability and scale of meningitis incidence characteristic of
the African meningitis belt.39 This finding is also consistent with in vivo studies in mice and in
vitro studies of human neutrophils which have shown that exposure to dust is associated with
reduced bacterial killing and increased bacterial load in the nasopharynx.38 This finding was
robust to variations in the definition of the dry season, with average rainfall being a slightly
better predictor of prevalence than humidity.
It is also demonstrated consistently across multiple studies. One study, MenAfriCar 2015,
showed a strong opposite effect when fit with a mixed effects model but the trend was consistent
with the others when fit with a fixed effects model.40 The mixed effects model compares carriage
prevalence only in the same year, whereas the fixed effects model compares carriage prevalence
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over the entire study. The prevalence of carriage in the MenAfriCar study is lower in the 2010
dry season than in the 2010 rainy season: 0.2% compared to 1.5% (see Table 5.7). In 2012, the
prevalence of carriage is higher in the dry season (2.9%) than in the rainy season (0%), but the
sample size in the rainy season is particularly small (n=304). This is why the odds ratio in
the mixed effects model, which separates comparisons by year, favours higher prevalence in the
rainy season.
However, it is important to emphasize that the increased odds of carriage during the dry
season and during outbreaks are not sufficient to fully account for the dramatic increase in
disease incidence observed during these periods. There is evidence that individual susceptibility
to invasive disease also increases during the dry season and during outbreaks.35
The serogroup-specific analysis showed some significant differences between serogroups by
season, but patterns by age did not vary substantially. It is interesting to note the much higher
prevalence of carriage of serogroups W and Y compared to A. This has relevance both for
modelling the impact of and designing studies to demonstrate the efficacy of the pentavalent
pneumococcal conjugate vaccine. It is unfortunate that I did not have sufficient data to
investigate patterns of serogroup C carriage, an important cause of bacterial meningitis in the
belt following the emergence of a novel strain in Nigeria in 2013.47 This is something that will
be important to study in the future.
Mass group A conjugate vaccination has no significant effect on overall carriage prevalence
in the model. Serogroup A meningococci accounted for just 10% of all carriage isolates in
pre-vaccine studies (Table 5.4), so it is not surprising that the overall model did not capture any
change due to vaccine-related reductions in group A carriage. As expected, carriage of group
A meningococci substantially decreased from 0.4% overall before mass campaigns to less than
0.005% overall after (OR 0.01 95% CI (0.002-0.03)).
This model has some limitations. Cross-validation predictions are well correlated with
true prevalence (Pearson’s ρ 0.89), but substantial variability in carriage prevalence remains
unexplained, with fewer than half of observations falling within the 95% confidence intervals for
model predictions. There is additional missing uncertainty in the model due to the assumption
that all individuals in a given age group are of the median or midpoint age which is not
captured by the bootstrapping process. The amount of information which is lost by grouping
individuals by age could be tested by fitting the same model to grouped and ungrouped data
and comparing the results. Another approach could be to use a Monte Carlo approach to
estimate the underlying function of carriage by age, simulating the grouping process in addition
to the uncertainty arising from binomial samples. Additional variability may also be driven by
heterogeneity between serogroups, differences in the intensity of seasonality at different sites and
different sampling times, and a variety of other risk factors, including smoke exposure, crowded
housing conditions, and upper respiratory infection, which are not measured or reported. Some
of these individual- and household-level risk factors are investigated in the following chapter.
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The model is principally informed by two large serial cross-sectional studies carried out
between 2009 and 2012, one based in Burkina Faso (50,810 subjects)41,73,168 and the multi-
country African Meningococcal Carriage Consortium study (48,405 subjects).40 The results of
the study in Burkina Faso were reported over three manuscripts but they used the same study
sites, staff, and sampling and laboratory procedures. These are both high quality characteristic
multi-site studies, but this does mean that the majority of the data that informed the model
come from a particular time period. Thus, while these findings may not necessarily be useful
for explaining historical trends, including NmA epidemics, they should be useful in guiding
modelling and policy decisions around non-NmA meningitis prevention.
Gender was not included in the model because this was not consistently reported, but
the age distribution of carriage may be modified by gender because of differences in social
behaviour.188 A number of studies have also shown higher prevalence of carriage in males overall,
but this would not be expected to bias the results of this analysis unless the gender distribution
of participants were substantially different between age groups.40,127 There was no significant
difference in carriage prevalence between densely and sparsely populated locations, although a
prior study which was included in this meta-analysis did demonstrate increased odds of carriage
in rural locations.40
Because of the sparseness of sampling in older age groups, a linear relationship between
carriage prevalence and age above 30 years was assumed. As a result, carriage appears to decline
steadily throughout middle and later adulthood. In reality, carriage may increase in the elderly
as immunity wanes. Further study of this age group will be important as older people comprise
an increasing proportion of the population in the African meningitis belt.
This chapter finds that older children in the African meningitis tend to be the age group in
which carriage is most prevalent. The odds of carriage are significantly higher during the dry
season and during outbreaks, and carriage of group A meningococci has substantially decreased
in countries where mass MenAfriVac vaccination has been implemented. Given the importance
of herd protection from conjugate vaccines, this meta-analysis may help to guide vaccination
policy, both to maintain control of group A disease and in the implementation of effective and
affordable multivalent vaccination programmes.
Chapter 6
Risk factors for acquisition of meningococcal car-
riage: a longitudinal household study
This work was undertaken in collaboration with the African Meningococcal Carriage Con-
sortium, the members of which conducted a multi-site serial cross-sectional carriage study in
the African meningitis belt between 2010 and 2012. Anna Robson, Caroline Trotter, and James
Stuart provided input on the statistical analysis and the interpretation of the findings. I carried
out the analysis and wrote the first draft of the manuscript. All authors contributed to the
editing and review of the final manuscript. A version of this chapter has been published in
Tropical Medicine and International Health (see Appendix A).
6.1 Introduction
The African Meningococcal Carriage Consortium (MenAfriCar) undertook 20 cross-sectional
carriage surveys in seven African meningitis belt countries from July 2010 to July 2012, involving
the collection of over 48 000 pharyngeal swabs. These studies found a higher frequency of
carriage in children aged 5-14 years, in the dry season and in rural populations.40 During these
surveys, households with at least one pharyngeal carrier of N. meningitidis were recruited for
longitudinal studies.14 Previous longitudinal studies in the meningitis belt have been undertaken
mainly at the population level.57,168,169 Fewer have investigated the transmission and acquisition
of carriage at an individual level.13,127 The aim of this study was to investigate a comprehensive




Households included in this study were recruited during the course of cross-sectional surveys
conducted in seven countries in the African meningitis belt (Chad, Ethiopia, Ghana, Mali,
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Niger, Nigeria, and Senegal) in 2010, 2011, and 2012.40 Details of the survey methods employed
have been published previously.14 Longitudinal surveys were triggered by the identification
of a putative carrier during a cross-sectional survey (Visit 0). This initial identification of
carriers relied on conventional microbiology and was later confirmed via molecular methods at
the University of Oxford. In some cases, molecular methods did not confirm the presence of
meningococci, so 51 of 184 households recruited to the study did not have an index carrier.
Within four weeks of the identification of a carrier, all members of the putative carrier’s
household were invited to take part in further studies (Visit 1). The head of the household
was asked about characteristics of the household, including numbers of rooms and bedrooms,
sleeping arrangements, location of kitchen, type of cooking fuel, house construction, drinking
water source, toilet facilities, and household assets such as vehicle ownership, livestock, and
electrical goods.
A pharyngeal swab sample was obtained from all members of a household who gave their
consent and a questionnaire completed which included questions on: smoking, social activities,
symptoms of recent respiratory tract infection, socio-economic status and educational level,
school attendance, travel history, recent medication including antibiotics, meningitis vaccination,
and ethnic group. Carrier households were followed up bi-weekly for two months (Visits 2-5)
and monthly for a further four months (Visits 6-9). At each follow up visit, each household
member was asked for a pharyngeal swab sample and to answer a short follow-up questionnaire
on factors that might have changed since the previous visit, such as symptoms of a respiratory
tract infection.
6.2.2 Laboratory methods
Pharyngeal swab samples, taken from the posterior pharynx and tonsillar fossa via the
mouth, were plated directly onto Modified Thayer Martin agar plates in the field, taken to the
laboratory within six hours of collection, and processed as previously described.14 A sample
of boiled suspensions of Gram negative oxidase positive bacteria was sent to the University
of Oxford for molecular analysis. Amplification and sequencing of the rplF gene was used to
confirm the presence of, and differentiate between, Neisseria species. Confirmed N. meningitidis
were further characterised by genogroup (including capsule null) and porA genosubtype.
6.2.3 Data management
Data were managed using the Teleform system (version 10.4.1, Autonomy, Cambridge UK)
with a separate database module linking the main study database with genetic laboratory
results from the Oxford PubMLST database (https://pubmlst.org/neisseria). Data from the
longitudinal questionnaires were merged using a common person ID, or census number, person
matching was checked, any duplicate entries were removed, and aberrant values excluded.
6.2 Methods 101
6.2.4 Statistical analysis
Genogroup-specific acquisition rates were calculated as Poisson rates, counting as events the
number of acquisitions occurring in non-index carriers and time at risk as the days between
the first carriage-negative swab and the first positive swab. A series of fixed-effects logistic
regressions were used to identify significant risk factors for acquisition. In the first round of
regressions, individual risk factors were included in a multivariable logistic regression with the a
priori variables sex, age group, and country. In the second round, risk factors with p<0.1 in
round 1 were added to a single model with a priori variables. In the third round, risk factors
with p<0.05 in round 2 were retained in the multivariable model. In the fourth round, all factors
dropped in round 3 were added back in to the model one by one and all variables with p<0.05
were retained, giving the final models. The study-long and visit-by-visit models were then run
with household ID and both household and individual ID as random effects, respectively, to
account for study design, and factors that were no longer significant (p≥0.05) were dropped.
Acquisition was assessed over the full study period (study-long) and visit-by-visit. Individuals
were defined as positive for study-long acquisition if they had a negative swab (no meningococci
isolated) at visits 0 or 1 and a positive swab (any meningococci isolated) at any following visit.
Individuals were defined as negative for study-long acquisition if they had a negative swab at
visits 0 or 1 and no positive swab at any subsequent visit. Individuals with three or more missed
visits in total were excluded, as the possibility of acquisition during this missed period could
not be ruled out, and individuals carrying at visits 0 or 1 were also excluded.
Individuals were defined as positive for visit-by-visit acquisition on a given visit if the
individual had a positive swab at the current visit and a negative swab at the previous visit or
carried a different strain at the previous visit and the strain was not previously carried during
the study. Strains were assessed by genogroup and porA variable regions 1 and 2. Individuals
were defined as negative for visit-by-visit acquisition on a given visit if the individual had
a negative swab at the previous visit and a negative swab at the current visit. Individuals
carrying an identical strain to that obtained at the previous visit and individuals who cleared
carriage were excluded from the analysis. Tables 6.1 and 6.2 provide the classification of cases
for study-long and visit-by-visit acquisition.
Table 6.1 Case definition for study-long acquisition.
Classification Carriage at







Not acquisition No No No 692
Acquisition No Yes No 169
Excluded No No Yes 231
Excluded No Yes Yes 18
Excluded Yes No No 42
Excluded Yes No Yes 18
Excluded Yes Yes No 159
Excluded Yes Yes Yes 22
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Not acquisition No No Not applicable 6768
Acquisition No Yes No 226
Acquisition Yes Yes No 47
Excluded No Yes Yes 183
Excluded Yes Yes Yes 366
Excluded No No data Not applicable 1180
Excluded Yes No Not applicable 516
Excluded Yes No data Not applicable 128
Excluded No data No Not applicable 1677
Excluded No data Yes Not applicable 304
Excluded No data No data Not applicable 2115
The dry season was defined as January to May and the rainy season as June to December.
Because I found a significant association between sore throat and season and because previous
studies have demonstrated an interaction between meningococcal carriage, upper respiratory
tract infection, and season, I also tested for interaction between sore throat and season in the
final model and found that the model with an interaction term fitted better than the model
with no interaction (Tables 6.3 and 6.4).
Table 6.3 Odds of sore throat adjusting for age, country, sex and season.
Factor Total Reporting sore throat (%) OR 95% CI
Age (years)
30 plus 2024 6.6 1
Under 5 1914 2.4 0.372 (0.261, 0.522)
5–14 2806 2.6 0.399 (0.295, 0.534)
15– 29 1752 7.4 1.13 (0.873, 1.45 )
Country
Chad 1038 5.8 1
Ethiopia 940 7.1 1.27 (0.883, 1.83 )
Ghana 1135 8.6 1.41 (1.01 , 1.98 )
Mali 1854 1.1 0.174 (0.101, 0.287)
Niger 3179 4.3 0.728 (0.532, 1.01 )
Senegal 350 0
Sex
Female 4424 4.3 1
Male 4072 4.6 1.14 (0.92 , 1.4 )
Season
Rainy: June to December 3617 4.4 1
Dry: January to May 4879 4.5 1.27 (1.02 , 1.57 )
6.2.5 Ethics
The study was approved by the ethics committee of the London School of Hygiene and
Tropical Medicine and by the relevant ethical authorities in each African centre.14 The head of
the household or another responsible adult gave verbal informed consent for the household to
be included in the study. Each individual recruited within the household gave written informed
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Table 6.4 Likelihood ratio test comparing visit-by-visit model with and without term of interaction between
season and sore throat.
Chi-square





Sore throat 14 1660 1754 -815.82 1631.6
Sore throat, season 15 1662 1763 -815.77 1631.5 0.099 0.75
Sore throat, season, interaction 16 1656 1764 -811.97 1623.9 7.6 0.006
consent; for children under the age of 18 years a parent or guardian gave written consent and
children aged over 12 years were additionally asked to give written assent.
6.3 Results
6.3.1 Acquisition over course of the study
Overall, 169/861 (20%) of non-index carriers acquired carriage at least once over the course
of the study. A higher proportion of 5- to 14-year-olds acquired carriage than other age groups,
and a higher proportion of participants acquired carriage in Senegal, Niger, Ghana, and Ethiopia
relative to Chad and Mali (Table 6.5).
A wide variation in acquisition rates and predominant serogroups was observed between
countries. NmA was predominant in Chad, cnl and NmY in Ethiopia, NmW in Ghana and
Mali, cnl and NmW in Niger, and NmW and Y in Senegal. Genogroup W and capsule-null
(cnl) meningococci accounted for the majority (83%) of acquisitions. The acquisition rate of
genogroup W meningococci was 2.0% per month (95% CI 1.6-2.4): roughly double that of cnl
meningococci at 1.0% per month (95% CI 0.74-1.4). Genogroups A, C, Y, and other genogroup
(i.e. other than A, B, C, W, X, Y, or cnl) acquisitions were uncommon, and no genogroup B or








Table 6.5 Risk factors for Neisseria meningitidis acquisition over the full study period: single risk factor analysis and multi-variable model. Adjustment was made
in both single and multi-variable analysis for age, country and sex. N.B. Total number of individuals may not sum to 861 in every case because of missing values. *
p-value less than 0.1 in single risk factor analysis. §p-value less than 0.05.
Factor Single risk factor analysis Multi-variable model
Total Acquisition (%) OR 95% CI Total Acquisition (%) OR 95% CI
Age (years)
30 plus 205 11.7 1
Under 5 91 28.6 3.12 (1.27 , 8.05 )
5–14 108 23.1 3.62 (1.42 , 9.93 )
15–29 161 21.1 2.38 (1.22 , 4.76 )
Country
Chad 54 5.6 1
Ethiopia 64 26.6 7.65 (1.81 , 44.4 )
Ghana 74 23.0 6.77 (1.52 , 40.1 )
Mali 157 5.7 0.532 (0.110, 3.22 )
Niger 206 28.6 10 (2.53 , 57.3 )
Senegal 10 40.0 13.3 (1.23 , 159 )
Sex
Female 326 17.5 1
Male 239 21.8 1 (0.585, 1.71 )
Exposure to wood smoke in house (apart
from cooking)*
No 372 20.2 1 261 19.2 1
Yes 478 19.0 2.74 (1.76 , 4.32 ) 304 19.4 2.6 (1.26 , 5.59 )
Tobacco exposure*
None 234 14.1 1 230 13.5 1
Passive smoke 312 22.8 1.92 (0.965 , 3.77 ) 312 22.8 1.92 (0.823, 4.55 )
Active smoker 23 30.4 3.75 (1.23 , 10.8 ) 23 30.4 3.57 (0.978, 13.0 )§
Any sore throat reported *
No 651 17.8 1
Yes 208 25.5 1.66 (1.09 , 2.53 )
Any runny nose reported *
No 184 20.7 1
Yes 675 19.4 1.57 (0.995 , 2.51 )
Use gas as primary cooking fuel*
No 832 20.0 1
Yes 25 12.0 0.311 (0.0664, 1.03 )





Table 6.5 – Continued from previous page
Factor Single risk factor analysis Multi-variable model
Total Acquisition (%) OR 95% CI Total Acquisition (%) OR 95% CI
Completion of primary school (over 17
years)*
No 269 18.2 1
Yes 99 11.1 0.381 (0.170 , 0.793)
Household member completed secondary
school*
No 444 22.3 1
Yes 415 16.9 0.67 (0.455 , 0.983)
More than 2 participants per room*
No 484 14.5 1
Yes 375 26.4 1.44 (0.996 , 2.10 )
Attending primary school (ages 5 to 17)
No 52 25.0 1
Yes 254 23.2 0.721 (0.325 , 1.65 )
Regular social meetings
None 202 20.3 1
1–2 per week 68 16.2 0.916 (0.404 , 1.96 )
3–4 per week 48 8.3 0.531 (0.141 , 1.61 )
5–7 per week 52 5.8 0.356 (0.0793, 1.14 )
Index carrier in household
No 259 12.0 1
Yes 600 23.0 1.32 (0.826 , 2.16 )
Use wood as primary cooking fuel
No 31 12.9 1
Yes 828 19.9 1.02 (0.340 , 3.83 )
Indoor kitchen
No 660 16.4 1
Yes 199 30.7 1.28 (0.838 , 1.94 )
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In the final multivariable model, the highest odds of acquisition were among 5- to 14- year
olds, with odds in all age groups under 30 years of age being significantly higher than the
reference group of individuals 30 years and older (Table 6.5). Active smokers had higher odds
of acquiring carriage than non-smokers living in households with no smokers, with a lower
confidence bound just below 1 (OR 3.57 95% CI 0.98-12.99). Non-smokers living in households
with smokers also had elevated odds of acquisition but the difference was not statistically
significant. Wood was the ubiquitous cooking fuel, with 96% of participants using this as
cooking fuel; 56% of participants had additional wood smoke exposure. Participants with
household exposure to wood smoke (independent of using wood as cooking fuel) had higher odds
of acquiring carriage than those without (OR 2.60 95% CI 1.26-5.59). Although not significant
in the regression analysis, higher acquisition rates were observed in households with an indoor
kitchen and in households which used wood as the primary cooking fuel than in those who did
not.
6.3.2 Visit-specific acquisition analysis
Participants who reported sore throat since the previous visit during the dry season were
significantly more likely (OR 3.67 95% CI 1.95-6.65) to have acquired carriage in that time
period than those who did not have a sore throat in the rainy season (Table 6.6). Those who
reported taking antibiotics since the previous visit were significantly less likely (OR 0.169 95%





Table 6.6 Risk factors for visit-by-visit N. meningitidis acquisition: single risk factor analysis and multi-variable model. Adjustment was made a priori in both
single and multi-variable analysis for age, country, and sex. *p-value less than 0.1 in single risk factor analysis.
Factor Single risk factor analysis Multi-variable model
Total Acquisition (%) OR 95% CI Total Acquisition (%) OR 95% CI
Age (years)
30 plus 1504 1.8 1
Under 5 1539 3.4 1.99 (1.22 , 3.32 )
5–14 2129 4.2 2.76 (1.75 , 4.48 )
15–29 1239 3.0 1.83 (1.08 , 3.15 )
Country
Chad 990 0.6 1
Ethiopia 564 4.6 7.54 (2.59 , 24.5 )
Ghana 828 3.5 5.7 (1.96 , 18.6 )
Mali 1574 0.9 1.51 (0.483 , 5.13 )
Niger 2281 5.2 11.5 (4.53 , 34.5 )
Senegal 174 7.5 14.2 (3.6 , 60.7 )
Sex
Female 3405 2.9 1
Male 3006 3.6 1.23 (0.907 , 1.68 )
Antibiotic taken*
No 6592 3.5 1 6150 3.3 1
Yes 261 0.8 0.197 (0.0323, 0.623) 261 0.8 0.169 (0.0271, 0.564)
Interaction term*
No sore throat, rainy 2643 3.3 1 2643 3.3 1
No sore throat, dry 3481 2.8 0.88 (0.651 , 1.19 ) 3481 2.8 0.844 (0.617 , 1.16 )
Sore throat, rainy 123 2.4 0.906 (0.218 , 2.52 ) 123 2.4 0.82 (0.192 , 2.39 )
Sore throat, dry 164 11 3.72 (2.09 , 6.34 ) 164 11 3.67 (1.95 , 6.65 )
Sore throat*
No 6566 3.3 1
Yes 287 7.3 2.64 (1.58 , 4.19 )
Season
Rainy: June to December 1944 3.1 1
Dry: January to May 4467 3.3 1.07 (0.78 , 1.47 )
Meningitis vaccination
No 5743 3.7 1
Yes 1110 2.0 1.54 (0.899 , 2.55 )
Attendance at social event
No 3319 4.4 1








Table 6.6 – Continued from previous page
Factor Single risk factor analysis Multi-variable model
Total Acquisition (%) OR 95% CI Total Acquisition (%) OR 95% CI
Yes 3534 2.5 0.851 (0.63 , 1.14 )
Travel greater than one hour
No 6055 3.6 1
Yes 798 2.0 0.955 (0.538 , 1.58 )
Cough
No 5163 3.6 1
Yes 1690 3.0 0.955 (0.682 , 1.31 )
Runny nose
No 4634 3.8 1
Yes 2219 2.6 0.961 (0.689 , 1.32 )
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6.4 Discussion
This longitudinal study found a higher risk of acquisition amongst individuals who reported
a sore throat since the previous visit, but only during the dry season. An association between
an upper respiratory tract infection and meningococcal carriage has been reported previously.127
A sore throat could be caused by an initial inflammation of the pharynx from meningococcal
colonisation or by a concurrent unrelated infection that predisposes an individual to acquisi-
tion.189 If the latter is true, upper respiratory tract infection in combination with dust and
low humidity may be an important driver for the high risk of meningitis epidemics in the
dry season. This hypothesis is supported by a recent study indicating an association between
incidence of upper respiratory tract infection (otitis, severe sore throat, and rhinopharyngitis)
and meningitis outbreaks in Burkina Faso.190 Such infections could plausibly increase both the
risk of acquisition and the risk of invasion after acquisition.
The 5-14 year-old age group had the highest acquisition rate. The highest prevalence of
carriage in cross-sectional MenAfriCar studies was similarly highest in 5-14 year olds.40 An
overall acquisition rate of 2.4% (95% CI 1.6 to 4.0%) per month was estimated from this same
study using a hidden Markov model.14 There were no significant differences reported by age
group, but data were subdivided by control and index households and there was no adjustment
for exposure to other risk factors.
Additional factors linked to acquisition of meningococci over the course of this study were
smoking tobacco and exposure to wood smoke. Smoking, passive exposure to smoke, and to
smokers has been shown to convey a high risk of carriage and invasive disease in high-income
countries.191–194 Exposure to cigarette smoke has also been linked to the risk of carriage in the
meningitis belt.40,127 The higher risk of acquisition from smoke exposure in this study suggests a
direct risk from smoke itself, potentially from interference with mucosal immunity, as exposure
to wood smoke was an independent risk factor. Exposure to smoke from wood fires has also
been shown as a risk factor for meningococcal meningitis in northern Ghana.195 Although use
of wood as primary cooking fuel was not found to be a significant risk factor, this could be
explained by the fact that nearly all study participants relied on wood as primary fuel.
Strengths of this study are the multi-centre design, including a mix of urban and rural
populations with a broad age range, the use of standardised field and laboratory protocols,
and large sample size. Measuring acquisition rather than carriage ensures that the risk factors
identified in this study are not biased by factors associated with longer carriage duration. A
comprehensive range of risk factors was included, so that important confounding factors are
unlikely to have been missed; however, the sampling of carriers and non-carriers was not random
and some misclassification of carriage status is expected.
The acquisition of meningococci measured in this longitudinal study and the prevalence of
carriage in the MenAfriCar cross-sectional studies varied considerably by country. Although
laboratory methods were standardised across centres, differences in laboratory techniques
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and conditions could still have contributed to some of the differences observed. As most
meningococcal acquisitions were either genogroup W or capsule null and outside epidemics, it
cannot be assumed that risk factors for acquisition of other genogroups or during epidemics
would be the same as those identified in this study.109
Chad and Mali had the lowest risks of carriage acquisition: about 5% over the course of the
study, whereas the other countries had more than 20% acquisition. It is possible that differences
in laboratory conditions could have negatively affected the sensitivity of culture in Chad and
Mali. The cross-sectional study also found especially low carriage prevalence in these two
countries (between 0.5 and 1.7% compared to an average of 3.4%).40 Most of the isolates in the
household study in Chad were NmA (25 of 37) and a high proportion of participants reported
receiving a recent meningitis vaccine which was likely MenAfriVac (59%). Vaccination may have
reduced transmission of NmA carriage in Chad. In Mali, a high proportion of households lacked
index carriers (70%), but acquisition rates were not significantly different in households with
index carriers (4 in 66 compared to 6 in 129).
It was surprising that some risk factors such as household crowding that have previously been
found to raise the risk of carriage and disease13,40,196,197 were not associated with acquisition in
this study. Crowding was measured by number of individuals sharing a bedroom or bedmat, and
by numbers of study participants per room in the household. It is possible that crowded living
conditions are so prevalent across the study locations that any effect of crowding on acquisition
is not detectable. A study in rural Gambia did not find any differences in crowding between
compounds with and without cases of meningococcal meningitis during an epidemic.198
This is the largest longitudinal household study of meningococcal carriage in the African
meningitis belt to date. One previous longitudinal study had a similar design to this one,
sampling members of 37 randomly-selected households in Ghana five times between March 1998
and April 2000.199 Other household studies have examined prevention of secondary cases of
disease by vaccination or chemoprophylaxis for household contacts200,201 and the global spread
of novel variants by Hajj pilgrims to their household contacts.202,203
It was not possible to draw any conclusions regarding the relationship between carriage
acquisition and disease incidence because none of the study sites reported an outbreak of
meningitis during the follow-up period.
Reported vaccination was clustered in particular time periods and countries corresponding
to the introduction of group A conjugate vaccine. Vaccination was not found to be protective
against carriage acquisition. However, group A conjugate vaccination would not be expected to
have a significant impact on carriage in this study as very few group A carriers were detected.
Longitudinal acquisition studies like this one could be used to estimate the efficacy of the
new pentavalent meningococcal conjugate vaccine NmCV-5.204 Further specifics would need
to be defined, including whether the comparator would take the form of a non-meningococcal
vaccine that did not interfere with the nasopharyngeal environment (measuring efficacy directly)
or a currently licensed polyvalent meningococcal conjugate vaccine (measuring non-inferiority),
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and whether to measure the effect of the vaccine on acquisition, carriage duration, or both.205
Longitudinal studies allow measurement of the vaccine effects on both acquisition rates and
carriage duration. A Markov model could be used to analyse the resulting data. This method
was used to estimate acquisition, clearance, and replacement rates of 27 pneumococcal serotypes
in Kenyan children.17 In this study design it would be important to designate carriage of each
serogroup as a separate state, because combining states tends to underestimate acquisition rates
and overestimate carriage duration.17 This would also necessitate a larger study to accurately
estimate the additional parameters. Unfortunately, two of the most important causes of
outbreaks, NmC and X, were found very rarely in this study. It is not too surprising that NmC
was rarely observed because the study took place before the emergence of the hypervirulent
NmC strain. Given the dynamic nature of meningococcal carriage in the African meningitis
belt, it might be advantageous to run a pilot study across multiple sites to identify places where
transmission of relevant serogroups is likely to be observed.40 These sites could then be followed
up in a longitudinal study, with sample sizes estimated from a simulation mirroring the study
design and using acquisition rates observed in the pilot study.
This study demonstrated significantly higher acquisition among individuals under 30 years
of age, with the highest rate in 10- to 14-year olds, and significantly higher acquisition among
individuals reporting sore throat, particularly in the dry season. These findings are consistent
with the findings in Chapter 5, which identified a peak in meningococcal carriage prevalence
around 10 years of age and significantly higher odds of carriage in the dry season compared to
the rainy season. This analysis adds individual risk factors which could not be evaluated in
the meta-analysis, highlighting respiratory infection as a potential explanation for the observed
seasonality in carriage prevalence. However, this finding is difficult to interpret with certainty
because a sore throat could be directly caused by meningococcal colonisation or by a concurrent
unrelated infection that predisposes an individual to acquisition. Further research on interactions
in the pharyngeal microbiome could help to clarify this relationship.

Chapter 7
Spatio-temporal analysis of serogroup C meningo-
coccal meningitis spread in Niger and Nigeria
and implications for epidemic response
This work was undertaken in collaboration with Olivier Ronveaux and Katya Fernandez
from the Department of Pandemic and Epidemic Diseases at the World Health Organization in
Geneva, Switzerland, Clement Lingani from the Inter-country Support Team for West Africa
at the World Health Organization in Ouagadougou, Burkina Faso, Kadade Goumbi from the
Ministry of Public Health of Niger, Chikwe Ihekweazu from the Nigeria Center for Disease
Control, and Marie-Pierre Preziosi and Antoine Durupt from the Department of Immunization,
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7.1 Introduction
Since guidelines were first issued by the WHO in 1995, reactive vaccination policy in the
African meningitis belt has evolved in response to changes in disease burden and continuing
insights from research. This chapter aims to re-evaluate reactive vaccination policy in light
of the recent emergence and continued epidemics of serogroup C meningococcal meningitis in
Nigeria and Niger. Prior studies of meningitis patterns in Niger have demonstrated significant
spatial heterogeneity and strong inter-annual and intra-district variation in meningitis incidence.
Previous modelling studies have suggested that surveillance on finer spatial scales may improve
the timeliness and targeting of epidemic response.97,98,121 Because subdistrict-level data is not
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widely available, I wanted to investigate whether vaccinating neighbouring communities at the
district level might prevent more cases and allow for more efficient use of vaccine. I extend the
scope of these earlier studies by including data from Nigeria in the analysis, and considering the
full time period from the outbreak strain’s emergence in 2013.47
Considering the recent use of conjugate vaccines in reactive vaccination campaigns in response
to the emergence of serogroup C and in anticipation of licensure of an affordable pentavalent
conjugate meningococcal vaccine for Africa, I also wished to investigate the relative benefit
of the use of conjugate versus polysaccharide vaccine in reactive vaccination. Although one
previous study modelled the impact of using the conjugate pentavalent vaccine for reactive
vaccination in addition to mass preventative campaigns,81 there has been no previous direct
comparison of polysaccharide and conjugate vaccines in the context of reactive vaccination.
These findings can help guide the International Coordinating Group (ICG) on Vaccine Provision,




Surveillance data on suspected cases of meningitis from the enhanced district-level surveillance
system established in 2003 were used as proxy for incidence of confirmed bacterial meningitis.34
A suspected case is defined as any person with sudden onset of fever (>38.5°C rectal or 38.0°C
axillary) and any one of the following signs: neck stiffness, flaccid neck (infants), bulging
fontanelle (infants), convulsion, or other meningeal signs. Weekly district-level counts of
suspected cases are collated nationally and then reported to the WHO Inter-country Support
Team (WHO-IST) for West Africa. The analysis focuses on data from Niger and Nigeria during
the period from 2013 to 2017, when serogroup C was dominant. Incidence was calculated using
the district-level population sizes reported by each country to WHO-IST. This is a subset of the
surveillance data set that is used in Chapter 3.
Annual national-level data on confirmed cases of meningitis were used to estimate the overall
proportion of cases caused by serogroup C and preventable by vaccination (Table 7.1). CSF
samples are tested by national reference laboratories using PCR, culture, or latex agglutination
and these results are collated by WHO-IST.130 Because of the lack of microbiological data for
Nigeria in 2016, the etiological proportions were assumed to be the same as in Niger 2016 for
the purposes of the model.
Anonymised line list data which includes the age of cases and more detailed laboratory
confirmation data for Niger 2015 to 2017 and Nigeria 2017 were also used to validate model






Table 7.1 Confirmed and suspected cases of meningitis and estimated proportion of suspected cases that could have been prevented by C, ACW, ACWY vaccines
between 2013 to 2017 in Niger and Nigeria (Nm = Neisseria meningitidis). 95% binomial confidence intervals shown in parentheses.
Confirmed cases Covered by vaccine
Year Country Suspected cases Total Nm A C X Y W C ACW ACWY
2013 Niger 311 11 0 0 0 0 11 0% (0-28%) 100% (72-100%) 100% (72-100%)
Nigeria 871 10 3 7 0 0 0 70% (35-93%) 100% (69-100%) 100% (69-100%)
2014 Niger 315 24 0 8 0 0 16 33% (16-55%) 100% (86-100%) 100% (86-100%)
Nigeria 1 175 38 0 38 0 0 0 100% (91-100%) 100% (91-100%) 100% (91-100%)
2015 Niger 7 978 1436 0 1183 1 0 206 82% (80-84%) 97% (96-98%) 97% (96-98%)
Nigeria 2 655 20 0 20 0 0 0 100% (83-100%) 100%(83-100%) 100%(83-100%)
2016 Niger 1 976 357 0 312 15 0 25 87% (83-91%) 94% (91-97%) 94% (91-97%)
Nigeria 831 - - 22 - - - - - -
2017 Niger 3 387 1073 0 848 220 0 4 79% (76-81%) 79% (77-82%) 79% (77-82%)
Nigeria 9 918 18 1 14 0 0 1 78% (52-94%) 89% (65-99%) 89% (65-99%)
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7.2.2 Maps
Districts were matched to their locations on district-level maps obtained from WHO using
place names. Where no match was found between the map names and a surveillance database
place name, I used the GeoNames database to situate the unknown place name within a known
district.206 Large districts that divided into two or more smaller districts during the study period
(2013-2017) were kept as a single district to allow for tracking of vaccine coverage over time and
to avoid introducing bias by sudden population changes (Table D.1). Neighbours were defined as
those districts sharing a border with the focal district. This definition of neighbouring districts
included those across national borders.
7.2.3 Cluster detection
The global Moran’s I statistic was used to test for non-random spatial distribution of annual
cumulative incidence for each year 2013 to 2017.207 Measures of spatial autocorrelation can be
highly dependent on the imposed spatial structure, i.e. what is considered a neighbour and how
each neighbour is weighted.208 For this reason, Moran’s global I statistic was calculated using
three different weighting structures - by simple contiguity, great circle distance (within 50 km
of centroid), and taking the five nearest neighbours, with distance calculated by great circle
centroid-to-centroid (Table 7.2), using the “spdep” package in R.
Table 7.2 Moran’s global I statistic for each year using three types of spatial weighting structures. P-values from
999 Monte Carlo permutations.
Moran’s global I statistic
Year Contiguity Distance (50 km) Five nearest neighbours
2013 0.28 (1e-04) 0.29 (1e-04) 0.33 (4e-04)
2014 0.19 (1e-04) 0.16 (1e-04) 0.15 (9e-04)
2015 0.23 (3e-04) 0.15 (0.0013) 0.21 (0.0012)
2016 0.49 (1e-04) 0.33 (1e-04) 0.40 (1e-04)
2017 0.69 (1e-04) 0.70 (1e-04) 0.68 (1e-04)
For the distance-based weight, distances between 20 and 100 kilometres were evaluated. Fifty
kilometres was chosen because it maximised spatial effects in most years. All districts meeting
neighbour criterion were weighted equally. The significance of these values was determined by
rank within 999 Monte Carlo permutations.
As all weighting methods detected significant positive spatial autocorrelation of similar
magnitude in each year, contiguity weights were used for the analysis of local clusters. Anselin’s
local Moran’s I statistics were calculated for each district in each year to locate clusters of
districts with high incidence or outlier districts with higher incidence than neighbours.121,209
Both the “spdep” package in R and GeoDa software were used for methodological comparison. In
GeoDa, a permutation approach with 99999 permutations was used to generate pseudo-p-values,
which were then compared to the analytical results from the “spdep” package, using an overall
7.2 Methods 117
alpha of 0.05 and a Bonferroni adjustment for repeated testing. As the analytical p-values
and the pseudo-p-values gave inconsistent results, only the clusters found significant by both
methods were reported (Table D.2, Figure 7.2).
Clusters of cases in space and time were also located using the Kulldorff spatio-temporal
scan implemented in SaTScan software (freely available at www.satscan.org). The Kulldorff
scan statistic identifies circular windows in space with a depth of cluster time length with
significantly higher case counts than under the null hypothesis, which in this case was defined as
uniform incidence (Poisson-distributed case counts drawing from district population size). The
p-values of the log-likelihood ratios (LLR) for clusters were estimated using 999 Monte Carlo
simulations. Because this method uses points to situate cases rather than aggregated areas,
the district centroid was chosen as a proxy for location of individual cases.210 The size of the
spatial cluster was allowed to range from a 0 km radius (i.e. a single district) to a maximum
encompassing 50% of the total population at risk and the cluster time length to range from one
week minimum to 156 weeks maximum (50% of the study period 2013-2017).
7.2.4 Definitions
Weekly suspected cases as reported are referred to as observed suspected cases (OSC), and
cases expected in the absence of the vaccination campaigns taking place in selected districts
in 2015, 2016, and 2017 as modelled suspected cases (MSC). Epidemic and alert incidence
thresholds are consistent with current WHO guidelines, with alert defined as more than 3
suspected cases per 100,000 population per week or more than 2 cases total per week for districts
with less than 30,000 population and epidemic with as more than 10 suspected cases per 100,000
population per week or more than 5 cases total per week or a doubling of cases in a two-week
period for districts with less than 30,000 population.90 A meningitis outbreak period is defined
as the period of time and space in which N. meningitidis is the dominant cause of meningitis
nationally and the incidence of OSC exceeds the alert incidence threshold.
7.2.5 Estimating cases in the absence of intervention
Reactive vaccination campaigns occurred in 2015, 2016, and 2017 in 56 districts in response to
NmC outbreaks using polysaccharide vaccine, monovalent C conjugate vaccine, and quadrivalent
ACWY conjugate vaccine. To model suspected cases of meningitis in the absence of vaccination,
the following assumptions were made: 1) 80% of suspected cases during the outbreak period
are caused by Neisseria meningitidis (Nm); 2) 20% of cases outside the outbreak period are
caused by Nm; 3) the serogroup distribution is proportional to national annual proportions;
4) there is a delay of six weeks between triggering of the epidemic threshold and the onset of
protection from vaccination (Table 7.3). Where no threshold was triggered but vaccination still
took place, a best guess for the timing of the intervention was based on neighbouring districts.
For polysaccharide vaccine, the following further assumptions were made: 1) campaigns target
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2-29-year-olds, who make up 70% of the population and 90% of cases;150,211 2) 80% vaccine
efficacy against serogroups A, C, and W;212 3) protection lasts for 104 weeks (approximately
two years).213 This type of model has been used previously to estimate the impact of reactive
vaccination for meningitis outbreaks.89,91,93 It assumes no impact of the vaccine on carriage and
thus transmission of meningococci.
For the monovalent C conjugate vaccine, output from a dynamic model was used to approxi-
mate herd effects, assuming 85% vaccine efficacy against serogroup C meningitis, an average five
years duration of protection, and coverage levels calculated from reported population size and
vaccine use (see Figure 7.1).3,214 For the quadrivalent conjugate vaccine, the same dynamic model
was used to approximate herd effects, assuming 98% coverage of 2- to 15-year-olds (reflecting
the actual coverage in Ouallam), 85% vaccine efficacy against serogroups A, C, W, and Y,
and an average five years duration of protection.215 Vaccine coverage is calculated using the
district-level population reported in surveillance data, assuming the targeted population is 2- to
29-year-olds, representing 70% of total population, and the number of doses of vaccine released
by the ICG or population vaccinated as reported in the Weekly Epidemiological Record where
available.138,216,217 For all coverage calculations, 10% vaccine wastage was also assumed.
Table 7.3 Summary of model assumptions.










Polysaccharide Actual Variable* 80% ACW 2 y 6 No 2-29 y
Monovalent
conjugate
Actual Variable* 85% C 5 y 6 Yes 1-19 y
Quadrivalent
conjugate
Actual Variable* 85% ACWY 5 y 6 Yes 2-15 y
Polysaccharide Potential 85% 80% ACW 2 y 4-8 No 2-29 y
Monovalent
conjugate
Potential 85% 85% C 5 y 4-8 Yes 2-29 y
Pentavalent
conjugate
Potential 85% 85% ACWYX 5 y 4-8 Yes 2-29 y
*Calculated from ICG data.
In the model, I calculate suspected cases in the absence of intervention as a function of the
observed suspected cases over time i in a given district j (Ci,j), the proportion of meningococcal
meningitis cases occurring in the 2- to 29-year age group (a), the coverage of the reactive
vaccination campaign in district j (κj), the proportion of cases caused by N. meningitis during
the epidemic period and outside of the epidemic period (νE, νN ), the proportion of N. meningitis
cases caused by vaccine-type serogroups (σ), the individual efficacy of a single dose of vaccine
(ϵ), the week the incidence threshold is exceeded (it), the delay to implementing a campaign (d),
and the duration of vaccine protection (δ).
ν = νE, Ci > 2/100000







For conjugate vaccine, individual efficacy (ϵ), overall coverage (κ), and age coverage (a) are





1 − H(i, ϵ, κ, a)σν




where α is the proportion of the population between 2 and 29 years of age, Di,j is the number
of doses used in the campaign, Pj is the total population size of the district where vaccination
occurs, and w is the wastage percentage.
As a sensitivity analysis, I repeated this process 1,000 times, resampling the following
parameters: d, a, ϵ, σ, νE,νN , w, and δ for polysaccharide vaccine (shown in Table 7.4). I
present the 2.5th and 97.5th percentiles of this process as an uncertainty interval.
Table 7.4 Variables included in sensitivity analysis.
Variable Meaning Base Distribution
d Delay to implementing campaign 6 Discrete uniform(4,8)
δ Duration of vaccine protection (years) 2 Discrete uniform(1,3)
a Proportion of cases in 2- to 29-year age group 90% Uniform(80%, 100%)
ϵ Vaccine efficacy 80% Uniform(70%, 90%)






νE Proportion of cases caused by N. meningitidis
(epidemic)
80% Uniform(70%, 90%)
νN Proportion of cases caused by N. meningitidis
(non-epidemic)
20% Uniform(10%, 30%)
w Vaccine wastage 10% Uniform(5%, 15%)
7.2.6 Modelling new vaccination strategies
Uniform application of the current strategy was compared to three alternative reactive
vaccination strategies, making the same assumptions as above (Table 7.3). Under the current
strategy, mass vaccination takes place on a district level where the weekly incidence of suspected
cases exceeds the epidemic threshold and a vaccine-preventable causative serogroup can be
identified. The requirement for etiological confirmation was dropped for the modelling analysis
because weekly district level lab data were unavailable. In alternative strategy A, vaccination
takes place when the alert threshold is exceeded. In strategy B, all neighbouring districts which
have not received vaccine in the last five years are targeted in addition to the district exceeding
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the epidemic threshold. In strategy C, only those neighbouring districts in alert are targeted in
addition to the focal district in epidemic. In comparing these strategies, three types of vaccine
were considered: a trivalent ACW polysaccharide, monovalent C conjugate, and pentavalent
ACWYX conjugate. For polysaccharide vaccine, the following further assumptions were made:
1) campaigns target 2-29-year-olds with 85% coverage, who make up 70% of the population
and 90% of cases;150 2) 80% vaccine efficacy against serogroups A, C, and W;212 3) protection
lasts for 104 weeks (approximately two years).213 For both conjugate vaccines, output from a
dynamic model described above was used to approximate herd effects, assuming 85% coverage
of 1- to 29-year-olds, 85% vaccine efficacy, and an average five years duration of protection
(Figure 7.1).3,214 The pentavalent vaccine is assumed to protect against serogroups A, C, W,
Y, and X, and the monovalent against C alone. For conjugate vaccination, no districts which
have received vaccine in the last five years are targeted in order to avoid repeated vaccination.
Delays of 4, 6, and 8 weeks between triggering a vaccine response and onset of vaccine protection
are assumed, effectively giving 2, 4, and 6 weeks for implementation and 2 weeks for vaccine




























Fig. 7.1 Output of dynamic model used to approximate herd effects at different levels of coverage.
7.2.7 Analysis of model results
The performance of the different strategies and vaccine types was evaluated by calculating the
cases averted, doses of vaccine required to prevent a case (NNV), and the sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV) of each strategy for
predicting outbreaks defined by different cumulative annual incidences (from 100 cases per
100,000 to 20 cases per 100,000).
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Fig. 7.2 Cumulative annual district-level incidence of suspected cases of meningitis in Niger and Nigeria 2013 to
2017. Significant clusters of high incidence by Anselin’s local Moran’s I outlined in black. High-incidence outlier
in 2016 indicated with asterisk. Spatial extent of Kulldorff spatio-temporal clusters indicated by black circles,
temporal extent in weeks noted above circles.
7.3.1 Spatial and temporal characterisation
Outbreak activity was first observed in northern Nigeria in 2013 and continued in 2014
(Figures 7.2 and 7.3). In 2015, activity spread to the southwestern region of Niger, including the
urban area of Niamey. Fewer outbreaks were observed in 2016, followed by relatively high case




































































































Fig. 7.3 Observed weekly suspected cases and modelled cases averted by vaccination counts, annual cases averted
by reactive vaccination, and doses of vaccine delivered in Niger and Nigeria, 2013 to 2017. Shaded ribbon and
vertical error bars show 2.5th and 97.5th percentiles of sensitivity analysis for cases averted.
counts in Niger and the highest case counts in Nigeria thus far in 2017. Twenty district-years
were detected with high incidence and positive spatial autocorrelation (i.e. centres of clusters of
high incidence). There were 46 districts neighbouring these centres, and one district with high
incidence and negative spatial autocorrelation, meaning it was an outlier from its neighbours.
Tambuwal local governmental area (LGA) in Sokoto State in Nigeria, where the group C outbreak
strain was first identified, was detected as the centre of high incidence clusters in 2013 and
2014, but did not pass the weekly epidemic incidence threshold of 10 cases per 100,000 (WIT10)
in 2014 and did not exceed a cumulative annual incidence of 100 suspected cases per 100,000
in either year (CAI100).47 Of the neighbouring districts, two and four districts respectively
surpassed the WIT10 in 2013 and 2014 and none exceeded CAI100. No significant clusters were
detected in 2015. High incidence clustered around Niamey in Niger in 2016. There was also a
spatial outlier of high incidence identified in Nguru LGA in Yobe State in north-central Nigeria.
In 2017, two large clusters were detected in Sokoto State and Zamfara State in Nigeria. All 15
of the centre districts and 16 of the 21 neighbouring districts surpassed WIT10 between weeks
10 and 18. Nine of the centre districts in these clusters and two neighbouring districts exceeded
CAI100. Table D.2 gives full details of all clusters detected by Moran’s local I.
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The Kulldorff spatio-temporal scan identified nine clusters with p-value less than 0.01. The
largest cluster centred on Augie, Nigeria, encompassing a population of more than 23 million
people from weeks 12 to 19 of 2017 with a relative risk (RR) of 120 (Figure 7.2, Table 7.5). A
secondary cluster of somewhat lower relative risk was detected that year centred on Biriniwa
from weeks 13 to 20 (RR 4.3, p-value <0.001). Two additional smaller clusters were detected
in Abaji, Nigeria, and at Ibadan North, Nigeria (RR 4.5 and 25, p-value <0.001 and 0.002,
respectively). Two small clusters were detected in 2016, one centred at Karu, Nigeria from week
37 to 41 (RR 18, p-value <0.001) and one at Lagos Island, Nigeria from week 42 to 45 (RR 21,
p-value = 0.002). One small cluster was detected in 2015 at Lokoja, Nigeria in week 30 (RR 20,
p-value = 0.002). Two clusters were detected at in 2014, one large cluster at week 9 centred
on Ebonyi, Nigeria (RR 110, p-value < 0.001) and one smaller cluster at week 10 centred on








Table 7.5 Clusters identified by Kulldorff spatio-temporal scan. LLR= log likelihood ratio; RR = relative risk. Population given in thousands.
Radius Cases
Cluster centre Week Year Coordinates (km) Population Observed Expected LLR RR p-value
Augie 12-19 2017 12.9, 4.6 286 23 025 9 550 120 34
000
120 <0.001
Ebonyi 9 2014 6.5, 8.1 30 898 58 0.51 220 110 <0.001
Atakunmosa
West
10 2014 7.5, 4.7 15 794 13 0.45 31 29 <0.001
Ibadan North 29-34 2017 7.4, 3.9 0 408 17 1.5 11 25 <0.001
Lagos Island 42-45 2016 6.5, 3.4 0 274 11 0.66 17 21 0.002
Lokoja 30 2015 8.2, 6.5 0 251 7 0.15 48 20 0.002
Karu 37-41 2016 9.0, 7.8 24 384 21 1.2 41 18 <0.001
Abaji 13-19 2017 8.9, 6.9 52 1 473 31 4.5 22 4.5 <0.001
Biriniwa 13-20 2017 12.8, 10.1 272 33 430 702 170 480 4.3 <0.001
Table 7.6 Cases of meningococcal meningitis prevented by reactive vaccination in Niger and Nigeria, 2015-2017. Numbers in parentheses show 2.5th and 97.5th
percentiles of sensitivity analysis.
Country Nm cases prevented Proportion of Nm cases prevented Total Nm cases (in absence of vaccination) Suspected meningitis cases (reported)
Niger 834 (215 - 1 730) 9% (4 - 14%) 9 250 (7 560 - 11 200) 13 400
Nigeria 265 (45 - 781) 3% (1 - 5%) 8 980 (7 550 - 10 600) 13 300
Total 1 100 (260 - 2 510) 6% (3 - 10%) 18 200 (15 100 - 21 800) 26 700
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7.3.2 Impact of reactive campaigns
Reactive vaccination campaigns were conducted in 2015, 2016, and 2017 in 60 districts in
response to NmC outbreaks using roughly 4 million doses of polysaccharide vaccine, monovalent C
conjugate vaccine, and quadrivalent ACWY conjugate vaccine (Table D.3). Our model estimates
that these campaigns prevented 1,100 of 19,000 (6%) cases of meningococcal meningitis overall
during the period 2015 to 2017 (270 of 10,000 [3%] cases in Nigeria and 830 of 9,000 [9%] cases
in Niger (Table 7.6). In the sensitivity analysis, the proportion of cases prevented ranged from



































































































































Fig. 7.4 Number of interventions (individual districts vaccinated), doses, proportion of total cases averted,
and number needed to vaccinate to prevent a case over the period 2013-2017 for different reactive vaccination
strategies using ACW polysaccharide, C conjugate, and ACWYX conjugate vaccine. Points show estimates for
four-week delays, lines show two- and six-week delays, with arrow heads indicating shorter delays.
7.3.3 Modelling alternative polysaccharide vaccination strategies
The current strategy required fewest interventions with 63 districts requiring 11 million
doses of polysaccharide vaccine between 2013 and 2017, followed by alternative strategy C which
would have targeted an additional 21 districts with 5 million additional doses. Strategies A
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Fig. 7.6 Cases averted by strategy, delay, and vaccine type.
and B would have required targeting 73 and 82 additional districts respectively, requiring an
additional 14 and 15 million doses of polysaccharide vaccine.
Strategy C had the greatest sensitivity in predicting small outbreaks, whereas the current
strategy had the least (Figure 7.7). Sensitivity was comparable across all strategies for large
outbreaks. The current strategy had the highest PPV at any cumulative incidence threshold,
followed by strategy C. Specificity and NPV were similar across all strategies.
Strategies A and B prevented the most cases, 19% and 18% of all meningococcal meningitis
cases, followed by strategy C (11%) and the current strategy (10%) (Figure 7.4).
With shorter delays of two weeks, A prevented the most cases; with longer delays of six
weeks, B prevented the most cases (Figure 7.6). Across all strategies, interventions with delays
of two weeks prevented between 1.3 and 1.9 times as many cases those with delays of six
weeks. Shortening the delay by two weeks while maintaining the current strategy would have
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Fig. 7.7 Sensitivity, specificity, positive predictive value, and negative predictive value of different vaccination
strategies for predicting cumulative annual incidence between 20 and 100 suspected cases per 100,000.
prevented 14% of cases, close to the proportion prevented by strategies A and B while requiring
no additional vaccine. No strategy outperformed the current strategy in terms of NNV, but A
was the second most efficient use of vaccine, with an NNV of 6 800 compared to the current
strategy at 5 900.
7.3.4 Modelling alternative conjugate vaccination strategies
Using polysaccharide vaccine resulted in between 3 and 28 more interventions than conjugate
vaccine depending on the strategy adopted. Using the pentavalent conjugate vaccine prevented
between 2.1 and 2.5 times as many cases as the polysaccharide vaccine (Figure 7.4). Conjugate
vaccine was more efficient in terms of NNV than polysaccharide. Comparing situations with the
same targeting strategies and the same delays, using polysaccharide vaccine requires between
1.9 and 2.7 times as many doses to prevent the same number of cases (Figure 7.5). Ignoring
operational costs of interventions, as these will be the same regardless of vaccine type, this
means that pentavalent conjugate vaccine could be at least equally cost effective at about 1.9
times the cost of the polysaccharide vaccine.
7.4 Discussion
There was significant clustering of high incidence districts in every year, with local clusters
occurring around Tambuwal in Nigeria in 2013 and 2014, around Niamey, Niger in 2016, and
two around Sokoto and Zamfara States in Nigeria in 2017. These two 2017 clusters were also
identified by spatio-temporal scan in a single cluster occurring between weeks 12 and 19 and
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centred on Augie. No significant local cluster was identified in 2015 although incidence was high
in Niamey and Tillaberi Regions, perhaps because the distribution of incidence was more even
in space. None of these clusters had previously been identified by formal statistical analysis,
but the 2013 and 2014 clusters were described by Funk and colleagues in their initial report on
the novel strain.47
There is no strong evidence to support a change in the methods currently used for predicting
and targeting outbreaks. The current weekly incidence threshold of 10 suspected cases per
100,000 is highly specific and sensitive to large outbreaks. Shortening delays between outbreak
detection and response offers a substantial benefit. These two results are consistent with previous
findings regarding group W outbreak response.89 Although the absolute values in NNV may
differ slightly between this and previous studies, adjustment for differing assumptions about
coverage and vaccine efficacy can largely account for these differences.89,97
These results demonstrate the importance of timeliness in effective reactive vaccination
campaigns. Delays are often associated with vaccine procurement. A recent trial of village-
wide antibiotic prophylaxis in response to an NmC outbreak in Niger demonstrated significant
reductions in incidence and no significant increase in carriage of antibiotic-resistant enterobac-
teria.201,218 Because antibiotics are much more readily available than meningitis vaccines, the
delay between detection and response to an outbreak can be substantially shortened. However,
despite the positive initial findings, the risk of antibiotic resistance is generally perceived to be
too great to justify widespread use of reactive chemoprophylaxis.
This study also highlights the substantial difference between the number of doses of vaccine
required to intervene as per WHO policy (roughly 11 million) and the number of doses that were
used in reactive vaccination campaigns between 2013 and 2017 (roughly 4 million). Although
some of this shortfall can be explained by the necessity of dropping the etiological confirmation
requirement in this model, it is clear that vaccine scarcity had an impact on decisions about
where and in which age groups to carry out reactive vaccination. A further development of this
work could identify a threshold that maximises case prevention for a constrained number of
doses of vaccine. This could make it easier to efficiently manage the ICG vaccine stockpile as
well as maximising the overall impact of reactive campaigns.
This analysis estimates that the reactive vaccination campaigns that took place between
2015 and 2017 prevented fewer than 10% cases of meningococcal meningitis. This is probably
due in part to the smaller scope of campaigns necessitated by vaccine scarcity. However, it
is important to emphasise that even under ideal conditions, reactive vaccination would only
have prevented 20% of cases. Two key aims of theMeningitis 2030 Roadmap are eliminating
meningitis epidemics and substantially reducing cases and deaths from vaccine-preventable
meningitis.6 Even with a timely and broad response, reactive vaccination alone would not achieve
either of these aims.
This is the first study to model reactive vaccination in a multi-year framework, recognising
that the benefits of outbreak response may be long-term as well as immediate. The model
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suggests that even over a relatively short period of time, using conjugate vaccine is more efficient
per dose than polysaccharide in this context, and may be more cost-effective depending on
how the vaccine is priced. Considering that conjugate vaccines have a long-lasting impact on
immunity and a substantial response was modelled in 2017 at the end of the period for which
data were available, this analysis presents an underestimate of the per dose impact of conjugate
vaccination. In future, the analysis could be extended to estimate the full benefit of doses
delivered in 2017.
Vaccination was modelled in a relatively broad age group (2 to 29 years) in order to remain
consistent with previous practice. However, it is possible that a similar effect could be achieved
by targeting a narrower age range of individuals most involved in carriage transmission. Further
simulations using an age-structured transmission model could help to inform potential future
targeting of particular age groups.
Although data from Nigeria on laboratory confirmed cases of meningitis were lacking, one
study confirmed our assumption that NmC was the predominant cause of meningitis in Nigeria,
with 172 of 173 Neisseria meningitidis isolates being from serogroup C.131
Table 7.7 Comparison of laboratory results in outbreak and non-outbreak periods. Data from Niger line list
2015-2017 and Nigeria line list 2015.
Laboratory result Non-outbreak period Outbreak period
No test reported 5 677 44% 7 538 47%
Test reported 7 257 56% 8 464 53%
Test result
Negative 4 636 64% 5 995 71%
N. meningitidis 2 175 30% 2 299 27%
S. pneumoniae 355 5% 139 2%
H. influenzae 83 1% 27 <1%
Other bacteria 8 <1% 4 <1%
Informed by expert opinion, this model assumes that 80% of suspected meningitis cases
occurring during outbreaks are caused by N. meningitidis, with just 20% of suspected cases
caused by N. meningitidis outside of outbreak periods. The rationale behind this assumption is
that a high incidence of suspected cases of meningitis indicates some common underlying cause,
and N. meningitidis is the most common cause of meningitis outbreaks in this region and time
period. However, line list data from Niger between 2015 and 2017 and Nigeria in 2015 suggests
that only 27% of suspected cases occurring during outbreaks are confirmed as meningococcal
meningitis, with a similar proportion occurring outside of outbreak periods (Table 7.7). A
majority of CSFs test negative for common bacterial pathogens both during and outside of
outbreak periods. A variety of factors may contribute to a high rate of false negatives, including
administration of antibiotics before collecting CSF, sample degradation due to testing delays,
and the use of lower-sensitivity culture-based methods and latex agglutination tests.219–222
However, some degree of clinical misclassification of suspected meningitis cases cannot be
excluded. Misidentification of malaria cases seems unlikely because the malaria and meningitis
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seasons in this region are not concurrent.223 Misidentification of measles, though possible due to
its seasonal co-occurrence with meningitis, also seems unlikely because of measles’ characteristic
rash. Nonetheless, this model may overestimate the burden of preventable bacterial meningitis.
Meningococcal meningitis in the African meningitis belt is notoriously difficult to predict.
The aim of this analysis was to evaluate the magnitude of spatiotemporal heterogeneity and
its implications for outbreak response, not to explain the drivers of this heterogeneity. Diverse
factors including variation in local levels of immunity, household crowding, smoke exposure,
and co-circulation of viral infections may contribute to small-scale spatial heterogeneity, while
climactic factors appear to drive year-to-year variation on a larger spatial scale.105,126,127,195,224
The results described here are only relevant insofar as the behaviour of group C meningitis
remains roughly the same. There is a high degree of uncertainty about which epidemiological
characteristics may be considered typical given the strain’s recent emergence. In any case,
it is important to continue with careful surveillance throughout the meningitis belt, striving
especially to improve laboratory diagnostics in outbreak settings.
Chapter 8
Discussion
Numerous challenges must be overcome to achieve the aims stated in the global roadmap to
defeat meningitis in the African meningitis belt by 2030. Short-term strategies are required to
respond to meningococcal meningitis epidemics in the absence of NmCV-5, and long-term plans
need to be formulated about the eventual use of NmCV-5. It has become increasingly apparent
that S. pneumoniae causes a substantial proportion of bacterial meningitis in Africa, and is
capable of causing localised outbreaks similar to N. meningitidis. At the time of writing, there
are no guidelines for response to outbreaks of pneumococcal meningitis.
The aim of this thesis was to characterise the epidemiology of bacterial meningitis in the
African meningitis belt, in particular focusing on non-A meningococci and S. pneumoniae,
which are the predominant causes of bacterial meningitis in the region following the successful
introduction of MenAfriVac. In particular, I considered the impact of mass reactive vaccination
campaigns in response to outbreaks caused by NmC in Niger and Nigeria and S. pneumoniae in
Ghana and modelled potential alternative strategies to increase efficiency and impact of these
campaigns. Although reactive campaigns are inefficient and offer imperfect protection, they
represent the best short-term response to outbreaks of meningitis in the region. I described
patterns of meningitis in space, characterising district- and national-level incidence before and
after the introduction of MenAfriVac and examining whether spatial information could be used
to improve reactive vaccination strategies. In addition to studying patterns of disease, I also
examined carriage, a phenomenon that is essential to establishing herd immunity. Knowledge of
carriage patterns by age and according to serogroup will inform the use of conjugate vaccines
in reactive campaigns and the preventative use of NmCV-5. Finally, I quantified seasonality
in carriage prevalence and acquisition. Understanding seasonality can contribute to predicting
when and where outbreaks occur are likely to occur.
8.1 Summary of findings
There is little evidence to suggest that district-level outbreaks of bacterial meningitis differ
in character according to country or etiology, including S. pneumoniae, but they do occur with
differing frequency. Numerous studies have identified outbreaks of meningitis with similar high
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incidence, marked seasonality, and broad age distribution where S. pneumoniae is the causative
agent.21,61,132,133 The results presented in Chapter 4 suggest that reactive vaccination could be
equally effective in response to outbreaks of pneumococcal meningitis as for meningococcal
meningitis.
Elevated incidence in previous years and neighbouring districts were significant risk factors for
meningitis outbreaks, consistent with the hypothesis that transmission is sustained in intervening
rainy seasons. Although clear spatiotemporal structure of NmC outbreaks is demonstrated,
there is no strong evidence to support a change in the methods currently used for predicting
and targeting outbreaks in response to the re-emergence of NmC. Shortening delays between
outbreak detection and vaccination and choosing conjugate vaccine over polysaccharide offers a
substantial benefit.
This work identifies possible criteria for the introduction of the pentavalent vaccine, including
previous occurrence of suspected and confirmed non-A outbreaks. District-level analysis reaffirms
the importance of subnational variation in meningitis risk.120
Prevalence of predominantly non-NmA meningococcal carriage peaks at 10 years of age
in the African meningitis belt. The longitudinal household study presented in Chapter 6 also
found the highest acquisition rates in 5- to 14-year-olds. This contrasts with patterns in Europe,
where carriage peaks at 19 years of age,24 and may be explained by differences in social contact
patterns.186
Changes in carriage prevalence contribute to seasonal hyperendemicity and outbreaks of
meningitis. Prevalence of carriage is significantly higher during the dry season and where
outbreaks are reported. Carriage acquisition is also associated with history of sore throat during
the dry season. These findings are consistent with modelling which has shown that seasonal
forcing in transmissibility of carriage is required to reproduce the variability and magnitude of
incidence characteristic of the African meningitis belt.39 However, the mechanism underlying
this seasonality is uncertain - it may be directly caused by environmental factors38 or indirectly
by associated cofactors, including seasonal circulation of respiratory viruses.127,190
8.2 Strengths and limitations
This thesis draws on a broad range of data sets to characterise the epidemiology of bacterial
meningitis in the African meningitis belt, incorporating information on both carriage and invasive
disease across 23 countries and 19 years, and utilising diverse methods, including mathematical
modelling, geospatial statistics, and statistical regression. I address both N. meningitidis and
S. pneumoniae, the two predominant causes of bacterial meningitis in the African meningitis
belt. Chapter 5 presents the first formal meta-analysis of meningococcal carriage data from
the African meningitis belt and demonstrates seasonality and age patterns which are unique to
the region. Chapter 4 is the first analysis modelling a systematic response to pneumococcal
meningitis outbreaks and helped to inform the 2017 WHO position paper on pneumococcal
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conjugate vaccines.225 In further evidence of the quality and novelty of the work presented here,
the analyses in Chapters 4 to 7 have all been published in peer-reviewed journals.
The findings summarised above are limited principally by reliance on suspected case data
and inadequacy of the chosen methods to capture the full stochasticity inherent in the system.
The case definition used in meningitis surveillance is non-specific and laboratory confirmation
of cases is still too limited. Confidence in the surveillance data analysis in Chapter 3 is limited
by the underlying assumption that national laboratory confirmation is uniformly representative
of all districts and that causes of meningitis outbreaks are homogeneous within country-years.
Chapters 4 and 7 also rely on limited laboratory confirmation to infer the cause of suspected
cases.
Meningococcal meningitis in the African meningitis belt is notoriously difficult to predict.
The results described in Chapter 7 are only relevant insofar as the behaviour of group C
meningitis remains roughly the same. There is a high degree of uncertainty about which
epidemiological characteristics may be considered typical given the strain’s recent emergence.
Similarly, the findings of Chapter 4 are highly dependent on the age distribution of cases, the
proportion of cases due to S. pneumoniae, and the overall shape of the epidemic incidence curve
over time.
Substantial variability in carriage prevalence remains unexplained by the model developed in
Chapter 5. This is in part due to the unrealistic assumption that all individuals in a given age
group are of the median or midpoint age, and that carriage prevalence changes with respect to
age in the same way in all settings. Because of the sparseness of sampling in older age groups,
a linear relationship between carriage prevalence and age above 30 years was assumed. The
model is also principally informed by two large serial cross-sectional studies carried out between
2009 and 2012.40,41,73,168
8.3 Implications for policy
These findings have particular relevance to four specific policy questions. The first question
is whether the current policy for reactive vaccination for outbreaks caused by meningococci
should be adopted for outbreaks caused by pneumococci. Chapter 4 demonstrated that reactive
vaccination for meningitis outbreaks caused by S. pneumoniae is inefficient, but it is no less
efficient than for meningitis outbreaks caused by N. meningitidis. Considering the high CFR
associated with pneumococcal meningitis, a large number of deaths could be averted by adopting
this policy. However, there are other approaches to reducing the burden of pneumococcal
meningitis in the African meningitis belt. Age-structured mathematical modelling taking into
account both the burden of pneumonia and meningitis caused by S. pneumoniae could indicate
whether switching from 3+0 to 2+1 routine immunisation schedule would help to extend herd
immunity to older age groups, or whether a catch-up dose for older children might be warranted.
Reactive vaccination is not a substitute for figuring out how best to achieve indirect protection
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of older age groups by routine vaccination, and if implemented, should not direct resources away
from routine vaccination.
The second question is whether conjugate vaccines should be used in preference to polysac-
charide vaccines for reactive responses to meningococcal meningitis outbreaks. Conjugate
meningococcal vaccines have higher individual efficacy than polysaccharide vaccines and reduce
carriage acquisition, resulting in higher population-level efficacy. They are also more expensive
than polysaccharide vaccines. Chapter 7 compared using conjugate and polysaccharide vaccines
over a five year period and found that they would have prevented roughly twice the number of
deaths.
The third question is whether the current strategy for predicting meningococcal outbreaks
needs to be updated to reflect the changes in epidemiology since the introduction of MenAfriVac.
Originally designed to detect NmA outbreaks, this threshold has since been validated for NmW.
The findings in Chapter 7 indicate that the current weekly incidence threshold for detecting
meningococcal meningitis outbreaks is still sensitive and specific where NmC is predominant.
Finally, it is unclear where and how NmCV-5 should be used when it becomes available.
The findings in Chapter 5 indicate that undertaking a mass campaign two-thirds the size of the
previous MenAfriVac campaigns would reach more than half of all carriers. The data collected
in this chapter could be used to parameterise a mathematical model that would be used to
inform the choice of specific vaccination schedules, quantifying the additional benefit of mass
vaccination or smaller catch-up campaigns compared to routine immunisation alone. Chapter 3
identifies at least seven countries that are at high risk for non-NmA outbreaks and would be
strong candidates for NmCV-5 introduction.
8.4 Further development of this work
The work in this thesis sets up several avenues for further investigation. The findings
presented in Chapters 5 and 6 demonstrated increased carriage prevalence and acquisition rates
during the dry season, when meningitis outbreaks occur. I was not able, however, to disentangle
the roles played by climactic factors and associated co-factors, such as respiratory viruses, in this
seasonality. Understanding the relative contribution of changes in carriage and susceptibility to
invasion helps us to know what to do in response to outbreaks and seasonal hyperendemicity
- whether to prioritize protecting the most susceptible individuals or those most involved in
transmission.
The findings on carriage prevalence and acquisition patterns by age and serogroup can inform
the design of future evaluation studies for the pentavalent meningococcal vaccine. The spatial
characterisation of outbreak risk can be used to update the meningitis belt map, which has
not been re-evaluated since 2003. Together these findings can aid in the development of more
realistic age-structured and country-specific models, which can be used to help inform decisions
around the introduction of the pentavalent vaccine.
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Epidemiological information about carriage by serogroup are still scarce for the African
meningitis belt, but recent studies have demonstrated striking differences in the prevalence of
the different serogroups.40,73 Although Chapters 5 and 6 addressed carriage of NmW, X, and
Y, there is a distinct lack of data on NmC. A carriage study in Niger or Nigeria where it is
known to be circulating could provide valuable information on the prevalence, acquisition rate,
duration of carriage, and age patterns of this re-emergent serogroup.
8.5 Conclusions
The introduction of MenAfriVac in 2010 has significantly reduced incidence of meningitis
across the African meningitis belt. However, other meningococcal serogroups and Streptococcus
pneumoniae continue to cause outbreaks of meningitis in the region. This thesis set out to
evaluate the remaining challenges to control of bacterial meningitis in the African meningitis
belt and elimination of epidemic meningitis. It demonstrates that outbreaks caused by other
serogroups and Streptococcus pneumoniae, though less frequent, are not fundamentally different
from those caused by NmA. Therefore, similar control strategies should be effective. These
strategies can be enhanced by focusing on reducing transmission by vaccinating particular age
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a b s t r a c t
Streptococcus pneumoniae is increasingly recognised as an important cause of bacterial meningitis in the
African meningitis belt. The World Health Organization sets guidelines for response to outbreaks of
meningococcal meningitis, but there are no current guidelines for outbreaks where S. pneumoniae is
implicated. We aimed to evaluate the impact of using a similar response to target outbreaks of
vaccine-preventable pneumococcal meningitis in the meningitis belt. Here, we adapt a previous model
of reactive vaccination for meningococcal outbreaks to estimate the potential impact of reactive vaccina-
tion in a recent pneumococcal meningitis outbreak in the Brong-Ahafo region of central Ghana using
weekly line list data on all suspected cases over a period of five months. We determine the sensitivity
and specificity of various epidemic thresholds and model the cases and deaths averted by reactive vac-
cination. An epidemic threshold of 10 suspected cases per 100,000 population per week performed the
best, predicting large outbreaks with 100% sensitivity and more than 85% specificity. In this outbreak,
reactive vaccination would have prevented a lower number of cases per individual vaccinated (approx-
imately 15,300 doses per case averted) than previously estimated for meningococcal outbreaks. Since
the burden of death and disability from pneumococcal meningitis is higher than that frommeningococcal
meningitis, there may still be merit in considering reactive vaccination for outbreaks of pneumococcal
meningitis. More outbreak data are needed to refine our model estimates. Whatever policy is followed,
we emphasize the importance of timely laboratory confirmation of suspected cases to enable appropriate
decisions about outbreak response.
 2018 Elsevier Ltd. All rights reserved.
1. Introduction
Following the rollout of the serogroup A conjugate vaccine,
MenAfriVac, across the African meningitis belt since 2010, the inci-
dence of meningococcal meningitis due to serogroup A has sharply
declined [1]. With an accompanying increase in surveillance qual-
ity, it has become increasingly clear that meningitis due to Strepto-
coccus pneumoniae (Spn) represents a substantial proportion of the
burden of endemic meningitis in this region. In addition to this,
localized outbreaks of pneumococcal disease, in excess of normal
seasonal activity, have been reported [2–7].
The introduction of a 13-valent pneumococcal conjugate vac-
cine (PCV13) into Ghana’s routine immunization programme as a
3 + 0 schedule in 2013 is expected to have decreased the burden
of invasive pneumococcal disease in children aged under five years,
based on observations from other African countries [8]. It has been
shown in high-income countries that PCVs provide indirect protec-
tion against invasive pneumococcal disease to older children and
adults and that this is accelerated with the use of catch-up cam-
paigns, however the only country to show indirect benefit without
a catch up campaign in older children used a 2 + 1 schedule [9,10].
The scale of indirect effects that might be achieved following
https://doi.org/10.1016/j.vaccine.2017.12.069
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routine infant PCV immunization in African countries is not yet
clear. An outbreak of predominantly serotype 1 pneumococcal
meningitis in the Brong-Ahafo region of Ghana in late 2015 and
early 2016 demonstrated the ongoing vulnerability of older age
groups and the continuing potential of Spn to cause meningitis
outbreaks in spite of high PCV coverage in infants (94%) [2,11].
Outbreaks of meningococcal meningitis in the African meningi-
tis belt trigger a reactive vaccination response, with the public
health goal of curtailing the outbreak and thus preventing cases
and deaths. It has been suggested that outbreaks of pneumococcal
meningitis due to a vaccine-preventable serotype could also merit
such a response [7,12]. To quantify the potential benefits of reac-
tive vaccination for pneumococcal meningitis outbreaks we mod-
elled a reactive vaccination response to the Brong-Ahafo
pneumococcal meningitis outbreak. Under the currentWHO guide-
lines applied to outbreaks of meningococcal meningitis, when dis-
tricts exceed a threshold of 10 suspected cases per 100,000
population in a week, an epidemic response is triggered [13].
Countries may submit a request to the International Coordinating
Group on Vaccine Provision for Epidemic Meningitis Control for
supplies of meningococcal vaccines to deploy in affected districts.
However, this process takes some time as a request must be com-
pleted and reviewed and vaccine stocks must be delivered, often to
inaccessible areas. For this model, we considered the potential
impact of mass vaccination response in affected districts with
PCV13, to see whether similar guidelines may be appropriate for
outbreaks of pneumococcal meningitis.
When discussing disease in the African meningitis belt, it is
important to distinguish between seasonal fluctuations in endemic
disease, outbreaks – which may be defined as an isolated district
surpassing the epidemic weekly incidence threshold, and wide-
spread epidemics, which affect whole regions or countries in a sea-
son. For the purposes of this study, we define an outbreak of
pneumococcal meningitis using two criteria: (i) weekly incidence
on the regional or district level of suspected meningitis over a sin-
gle dry season exceeding some epidemic threshold that reflects the
upper bound of dry season endemic incidence, (ii) where pneumo-
coccus is the predominant cause. We retain the term ‘‘epidemic
threshold” for consistency with meningococcal vaccination policy,
but do not mean to imply that these events constitute widespread
epidemics.
2. Methods
Line list data on all suspected cases of meningitis reported in
the Brong-Ahafo Region between 2 December 2015 (week 49,
2015) and 11 April 2016 (week 15, 2016) were obtained from the
Ghana Health Service. Brong-Ahafo is a predominantly rural region
located in central Ghana, an area previously considered to be just
outside the main meningitis belt. A suspected case of meningitis
was defined as any person with sudden onset of fever and one of
the following signs: neck stiffness, flaccid neck (in infants), bulging
fontanelle (infants) convulsion, or other meningeal signs [14]. We
determined the sensitivity and specificity of a variety of incidence
thresholds (10, 7, 5, and 3 suspected cases per 100,000 per week)
for predicting a range of sizes of outbreaks (20, 40, 60, 80, and
100 cumulative cases per 100,000). We then modelled reactive
vaccination of 5- to 29-year-olds building on methods developed
in an earlier paper, using an epidemic threshold of 10 suspected
cases per 100,000 per week to define the beginning of the outbreak
and an endemic threshold of 2 suspected cases per 100,000 per
week to define the end of the outbreak [15]. We also performed
a sensitivity analysis using a lower epidemic threshold of 3 sus-
pected cases per 100,000 per week, which corresponds to the alert
threshold for meningococcal meningitis. We chose to target 5- to
29-year-olds because this would effectively extend coverage to
all individuals under 30 years of age (we assumed children under
the age of 5 years were protected by the routine infant PCV13 vac-
cine schedule) and because the highest incidence of confirmed
pneumococcal meningitis was observed in the 10 to 14- and 15
to 29-year age groups.
As a variety of laboratory tests were used for case confirmation,
aetiology was classified according to Table 1. In a large proportion
of cases (60%), aetiology could not be definitively determined. For
this reason, we modelled true cases of Spn meningitis weekly for
each district as (see Table 2)
CSpn ¼ Cs;ið1 pnÞpSpn
where Cs,i is the number of suspected cases reported in week i, pn is
the proportion of CSF samples in the district testing negative (in
Table 1, both probable and confirmed negative cases), and pSpn is
the proportion of all confirmed cases in the district due to Spn. This
modelled case count is hereafter referred to as likely Spn cases.
Because there was some uncertainty regarding false negative tests,
we performed a sensitivity analysis where pn is only the proportion
of CSF samples in the district testing negative by two or more tests
(in Table 1, confirmed negative cases).
We then simulated vaccination with PCV13 using the same
methods described in Trotter et al. [15], making the following
assumptions:
 5- to 29-year-olds represent 52% of the population [16]
 Case fatality ratio for pneumococcal meningitis cases is 23%, as
reported for confirmed pneumococcal meningitis cases in this
data set
 79% of cases of pneumococcal meningitis were caused by PCV13
vaccine-type serotypes [2]
 A single dose of PCV13 would protect at 90% of individuals 5–
29 years of age against PCV13 vaccine-type serotypes, giving
two weeks for the protection to take effect [17]
 5% vaccine wastage
One district, Sene West, was excluded from the analysis despite
having crossed the epidemic threshold because the majority of
confirmed cases were due to Nm.
We determined the cases prevented, deaths prevented, number
needed to vaccinate to prevent a case (NNV) and number needed to
vaccinate to prevent a death (NNVD) for three scenarios: where
vaccination occurs immediately, two, and four weeks after crossing
the epidemic threshold (lag of zero, two or four weeks,
respectively).
Table 1





Spn Any test (Pastorex, culture
or PCR) indicating Spn or
positive gram stain
168 23%
Nm Any test (Pastorex, culture
or PCR) indicating Nm or
negative gram stain
40 23%
Indeterminate Any sample with no test
results
209 15%
Probable negative One test (Pastorex, culture,
PCR or gram stain) failing to
indicate bacteria in CSF
366 2%
Confirmed negative Two or more tests (Pastorex,
culture, PCR or gram stain)
failing to indicate bacteria
in CSF
183 0%
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3. Results
Twenty of the 27 districts of the Brong-Ahafo Region were rep-
resented in the line list. The districts had a mean population size of
105,000. Over the 19-week study period, nine of these had cumu-
lative suspected meningitis incidence greater than 20 suspected
cases per 100,000; five had cumulative incidence greater than 40
per 100,000; four had cumulative incidence greater than 80 per
100,000, and three had cumulative incidence greater than 100
per 100,000. For predicting larger outbreaks of 60 suspected cases
per 100,000 and greater, all thresholds had a sensitivity and nega-
tive predictive value of 100%, but a threshold of 10 per 100,000 per
week had the best positive predictive values and specificity (Fig. 1).
Five districts (Jaman North, Nkoranza South, Tain, Techiman
North, and Wenchi) crossed the epidemic threshold of 10 cases
per 100,000 per week, three of which exceeded a cumulative inci-
dence of 100 cases per 100,000 (Fig. 2).
Sixty-six percent of suspected bacterial meningitis cases in the
five outbreak districts and 73% of confirmed pneumococcal menin-
gitis cases occurred in 5- to 29-year-olds. Fig. 3 shows the age dis-
tribution of suspected and confirmed incidence of meningitis in the
five districts triggering the epidemic threshold.
Vaccinating individuals between 5 and 29 years of age in the
five eligible districts would have required approximately 284,000
doses of vaccine (Table 3). If a vaccination campaign had been
implemented within two weeks of triggering the epidemic thresh-
old of 10 suspected cases per 100,000 per week, an estimated num-
ber of 36 cases would have been prevented during the outbreak
period, placing the number needed to vaccinate to prevent a case
at 15,300. With a delay of four weeks, 20 cases might have been
prevented, whereas immediate vaccination might have averted
61 cases.
Using a lower threshold of 3 cases per 100,000 per week pre-
vents only a fewmore cases, but raises the number needed the vac-
cinate to prevent a case significantly because districts with much
smaller outbreaks also trigger a response.
Using a stricter definition for bacteria negative CSFs results in a
much higher estimate of the number of likely Spn meningitis cases
(335 cases as opposed to 176 in the five outbreak districts) and a
lower number needed to vaccinate to prevent a case (Table S1).
With a delay of two weeks, 63 cases might have been prevented,
placing the number needed to vaccinate at 8800, whereas immedi-
ate vaccination might have averted 113 cases, placing the number
needed to vaccinate at 4800.
4. Discussion
An incidence threshold of 10 cases per 100,000 seems the
most appropriate epidemic threshold for pneumococcal meningi-
tis outbreaks given the limited data available. This threshold
would also have been triggered in four of five previous likely out-
breaks of pneumococcal meningitis identified in the WHO
enhanced meningitis surveillance system (Solenzo, Burkina Faso,
2009; Goundi, Chad, 2009; Karangasso Vigue, Burkina Faso,
2011; Pama, Burkina Faso, 2011) [1]. No attempt was made to
evaluate different microbiological criteria for defining a pneumo-
coccal outbreak. In this case, a simple majority of confirmed cases
due to Spn was required.
Excluding the sensitivity analysis, the number needed to vacci-
nate to prevent a case (NNV) is higher than the range of previous
estimates for reactive meningococcal campaigns (3700–11,600
for 2–4 week lag) [15], suggesting that reactive vaccination for
pneumococcal meningitis outbreaks may be less efficient in pre-
venting cases. Whilst the number needed to vaccinate to prevent
a death (NNVD) has not been estimated for reactive meningococcal
campaigns, the NNVD is expected to be lower for reactive vaccina-
tion in pneumococcal outbreaks given the higher case-fatality rates
typically associated with pneumococcal meningitis [18].
It is not certain how quickly immune response would build up
after PCV13 in the targeted age groups, however, a clinical trial of
naïve 10- to 18-year-olds showed high (>90%) responsiveness one
month post-vaccination [17]. A conjugate vaccine like PCV13
would also have additional indirect benefits, decreasing carriage
and transmission of vaccine-type serotypes where it is used,
although realizing the full indirect benefits would take several
months.
Serotype 1 was particularly dominant in this outbreak. Seven
other studies in the meningitis belt have reported serotype distri-
bution of pneumococcal meningitis cases, all in populations with
no PCV use [3,6,18–22]. Overall, 45% were serotype 1.
Kwambana-Adams 2016 reports a higher proportion of isolates
belonging to serotype 1 (67% overall) in the Brong Ahafo outbreak
than in the other studies [2]. Among the other studies, there are no
Table 2








weekly cases 10 per 105) exceeded
Cumulative
incidence per 105
Asunafo North 143,000 14 7 1 No 9.8
Asutifi North 60,800 1 0 0 No 1.6
Asutifi South 60,600 4 2 1 No 6.6
Atebubu-Amanten 121,000 12 3 0 No 9.9
Berekum 149,000 2 2 0 No 1.3
Dormaa East 58,300 6 1 0 No 10.3
Dormaa Municipal 129,000 27 7 1 No 21.0
Jaman South 106,000 7 5 7 No 6.6
Kintampo North 109,000 11 3 1 No 10.1
Pru 148,000 9 3 2 No 6.1
Sene East 69,400 5 1 0 No 7.2
Sunyani Municipal 141,000 28 9 0 No 19.8
Tano South 89,600 4 2 0 No 4.5
Techiman Municipal 169,000 77 10 4 No 45.5
Jaman North 95,200 364 39 2 Yes 382.3
Nkoranza South 116,000 100 24 6 Yes 86.4
Sene West 66,800 20 2 0 Yes 29.9
Tain 101,000 145 19 12 Yes 143.6
Techiman North 67,700 20 1 1 Yes 29.5
Wenchi 103,000 110 28 2 Yes 106.9
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marked differences between settings described as ‘‘epidemic” or
‘‘outbreak” and endemic settings. There are no appropriate data
available to support or contradict the hypothesis that outbreaks
or clusters of disease tend to be caused by a single serotype
because most serotyping data is published as aggregate data over
many years.
This model is more conservative than the model used to evalu-
ate reactive meningococcal vaccination [15]. Whereas the
meningococcal model assumed all cases occurred in individuals
under 30 years of age, this model estimates that only 70% of cases
occur in the targeted age group. The meningococcal model also
assumed that 79% of suspected cases were due to NmW. In addi-
tion, the surveillance system relies on a case definition of meningi-
tis; immunization against Spn may prevent additional cases of
pneumonia and septicaemia making these estimates conservative.
However, the predictions of this model are highly dependent on
the age distribution of cases, the proportion of cases due to Spn,
and the overall shape of the incidence curve over time. The data
from the Brong-Ahafo outbreak show a particularly strong peak
in the 15- to 29-year age group, similar to distributions reported
from endemic situations [18]. By contrast, the distribution of inci-
dence of Spn meningitis from Traore 2009 peaks sharply in infants
but is otherwise fairly even across age groups despite a description
in the discussion of ‘‘epidemic” patterns [3].
Because many cases had no associated laboratory data, we have
chosen to model suspected Spn meningitis cases. As our sensitivity
analysis has shown (Table S1), reactive vaccination may be more or
less effective depending on underlying assumptions about the true
proportion of suspected meningitis cases caused by S. pneumoniae.
The case-fatality rates in each category support our classification
system, with low rates in bacteria-negative cases, intermediate
rates in untested cases, and high rates in Spn- and Nm-confirmed
cases (Table 1).
These predictions are also dependent on how quickly the out-
break progresses. In this outbreak, 14% of suspected cases occurred
within four weeks of triggering the epidemic threshold – in other
words, 14% of suspected cases would be missed by a reactive
response with a lag of two weeks. A higher proportion of suspected
cases occurred in the first four weeks of past suspected pneumo-
coccal meningitis outbreaks: 18% in Goundi, Chad in 2009, 28% in
Karangasso Vigue, Burkina Faso in 2011, 21% in Pama, Burkina Faso
in 2011 and 38% in Solenzo, Burkina Faso in 2009 [1].
Fig. 1. Negative predictive value (NPV), positive predictive value (PPV), sensitivity, and specificity of various incidence thresholds (3, 5, 7, and 10 suspected cases per 100,000
per week) for predicting a range of sizes of outbreaks.
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Our estimates, based on data from the Brong-Ahafo outbreak,
suggest that reactive vaccination for pneumococcal meningitis
would have prevented fewer cases per dose of vaccine than previ-
ous estimates for meningococcal meningitis reactive vaccination (a
routine intervention in the African meningitis belt). As the size and
duration of outbreaks are likely to vary by country and by year,
data from future outbreaks are needed to refine these estimates.
It is clear that any reactive response must be timely in order for
it to be effective. A particular challenge is ensuring rapid microbi-
ological confirmation of the organism responsible for the outbreak
and serotyping of pneumococcal isolates to determine if the out-
break is due to a vaccine-type strain. In Brong-Ahafo, serotyping
facilities were initially not available locally and samples were sent
to the MRC laboratory in The Gambia, leading to an interval of sev-
eral weeks before results were available. A technical mission from
MRC the Gambia provided support to establish serotyping capacity
in Sunyani Hospital in Brong-Ahafo during the course of the out-
break. In addition, CDC established PCR capability at Tamali Zonal
Public Health Laboratory during the outbreak, which serves Brong-
Ahafo. If reactive vaccination for pneumococcal meningitis out-
breaks were to be recommended by WHO, it will be important to
ensure that other meningitis belt regions also establish and main-
tain serotyping capacity. Even if reactive vaccination for pneumo-
coccal meningitis outbreaks is not recommended, building
laboratory capacity in these regions will benefit health systems
more broadly.
This study does not evaluate the potential impact of mass pre-
ventive vaccination, or of extending PCV coverage to older age
groups through catch-up campaigns. WHO’s Strategic Advisory
Group of Experts (SAGE) on Immunization reviewed primary data
on PCV vaccine schedules and their impact on carriage and dis-
ease, together with evidence from modelling studies on the
impact of catch-up campaigns in October 2017 (http://www.
who.int/immunization/policy/sage/en/). Further work may be
warranted to quantify the impact of extending PCV to older ages
(over 5 years) in preventive campaigns, but this is beyond the
scope of this paper.
With the roll-out of PCV in the African meningitis belt, the risk
of pneumococcal meningitis outbreaks and the need for subse-
quent reactive vaccination responses may recede as increasing
numbers of birth cohorts are protected. The WHO is currently
reviewing whether a different vaccination schedule with a subse-
quent booster dose would be more appropriate for this setting
[12]. Meanwhile, this study provides the first evidence that
Fig. 2. Incidence of suspected meningitis, likely and confirmed pneumococcal meningitis in five districts crossing the epidemic threshold of 10 cases per 100,000. Grey
vertical lines indicate beginning and end of outbreak period.
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reactive pneumococcal vaccination could prevent cases and save
lives during confirmed outbreaks. Additional work is needed to
clarify the conditions warranting a response, and the logistical
implications of supplying PCV13 for reactive vaccine campaigns.
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Table 3






Cases prevented (% of total










10 0 61 35% 14 9100 39,100
10 2 36 21% 8 15,300 66,000
10 4 20 11% 5 27,800 120,000
3 0 63 32% 15 22,500 96,900
3 2 40 20% 9 35,300 152,000
3 4 23 12% 6 60,500 261,000
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Abstract
Meningococcal carriage dynamics drive patterns of invasive disease. The distribution of
carriage by age has been well described in Europe, but not in the African meningitis belt, a
region characterised by frequent epidemics of meningitis. We aimed to estimate the age-spe-
cific prevalence of meningococcal carriage by season in the African meningitis belt. We
searched PubMed, Web of Science, the Cochrane Library and grey literature for papers report-
ing carriage of Neisseria meningitidis in defined age groups in the African meningitis belt. We
used a mixed-effects logistic regression to model meningococcal carriage prevalence as a func-
tion of age, adjusting for season, location and year. Carriage prevalence increased from low
prevalence in infants (0.595% in the rainy season, 95% CI 0.482–0.852%) to a broad peak
at age 10 (1.94%, 95% CI 1.87–2.47%), then decreased in adolescence. The odds of carriage
were significantly increased during the dry season (OR 1.5 95% CI 1.4–1.7) and during out-
breaks (OR 6.7 95% CI 1.6–29). Meningococcal carriage in the African meningitis belt peaks
at a younger age compared to Europe. This is consistent with contact studies in Africa, which
show that children 10–14 years have the highest frequency of contacts. Targeting older
children in Africa for conjugate vaccination may be effective in reducing meningococcal
transmission.
Introduction
Most transmission of Neisseria meningitidis occurs amongst carriers; therefore vaccinating
carriers is the only way to generate herd protection. Experience with conjugate vaccines has
shown that with the correct age-specific strategy, such indirect effects make a profound con-
tribution to disease control [1]. To this end, it is important to understand the distribution of
meningococcal carriage to allow for efficient targeting of individuals who account for the most
transmission. The age distribution of meningococcal carriers in industrialised countries has
been described and synthesised; this showed that prevalence peaks around 19 years of age
[2]. Patterns of carriage are however known to differ in the African meningitis belt, a region
that experiences the highest burden of meningococcal disease in the world. Meningococcal
carriage is a common occurrence compared to invasive disease, although the overall prevalence
is highly variable, ranging from 0% to 30% [3,4]. Although the distribution of carriage preva-
lence by age also appears more variable in the African meningitis belt than in high-income
countries, some studies have shown that carriage is most prevalent in children [3].
Studies of meningococcal carriage in the African meningitis belt have identified a number
of risk factors apart from age. A multi-site cross-sectional study found increased odds of men-
ingococcal carriage in rural areas vs. urban and higher prevalence in males [4]. Household
crowding and pollution from tobacco and indoor kitchen facilities also increased the odds
of carriage significantly [4]. The association between respiratory infection and meningococcal
carriage remains unclear, but some studies indicate a positive relationship between carriage
acquisition and symptoms of respiratory disease, like sore throat or rhinitis [5]. Localised epi-
demics of meningococcal meningitis occur frequently in the belt, but there is no clear relation-
ship between epidemic status and the prevalence of carriage. One study found higher rates of
serogroup W carriage in a district experiencing a group W epidemic compared to a neighbour-
ing non-epidemic district, prompting speculation that it may be dominance of a strain rather
than overall prevalence that links carriage and epidemics [6].
Season is an important risk factor for carriage in the African meningitis belt. Meningitis
epidemics in the meningitis belt occur in the dry season and mathematical models of menin-
gococcal transmission dynamics currently require substantial ‘seasonal forcing’ of transmission
to reproduce the observed patterns of disease [7]. One study
found higher odds of carriage of capsular meningococci during
the dry season; [4] this has not been demonstrated consistently
but is compatible with the idea that the capsule protects the bac-
terium from drying during aerosol transmission. Carriage of
unencapsulated strains does not appear to have any association
with season [4].
Previous reviews of the literature on meningococcal carriage in
Africa have not been systematic in nature and have not examined
age-specific patterns in any quantitative way. The aim of this
paper was to conduct a systematic literature review of meningo-
coccal carriage prevalence by age and season in the African men-
ingitis belt and to synthesise these data in order to inform future
vaccination strategies.
Methods
Search and study selection
This paper was prepared in accordance with the meta-analysis of
observational studies in epidemiology (MOOSE) and PRISMA
guidelines [8,9]. The literature searches were performed by one
author (LVC) in January 2017 and updated in September 2017.
PubMed, Web of Science, the Cochrane Library and the grey lit-
erature were searched for papers reporting carriage of N. menin-
gitidis in defined age groups in locations within the African
meningitis belt, using the following search terms: ‘(‘Neisseria
meningitidis’ OR ‘N meningitidis’ OR meningitis OR meningo-
coccal OR meningococci OR meningococcus OR meningitidis)
AND (carriage OR carrier OR carriers) AND (Africa OR ‘menin-
gitis belt’ OR Gambia OR Senegal OR Guinea-Bissau
OR Mauritania OR Guinea OR Ghana OR ‘Burkina Faso’ OR
‘Upper Volta’ OR ‘Cote d’Ivoire’ OR ‘Ivory Coast’ OR Togo
OR Benin OR Nigeria OR Niger OR Chad OR Tchad OR
Cameroon OR ‘Central African Republic’ OR Sudan OR ‘South
Sudan’ OR Eritrea OR Ethiopia OR Uganda OR Kenya OR
‘Democratic Republic of Congo OR Zaire)’.
Studies were eligible for inclusion if they reported pharyngeal
carriage of all meningococcal serogroups in defined age groups
in generalisable populations in the African meningitis belt.
Longitudinal, cross-sectional and serial cross-sectional study
designs were included. Studies reporting carriage rates among
household contacts of Hajjis or other known carriers were
excluded. Studies in both English and French were included in
the systematic review. Two studies in Russian were excluded
because abstracts could not be obtained. The reference lists of
included papers were hand-searched to identify any papers that
were missed by the electronic search.
Data extraction and classification
We contacted authors for additional information if studies
reported age groups wider than 10 years and the median age
was not reported or if the time period of the study was not
reported. Where carriage prevalence was reported in age groups
of range 10 years or less, we used the midpoint age for analysis.
For open-ended age groups, we calculated a midpoint with an
upper age limit of 60 years. Using additional data from the
African Meningococcal Carriage Consortium cross-sectional
studies, we divided the oldest age group previously reported as
30 plus years into two groups, 30–44 years and 45 plus years.
For papers that included results from several populations or
studies, data were extracted only for observations meeting the
inclusion criteria. Extracted data included the study location,
time period, design, any mention of an outbreak or epidemic of
meningitis coinciding with the study period, whether the study
occurred before or after the MenAfriVac mass campaigns in the
study region, use of random sampling, laboratory used to culture
the pharyngeal swabs, time between sampling and plating, age
range of the individuals, median age of individuals in each
age group, number of individuals swabbed and the number of
individuals positive for capsulated meningococcal carriage. We
excluded individuals carrying capsule-null isolates from our def-
inition of capsulated meningococcal carriage but isolates charac-
terised as non-determinate or non-groupable were included.
Studies were assigned to the dry or rainy season on the basis of
the month in which the study took place, defining the dry season
as December–June and the rainy season as July–November.
Additional data from the studies by Kristiansen and colleagues
in Burkina Faso and Ethiopia were used to divide prevalence esti-
mates from these studies into dry and rainy season measures.
Studies were classified as having used random sampling if this
was specifically reported; otherwise ‘no’ was recorded.
Data were extracted independently by LVC and AK and differ-
ences were checked by CLT.
Data analysis
For the meta-analysis, we excluded data from age bands wider
than 20 years. For longitudinal studies, only the first observation
in the time series was used to avoid over-representing a particular
population in the meta-analysis.
A natural cubic spline (a piecewise cubic polynomial function
with linear tails) was used to model group median age [2,10]. The
basis matrix for the spline was generated using the ‘ns()’ function
in the R core package ‘splines’. Boundary knots (points in the
spline below and above which the function is defined to be linear)
were placed at 0 and 30 years because of the low density of sam-
pling in older age groups. The number of internal knots was
selected by comparing the AIC of models with two and three
internal knots, placing knots at appropriate quantiles (inner ter-
tiles for two knots, inner quartiles for three knots. Optimal place-
ment of these knots was determined by evaluating the AIC of
models with every possible combination of knots drawn from
the set of ages equidistant from every consecutive observed age
between 0 and 30 years. Internal knots placed at 9.25, 9.75 and
28.5 years of age gave the best model fit.
We modelled season and outbreak status as a three-tiered fixed
effect and a nested interaction term of location and year of swab-
bing as random effects. We used fixed effects for factors that had a
constant effect in all studies and random effects for factors for
which only a subset of all possible levels had been observed. We
tried using the physical laboratory as a proxy for differences in
ambient temperature, growth medium, swab type and other unre-
ported factors which might affect the likelihood of isolating men-
ingococci from a sample, but this did not improve model fit.
Other factors that were considered but did not improve model
fit included mass group A conjugate vaccination, country, decade,
latitude, time to plating and study.
We started with a simple logistic regression because this is the
traditional model for analysing prevalence data. However, when
we found that a low proportion of observations fell within the
bootstrapped 95% CI, we investigated three additional models
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which are commonly used to capture overdispersion: an
observation-level random effects model, a beta-binomial or hier-
archical model and a zero-inflated binomial model [11]. We
found that the simple logistic regression captured more of the
variability in the data than the observation-level random effects
model and provided a better fit than the beta-binomial and
zero-inflated binomial models, so we used a logistic structure
for our final model.
All candidate models allow overall carriage prevalence to vary
but constrain the distribution of prevalence by age to be the same
across all years and locations.
Models were fit using the lme4, spaMM and glmmADMB
packages in R [12–15]. To generate confidence intervals for the
model predictions and random effects, 10 000 iterations of boot-
strapping with replacement were performed and bias-corrected
95% confidence intervals were calculated [16]. Profile confidence
intervals for fixed effects parameters were calculated using the
lme4 package [12]. We assessed model fit by AIC and by per-
forming leave-one-out cross-validation, whereby the model is
refit on the full dataset excluding a single observation and this
new model is used to predict prevalence in the excluded observa-
tion. This prediction is then compared to the true value. To check
the results of the spline model, we identified the age group with
the highest carriage prevalence for each study measuring carriage
in more than one age group and performed a one-way proportion
test between this peak value and prevalence in all other age
groups. To adjust for repeated significance testing, we used an
upper P-value cut-off of 0.0005, yielding an overall confidence
of >95%.
We checked our season definition against average monthly
rainfall anomalies in each site using publicly available data from
the National Oceanic and Atmospheric Administration
(Fig. S1). In a sensitivity analysis, we excluded data from four
sites with non-characteristic rainfall patterns. These sites all fell
on the edges of the meningitis belt: Butajira, Ethiopia (2 sub-
sites), Arba Minch, Ethiopia (4 sub-sites) and Kpalkpalgbeni,
Bring-Ahafo District, Ghana.
For the visual presentation of the fixed-effects portion of the
model, we adjusted the observed carriage prevalence (Pobserved)
to account for the random effects in the full model as follows:
Padjusted = exp(log (Pobserved)-σLocation-σLocation-year), where σLocation
and σLocation -year are the random effects intercept for location
and year for a given observation.
To estimate the proportion of carriers that would be targeted
in a mass vaccination campaign covering four age groups (0–15
years, 0–17 years, 0–19 years and 0–29 years) we assumed a
population structure consistent with that of Niger in 2017 and
used the fitted estimate of carriage prevalence for the rainy season
(although results are consistent across seasons) [17]. We
accounted for uncertainty in this estimate by simulating 100 000
draws from a uniform distribution with boundaries at the 2.5th
and 97.5th percentile of the fitted prevalence, using these draws
as the rates for a random binomial draw with population size cor-
responding to each single year age cohort in Niger 2017 and then
taking the 2.5th and 97.5th percentiles of the proportion covered to
yield a 95% confidence interval.
Assessment of study quality and heterogeneity
We assessed the role of study design by comparing a model with
and without sampling procedure (random vs. non-random) and
with and without time to plating of swabs as fixed-effect variables.
Role of the funding source
The sponsor of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all the data in the
study and had final responsibility for the decision to submit for
publication.
Results
We identified 23 relevant articles that reported unique studies of
carriage by age in generalisable populations in the African men-
ingitis belt representing eight countries: Burkina Faso, Chad,
Ethiopia, Ghana, the Gambia, Mali, Nigeria and Niger. Eleven
were cross-sectional studies; five serial cross-sectional, four longi-
tudinal and three were vaccine trials (two polysaccharide and one
conjugate vaccine). Twelve of 23 articles did not report random-
isation in participant selection. Sixteen studies were eligible for
inclusion in the meta-analysis (Table 1). Seven of these 16 did
not report random sampling. Eighteen of 23 studies in the system-
atic review and 15 of 16 eligible for inclusion in the meta-analysis
reported information on the serogroups or genogroups of the car-
riage isolates (Table 2). See Figure 1 and Tables S1 and S2 for fur-
ther details of search and reasons for exclusion.
Systematic review
Longitudinal studies
Longitudinal studies reported high variation in carriage rates over
time (1–35%), but no significant differences in carriage prevalence
between age groups, probably because of smaller sample sizes
[18–21]. Prevalence recorded around the time of meningococcal
outbreaks was high in recent studies (2000s and 2010s), with
two studies showing particularly high rates in ages 5–29 years
(16–38%) [22–24]. Two early studies (1970s) of carriage during
a single group A meningococcal outbreak found lower rates of
carriage (2–5%) [25,26].
Studies of seasonal change
Most studies which specified months comprising the dry and
rainy seasons placed the beginning of the dry season between
November and January and the beginning of the rainy season
between April and July. One study also included a Harmattan sea-
son (October–January) between the rainy and dry seasons [27].
Early studies documented the variability of carriage prevalence
in the African meningitis belt but found little support for consist-
ent differences in prevalence by season. A year-long study in
Burkina Faso found a wide variation in carriage rates but no sig-
nificant changes associated with the onset of the rainy season
[21]. Two other studies found similarly variable results with no
obvious seasonal patterns [27,28]. One study in rural northern
Nigeria displayed remarkably stable prevalence over the year,
with carriage ranging from 2.1% to 2.7% at four sampling inter-
vals [28]. These early studies may have been limited by their rela-
tively short duration or small sample sizes.
An 8-year longitudinal study of a cohort (n∼ 300) in Northern
Ghana measured carriage twice annually, in April and November.
Although this was not noted in associated publications, the aver-
age carriage rate in November (4.4%) was substantially lower than
that in April (7.9%) [18]. This was the first study to produce evi-
dence supporting the hypothesis that carriage prevalence
increases during the dry season.
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A multi-site serial cross-sectional study in Burkina Faso meas-
uring carriage four times annually in 2009 and 2011 found signifi-
cantly higher carriage prevalence in dry season surveys than in
rainy [29,30]. Finally, a serial cross-sectional study across seven
countries of the meningitis belt found significantly elevated
odds of carriage during the dry season as compared with the
rainy (adjusted OR, 1.54; 95% CI, 1.37–1.75) [4].
Laboratory methods
All studies relied on culture for the initial identification of men-
ingococcal isolates. Between one and ten colonies were selected
for further testing, most commonly serogrouping. Fourteen of
23 studies (all published after 2000) reported using molecular
methods for confirmation and further characterisation of culture
isolates.
Meta-analysis
Data from 16 papers, comprising 114 331 individual swabs, were
available for quantitative data synthesis.
The four model variants tested did not vary greatly in their
parameter estimates and goodness of fit (Table S3). We selected
the simple logistic regression model because the greatest propor-
tion of observations fell within the 95% confidence interval of
bootstrapped predictions and the leave-one-out cross-validation
Table 1. Carriage studies included in meta-analysis. Summary of studies of meningococcal carriage by age in the African meningitis belt included in meta-analysis
Paper Location
Study
period Study design Study population Ages




Cross-sectional School children, children seen





Malumfashi, Nigeria Dec 1977
to Jun
1978











Navrongo, Ghana Apr 1998
to Nov
2005





Longitudinal School children 7–16
Yaro et al., 2007
[20]
Bobo-Dioulasso, Burkina Faso Feb–Jun
2003
Longitudinal General 4–29
Forgor et al., 2005
[23]a








Ouagadougou, Burkina Faso Mar 2006 Cross-sectional General 1–39
Trotter et al., 2013
[36]
Bobo-Dioulasso, Burkina Faso Mar 2008 Cross-sectional General 0–59
Kristiansen et al.,
2011[29]





Basta et al., 2013
[37]









Bamako, Mali; Narena and Siby, Mali; Butajira,
Ethiopiaa; Fatick, Senegal; Niakkar, Senegal;
Kassena-Nankana, Ghana; Navrongo, Ghana;
Konduga, Nigeria; Maiduguri, Nigeria; Mandelia,






















Fajikunda, the Gambia Jul 2013 Cross-sectional General 10–18
Bårnes et al., 2016
[39]a
Arba Minch, Ethiopia Mar–Sep
2014
Cross-sectional General 1–29
aObservations excluded in sensitivity analysis–climactic outlier sites.
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correlation was greatest for this model. This best-fitting model had
season as a fixed effect and location and year as random effects.
The fixed effects parameters of the final model are shown in
Table 3. The model suggests that meningococcal carriage preva-
lence in the African meningitis belt increases rapidly in child-
hood, peaks at 10 years of age (1.94% in the rainy season, 95%
CI 1.87–2.47%) and gradually declines after this point (Fig. 2).
In a country with the same population structure as Niger, our
model estimates that 58% of carriers are under the age of 16
and 84% are under the age of 30 (Table 4). Odds of carriage
were significantly increased for studies taking place during the
dry season (1.5 95% CI 1.4–1.7) as compared with the rainy sea-
son and further increased for studies taking place during out-
breaks (OR 6.7 95% CI 1.6–29), though the uncertainty in the
latter estimate is high as limited data on carriage during outbreaks
are available. No other risk factors were found to significantly
impact the odds of carriage.
Predicted carriage prevalence by age is shown in Figure 2,
incorporating only fixed effects.
One-way proportion testing between peak reported carriage
prevalence and prevalence in all other age groups confirmed
age-related trends, with four of 13 studies showing a peak in
age groups containing 10 years of age (the peak age identified
by the spline regression model) and the remaining nine showing
no significant difference between peak prevalence and the preva-
lence in the age group containing 10 years of age (Table S4).
Predicted carriage prevalence was not significantly different
when excluding data from sites that were climactic outliers
(Table 3, Figure S3).
Location and year contributed to substantial variation in over-
all carriage rates. Random effects intercepts are given in Tables S5
and S6. Figure S2 shows model predictions including random
effects. The variance for the location-year interaction intercept
was greater than that for the location intercept (1.02 vs. 0.55).
Neither location nor year alone was a consistent determinant of
the location-year intercept (Table S6).
Shown in Figure 3, leave-one-out cross-validation predicted
values were moderately correlated with true values (Pearson’s
rho 0.89). However, the median percent error for non-zero values
was substantial, 34%. The model performed poorly at predicting
observations of 0% carriage. More than half of all observations
were outside the 95% confidence intervals for the model predic-
tions (64%).
Discussion
We found that meningococcal carriage rates in the African men-
ingitis belt were significantly higher in individuals aged 5–19 than
Table 2. Meningococcal serogroup distribution. Summary of the serogroup distribution of N. meningitidis isolated from carriers in the African meningitis belt
Study Year of data collection Prevalence of carriage
Serogroup distribution
A C W X Y NG
Burian 1974[35] 1970 144/2569 (5.6%) 19% 1% … 9% 4% 56%
Sanborn 1971[40]a,d 1971 179/311 (57.6%) 52% … … … … …
Blakebrough 1980[25]d 1977 7/130 (5.4%) 43% … … … … …
Blakebrough 1983[26]d 1978 4/168 (2.4%) 50% … … … … …
Leimkugel 2007[18] 1998 14/300 (4.7%) 57% … 7% 0% 29% 7%
Raghunathan 2006[6]a 2002 203/899 (22.6%) 0% 1% 65% 6% … 28%
Amadou-Hamidou 2006[19] 2003 38/287 (13.2%) 0% … 34% … 11% 55%
Forgor 2005[23]b,d 2003 48/299 (16.1%) … … 71% … … …
Yaro 2007[20] 2003 16/456 (3.5%) … … 50% 0% 0% 50%
Mueller 2011[22] 2006 129/615 (21%) 74% … … … 26% …
Sié 2008[24]a,d 2006 24/180 (13%) 92% … … … … …
Trotter 2013[36] 2008 12/1037 (1.2%) … … 25% 8% 42% 25%
Kristiansen 2011[29] 2009 809/20 326 (4%) 10% 0% 9% 11% 56% 13%
Kristiansen 2013[30] 2010 1643/25 520 (6.4%) 0% 0% 6% 75% 13% 5%
MenAfriCar Consortium 2015[4]b 2010 896/48 405 (1.9%) 5% 3% 69% 2% 7% 11%
Kristiansen 2014[33] 2012 390/4964 (7.9%) 0% 6% 87% 8% 3% 2%
Manigart 2016[38]c 2013 33/999 (3.3%) 0% 6% 33% 0% 9% 30%
Bårnes 2016[39]b 2014 492/7479 (6.6%) 0% 1% 6% 14% 2% 76%
All meta-analysis 1970–2014 4703/114 331 (4.1%) 5% 1% 26% 31% 17% 17%
Pre-MenAfriVac 1970–2014 2637/73 202 (3.6%) 10% 2% 25% 9% 23% 27%
Post-MenAfriVac 2010–2012 2066/41 129 (5.0%) <1% <1% 27% 59% 9% 4%
aExcluded from meta-analysis.
bClimactic outliers excluded from meta-analysis in sensitivity analysis.
cTwo group E and five group B carriers also reported.
dPercentages do not sum to 100 because full serogroup data not reported.
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in age groups outside this range. A logistic regression showed that
carriage prevalence increases from a minimum in infants to a
broad peak in children centered at age 10 (1.94% in the rainy sea-
son, 95% CI 1.87–2.47%), then gradually decreases in later adoles-
cence and adulthood. The trends in prevalence by age captured by
the model are broadly consistent with contact studies in the
sub-Saharan Africa, which find the highest intensity of contacts
in 5–15-year-olds, especially close physical contacts and contacts
with individuals outside of the household [41]. In the context of
future strategies for use of the pentavalent meningococcal conju-
gate vaccine, this work shows that a substantial proportion of
meningococcal carriers could be targeted while lowering the
Fig. 1. Selection of studies on meningococcal carriage prevalence for systematic review and meta-analysis. For full details of all the papers that were reviewed,
including reasons for exclusion, please contact the corresponding author.
Table 3. Fixed effects parameters. Predicted odds ratios and profile confidence intervals and median bootstrapped odds ratios and 95% bootstrapped confidence
intervals for fixed effects parameters from fit on full dataset and on dataset excluding climactic outliers
Factor









Natural cubic spline of age
Spline I 3.4 (2.9–4.1) 3.5 (2.5–4.6) 3.6 (3–4.4) 3.7 (2.6–4.9)
Spline II 2 (1.6–2.4) 2 (1.5–2.9) 1.8 (1.4–2.2) 1.8 (1.3–2.6)
Spline III 5.2 (3.7–7.2) 4.9 (3–9.6) 4.9 (3.5–7.1) 4.7 (2.8–9.7)
Spline IV 0.79 (0.71–0.87) 0.79 (0.66–0.93) 0.7 (0.63–0.79) 0.71 (0.59–0.83)
Season
Rainy 1.0 1.0 1.0 1.0
Dry 1.5 (1.4–1.7) 1.5 (1.3–1.8) 1.6 (1.5–1.8) 1.6 (1.3–1.9)
Outbreak 6.7 (1.6–29) 7.9 (3.9–8.3) 4.9 (0.81–31) 5.7 (1.3–6.4)
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upper threshold for vaccination from 29 years of age to 17 or 19
years of age. However, we note that 17% of carriers in the data
that informed our model carried non-groupable strains, which
would not be targeted by a pentavalent vaccine.
The dry season in the African meningitis belt is characterised
by low humidity, high temperatures, increased wind speed and
high levels of airborne dust. We found that the odds of carriage
were significantly increased during the dry season and further
increased during outbreaks, all of which occurred during the
dry season. This is consistent with mathematical modelling
which has shown that seasonal forcing in transmissibility of
carriage is necessary to reproduce the extreme variability
and scale of meningitis incidence characteristic of the African
meningitis belt [7]. This finding is also consistent with in vivo
studies in mice and in vitro studies of human neutrophils
which have shown that exposure to dust is associated with
Fig. 2. Observed carriage prevalence measures and model predictions. Top panel: Circles show the data points included in the meta-analysis, with the larger circles
representing a larger sample size. Solid line shows model predictions including random effects. Shaded ribbon shows 95% bias-corrected confidence intervals.
Bottom panel: Circles show the data points included in the meta-analysis, with carriage prevalence adjusted for random effects intercept. Solid line shows
model predictions excluding random effects. Shaded ribbon shows 95% bias-corrected confidence intervals. Dry season predictions are shown in red; rainy season
in blue; outbreak in green.
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reduced bacterial killing and increased bacterial load in the
nasopharynx [31].
However, it is important to emphasise that the increased odds
of carriage during the dry season and during outbreaks are not
sufficient to fully account for the dramatic increase in disease inci-
dence observed during these periods. There is evidence that indi-
vidual susceptibility to invasive disease also increases during the
dry season and during outbreaks [32].
Mass group A conjugate vaccination has no significant effect
on overall carriage prevalence in the model. Serogroup A menin-
gococci accounted for just 10% of all carriage isolates in pre-
vaccine studies (Table 2), so it is not surprising that the model
did not capture any change due to vaccine-related reductions in
group A carriage. Carriage of group A meningococci did substan-
tially decrease from 0.4% overall before mass campaigns to
<0.005% overall after.
This model has some limitations. Cross-validation predictions
are well correlated with true prevalence (Pearson’s rho 0.89), but
substantial variability in carriage prevalence remains unexplained,
with fewer than half of observations falling within the 95% confi-
dence intervals for model predictions.
The model is principally informed by two large serial cross-
sectional studies carried out between 2009 and 2012, one based
in Burkina Faso (50 810 subjects) [29,30,33] and the multi-
country African Meningococcal Carriage Consortium study (48
405 subjects) [4]. These are both high-quality characteristic multi-
site studies, but this dependence may mean that our model is
more representative of recent epidemiological trends in the
African meningitis belt.
Gender was not included in the model because this was not
consistently reported, but the age distribution of carriage may
be modified by gender because of differences in social behaviour
[34]. A number of studies have also shown a higher prevalence of
carriage in males overall, but this would not be expected to bias
the results of this analysis unless the gender distribution of parti-
cipants were substantially different between age groups [4,5].
Because of the sparseness of sampling in older age groups, a
linear relationship between carriage prevalence and age above
30 years was assumed. As a result, carriage appears to decline
steadily throughout middle and later adulthood. However, in real-
ity, carriage may increase in the elderly as immunity wanes.
Further study of this age group will be important as older people
comprise an increasing proportion of the population in the
African meningitis belt.
Despite these shortcomings, we conclude that older children in
African meningitis tend to be the age group in which carriage is
most prevalent. The odds of carriage are significantly higher
during the dry season and during outbreaks and carriage of
group A meningococci has substantially decreased in countries
where mass MenAfriVac vaccination has been implemented.
This meta-analysis may help to guide vaccination policy, both
to maintain control of group A disease and in the implementation
of affordable multivalent vaccines.
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Abstract objective To investigate potential risk factors for acquisition in seven countries of the meningitis
belt.
methods Households were followed up every 2 weeks for 2 months, then monthly for a further
4 months. Pharyngeal swabs were collected from all available household members at each visit and
questionnaires completed. Risks of acquisition over the whole study period and for each visit were
analysed by a series of logistic regressions.
results Over the course of the study, acquisition was higher in: (i) 5-to 14-year olds, as compared
with those 30 years or older (OR 3.6, 95% CI 1.4–9.9); (ii) smokers (OR 3.6, 95% CI 0.98–13); and
(iii) those exposed to wood smoke at home (OR 2.6 95% CI 1.3–5.6). The risk of acquisition from
one visit to the next was higher in those reporting a sore throat during the dry season (OR 3.7, 95%
CI 2.0–6.7) and lower in those reporting antibiotic use (OR 0.17, 95% CI 0.03–0.56).
conclusions Acquisition of meningococcal carriage peaked in school age children. Recent
symptoms of sore throat during the dry season, but not during the rainy season, were associated with
a higher risk of acquisition. Upper respiratory tract infections may be an important driver of
epidemics in the meningitis belt.
keywords acquisition, risk factors, Neisseria meningitidis, Africa
Introduction
Epidemics of meningococcal meningitis occur periodically
in the African Meningitis Belt, an area of sub-Saharan
Africa stretching from Senegal in the west to Ethiopia in
the east [1]. These epidemics are highly seasonal, with
the majority of cases occurring during the dry season,
predominantly in the first 5 months of the year [2]. Given
that asymptomatic pharyngeal carriage of meningococci
is relatively frequent (ranging from 3% to 30% of the
population) [3] and because meningococcal acquisition
only occasionally leads to invasive disease, one explana-
tion for this striking seasonality is an increased risk of
invasive disease in the dry season, due to mucosal dam-
age from environmental factors such as low absolute
humidity and dust [1, 4, 5]. Another hypothesis suggested
by mathematical modelling is that higher rates of
meningococcal transmission during the dry season,*MenAfriCar Consortium members are in Appendix 1.
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combined with population immunity, may be sufficient to
explain epidemic patterns [6]. Although a review of car-
riage in the meningitis belt published in 2007 found no
evidence to support a seasonal effect on carriage [3],
more recent studies have found a higher prevalence of
carriage in the dry season [7, 8].
Studies of carriage prevalence and acquisition will,
therefore, lead to a better understanding of the epidemi-
ology of meningococcal meningitis in the African menin-
gitis belt. The African Meningococcal Carriage
Consortium (MenAfriCar) undertook 20 cross-sectional
carriage surveys in seven African meningitis belt countries
from July 2010 to July 2012, involving the collection of
over 48 000 pharyngeal swabs. These studies found a
higher frequency of carriage in children aged 5 to
14 years, in the dry season and in rural populations [7].
During these surveys, households with at least one pha-
ryngeal carrier of N. meningitidis were recruited for lon-
gitudinal studies [9].
Previous longitudinal studies in the meningitis belt have
been undertaken mainly at the population level [10–12]
and few have investigated the transmission and acquisi-
tion of carriage at an individual level [13, 14]. The aim
of this MenAfriCar study was to investigate a compre-
hensive set of potential risk factors for the acquisition of




Households included in this study were recruited during
the course of cross-sectional surveys conducted in seven
countries in the African meningitis belt (Chad, Ethiopia,
Ghana, Mali, Niger, Nigeria and Senegal) in 2010, 2011
and 2012. Details of the survey methods employed have
been published previously [7]. Longitudinal surveys were
triggered by the identification of a putative carrier during
a cross-sectional survey (Visit 0). This initial identifica-
tion of carriers relied on conventional microbiology and
was later confirmed via molecular methods at the Univer-
sity of Oxford. In some cases, molecular methods did not
confirm the presence of meningococci, so 51 of 184
households recruited to the study did not have an index
carrier.
Within 4 weeks of the identification of a carrier, all
members of the putative carrier’s household were invited
to take part in further studies (Visit 1). The head of the
household was asked about characteristics of the house-
hold, including numbers of rooms and bedrooms, sleep-
ing arrangements, location of kitchen and cooking fuel,
house construction, drinking water, sanitation and house-
hold assets such as vehicle ownership, livestock and elec-
trical goods.
A pharyngeal swab sample was obtained from all
members of a household who gave consent and a ques-
tionnaire completed which included questions on: smok-
ing; social activities; symptoms of recent respiratory tract
infection; socio-economic status and educational level;
school attendance; travel history; recent medication
including antibiotics; meningitis vaccination; and ethnic
group. Carrier households were followed up 2-weekly for
2 months (Visits 2–5) and monthly for a further four
months (Visits 5–9). At each follow-up visit, each house-
hold member was asked for a pharyngeal swab sample
and to answer a short follow-up questionnaire on factors
that might have changed since the previous visit, such as
symptoms of a respiratory tract infection.
Laboratory methods
Pharyngeal swab samples, taken from the posterior phar-
ynx and tonsillar fossa via the mouth, were plated
directly onto Modified Thayer Martin agar plates in the
field, taken to the laboratory within 6 h of collection and
processed as previously described [9]. A sample of boiled
suspensions of Gram-negative oxidase positive bacteria
was sent to the University of Oxford for molecular analy-
sis. Amplification and sequencing of the rplF gene was
used to confirm the presence of, and to differentiate
between, Neisseria species. Confirmed N. meningitidis
were further characterised by genogroup (including cap-
sule-null) and porA genosubtype.
Data management
Data were managed using the Teleform system version
10.4.1 (Autonomy, Cambridge, UK) with a separate data-
base module linking the main study database with genetic
laboratory results from the Oxford PubMLST.org/neisse-
ria database (https://pubmlst.org/neisseria). Data from the
longitudinal questionnaires were merged using a common
person ID or census number, person matching was
checked, any duplicate entries were removed and aber-
rant values excluded.
Statistical analysis
The genogroup-specific acquisition rates and 95% confi-
dence intervals were calculated as Poisson rates, counting
the number of acquisitions occurring in non-index carri-
ers and the time at risk as the days between the first car-
riage-negative swab and the first positive swab. A series
© 2019 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 393
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of fixed-effects logistic regressions were used to identify
significant risk factors for acquisition. In the first round
of regressions, individual risk factors were included in a
multi-variable logistic regression with the a priori vari-
ables sex, age group and country. In the second round,
risk factors with P < 0.1 in round 1 were added to a sin-
gle model with a priori variables. In the third round, risk
factors with P < 0.05 in round 2 were retained in the
multi-variable model. In the fourth round, all factors
dropped in round 3 were added back in to the model one
by one and all variables with P < 0.05 were retained, giv-
ing the final models. The study-long and visit-by-visit
models were then run with household ID and both house-
hold and individual ID as random effects respectively, to
account for clustering and factors that were no longer
significant (P ≥ 0.05) were dropped.
Acquisition was assessed over the full study period
(study-long) and visit-by-visit. Individuals were defined as
positive for study-long acquisition if they had a negative
swab (no meningococci isolated) at visits 0 or 1 and a
positive swab (any meningococci isolated) at any follow-
ing visit. Individuals were defined as negative for study-
long acquisition if they had a negative swab at visits 0 or
1 and no positive swab at any subsequent visit. Individu-
als with three or more missed visits in total were
excluded, as the possibility of acquisition during this
missed period could not be ruled out and individuals car-
rying at visits 0 or 1 were also excluded.
Individuals were defined as positive for visit-by-visit
acquisition on a given visit if the individual had a posi-
tive swab at the current visit and a negative swab at
the previous visit or carried a different strain at the
previous visit and the strain was not previously carried
during the study. Strains were assessed by genogroup
and porA variable regions 1 and 2. Individuals were
defined as negative for visit-by-visit acquisition on a
given visit if the individual had a negative swab at the
previous visit and a negative swab at the current visit.
Individuals carrying an identical strain to that obtained
at the previous visit and individuals who cleared car-
riage were excluded from the analysis. Tables S1 and
S2 provide the classification of cases for study-long and
visit-by-visit acquisition.
We defined the dry season as January to May and the
rainy season as June to December. Because we found a
significant association between sore throat and season
and also previous studies have demonstrated an interac-
tion between meningococcal carriage, upper respiratory
tract infection and season, we also tested for interaction
between sore throat and season in our final model and
found that the model with an interaction term fitted bet-
ter than the model with no interaction (Table S4).
Ethics
The study was approved by the ethics committee of the
London School of Hygiene and Tropical Medicine and by
the relevant ethical authorities in each African centre [9].
The head of the household or another responsible adult
gave verbal informed consent for the household to be
included in the study. Each individual recruited within
that household gave written informed consent; for chil-
dren under the age of 18 years a parent or guardian gave
written consent and children aged over 12 years were
additionally asked to give written assent.
Results
Acquisition over course of the study
Overall, 169/861 (20%) of the non-index carriers became
pharyngeal carriers of a meningococcus at least once over
the course of the study. A higher proportion of 5- to 14-
year-olds acquired carriage than other age groups and a
higher proportion of participants acquired carriage in
Senegal, Niger, Ghana and Ethiopia relative to Chad and
Mali (Table 1). A wide variation in acquisition rates was
observed between countries. Genogroup W and capsule-
null (cnl) meningococci accounted for the majority (83%)
of acquisitions. The acquisition rates of genogroup W
meningococci were 2.0% per month (95% CI 1.6–2.4)
double that of cnl meningococci at 1.0% per month
(95% CI 0.74–1.4). Genogroups A, C, Y and other gen-
ogroup (i.e. other than A, B, C, W, X, Y or cnl) acquisi-
tions were uncommon and no genogroup B or X
acquisitions were detected.
In the final multi-variable model, the highest odds of
acquisition were amongst 5- to 14- year olds, with odds
in all age groups under 30 years of age being signifi-
cantly higher than the reference group of individuals
30 years and older (Table 1). Active smokers had higher
odds of acquiring carriage than non-smokers living in
households with no smokers, with a lower confidence
bound just below 1 (OR 3.57 95% CI 0.98–12.99).
Non-smokers living in households with smokers also
had elevated odds of acquisition but the difference was
not statistically significant. Wood was the ubiquitous
cooking fuel, with 96% of the participants using this as
cooking fuel; 56% of the participants had additional
wood smoke exposure. Participants with household
exposure to wood smoke (independent of using wood as
cooking fuel) had higher odds of acquiring carriage than
those without (OR 2.60 95% CI 1.26–5.59). Although
this trend was not significant in the regression analysis,
higher acquisition rates were observed in households
394 © 2019 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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Table 1 Risk factors for Neisseria meningitidis acquisition over the full study period: single risk factor analysis and multi-variable
model. Adjustment was made in both single and multi-variable analysis for age, country and sex
Factor
Single risk factor analysis Multi-variable model
Total Positive (%) OR 95% CI Total Positive (%) OR 95% CI
Age
30 plus 205 11.7 1
Under 5 91 28.6 3.12 (1.27, 8.05)
5–14 108 23.1 3.62 (1.42, 9.93)
15–29 161 21.1 2.38 (1.22, 4.76)
Country
Chad 54 5.6 1
Ethiopia 64 26.6 7.65 (1.81, 44.4)
Ghana 74 23 6.77 (1.52, 40.1)
Mali 157 5.7 0.532 (0.110, 3.22)
Niger 206 28.6 10.0 (2.53, 57.3)
Senegal 10 40 13.3 (1.23, 159)
Sex
Female 326 17.5 1
Male 239 21.8 1.00 (0.585, 1.71)
Exposure to wood smoke in house (apart from use in cooking)*
No 372 20.2 1 261 19.2 1
Yes 478 19.0 2.74 (1.76, 4.32) 304 19.4 2.60 (1.26, 5.59)
Tobacco exposure*
None 234 14.1 1 230 13.5 1
Passive (secondhand) smoke 312 22.8 1.92 (0.965, 3.77) 312 22.8 1.92 (0.823, 4.55)
Active smoker 23 30.4 3.75 (1.23, 10.8) 23 30.4 3.57 (0.978, 13.0)§
Any sore throat reported*
No 651 17.8 1
Yes 208 25.5 1.66 (1.09, 2.53)
Any runny nose reported*
No 184 20.7 1
Yes 675 19.4 1.57 (0.995, 2.51)
Use gas as primary cooking fuel*
No 832 20.0 1
Yes 25 12.0 0.311 (0.0664, 1.03)
Completion of primary school (amongst over 17 years)*
No 269 18.2 1
Yes 99 11.1 0.381 (0.170, 0.793)
Household member completed secondary school*
No 444 22.3 1
Yes 415 16.9 0.670 (0.455, 0.983)
More than 2 participants per room*
No 484 14.5 1
Yes 375 26.4 1.44 (0.996, 2.10)
Attending primary school (ages 5–17)
No 52 25 1
Yes 254 23.2 0.721 (0.325, 1.65)
Regular social meetings
None 202 20.3 1
1–2 per week 68 16.2 0.916 (0.404, 1.96)
3–4 per week 48 8.3 0.531 (0.141, 1.61)
5–7 per week 52 5.8 0.356 (0.0793, 1.14)
Index carrier in household
No 259 12.0 1
Yes 600 23.0 1.32 (0.826, 2.16)
© 2019 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 395
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with an indoor kitchen and in households which used
wood as the primary cooking fuel than in those who
did not.
Visit-specific acquisition analysis
Participants who said they had a sore throat since the
previous visit during the dry season were significantly
more likely (OR 3.67 95% CI 1.95–6.65) to have
acquired carriage in that time period than those who did
not have a sore throat in the rainy season (Table 2).
Those who reported taking antibiotics since the previous
visit were significantly less likely (OR 0.169 95% CI
0.0271–0.564) to have acquired carriage.
Discussion
This longitudinal study found a higher risk of acquisition
amongst individuals who reported a sore throat since the
previous visit, but only during the dry season. An associa-
tion between an upper respiratory tract infection and
meningococcal carriage has been reported previously
[14]. A sore throat could be due to an initial inflamma-
tion of the pharynx from meningococcal colonisation or
could be caused by a concurrent unrelated infection that
predisposes an individual to acquisition [15]. If the latter
is true, upper respiratory tract infections in combination
with dust and low humidity may be an important driver
for the high risk of meningitis epidemics in the dry sea-
son. This hypothesis is supported by a recent study indi-
cating an association between upper respiratory tract
infection (defined as otitis, severe sore throat and
rhinopharyngitis) and meningitis outbreaks in Burkina
Faso [16]. Such upper respiratory tract infections could
plausibly increase both the risk of acquisition and the risk
of invasion after acquisition.
The 5 to 14-year-old age group had the highest acquisi-
tion rate. The highest prevalence of carriage in cross-sec-
tional MenAfriCar studies and in Burkina Faso in 2009
was similarly highest in 5 to 14-year olds [7, 17]. An
overall acquisition rate of 2.4% (95% CI 1.6–4.0%) per
month was estimated from this same study using a hid-
den Markov model [9]. There were no significant differ-
ences reported by age group, but data were subdivided
by control and index households and there was no
adjustment for other risk factors.
Additional factors linked to acquisition of meningo-
cocci over the course of this study were smoking
tobacco and exposure to wood smoke. Smoking, pas-
sive exposure to smoke and to smokers has been
shown to convey a high risk of carriage and invasive
disease in high-income countries [18–21]. Exposure to
cigarette smoke has also been linked to the risk of car-
riage in the meningitis belt [7, 14]. The higher risk of
acquisition from smoke exposure in this study suggests
a direct risk from smoke itself, potentially from inter-
ference with mucosal immunity, as exposure to wood
smoke was an independent risk factor. Exposure to
smoke from wood fires has also been shown as a risk
factor for meningococcal meningitis in northern Ghana
[22]. Although use of wood as primary cooking fuel
was not found to be a significant risk factor, this could
be explained by the fact that nearly all study partici-
pants relied on wood as primary fuel or that some
households used outdoor kitchens, thus moderating the
degree of exposure.
Strengths of this study are the multi-centre design
across seven countries of the meningitis belt conducted at
the same time, including a mix of urban and rural popu-
lations with a broad age range, the use of standardised
field and laboratory protocols and a large sample size.
Measuring acquisition rather than carriage ensures that
Table 1 (Continued)
Factor
Single risk factor analysis Multi-variable model
Total Positive (%) OR 95% CI Total Positive (%) OR 95% CI
Use wood as primary cooking fuel
No 31 12.9 1
Yes 828 19.9 1.02 (0.340, 3.83)
Indoor kitchen
No 660 16.4 1
Yes 199 30.7 1.28 (0.838, 1.94)
NB Total number of individuals may not sum to 861 in every case because of missing values.
*P-value less than 0.1 in single risk factor analysis.
§P-value less than 0.05.
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the risk factors identified in this study are not biased by
factors associated with longer carriage duration. A com-
prehensive range of risk factors was included, so that
important confounding factors are unlikely to have been
missed; however, the sampling of carriers and non-
carriers was not random and we would expect some mis-
classification of carriage status from the known low sen-
sitivity of pharyngeal swabbing.
Both the acquisition of meningococci found in this lon-
gitudinal study and prevalence of carriage in the
Table 2 Risk factors for visit-by-visit Neisseria meningitidis acquisition: single risk factor analysis and multi-variable model. Adjust-
ment was made a priori in both single and multi-variable analysis for age, country and sex
Factor
Single risk factor analysis (plus a priori) Multi-variable model
Total Positive (%) OR 95% CI Total Positive (%) OR 95% CI
Age
30 plus 1504 1.8 1
Under 5 1539 3.4 1.99 (1.22, 3.32)
5–14 2129 4.2 2.76 (1.75, 4.48)
15–29 1239 3 1.83 (1.08, 3.15)
Country
Chad 990 0.6 1
Ethiopia 564 4.6 7.54 (2.59, 24.5)
Ghana 828 3.5 5.7 (1.96, 18.6)
Mali 1574 0.9 1.51 (0.483, 5.13)
Niger 2281 5.2 11.5 (4.53, 34.5)
Senegal 174 7.5 14.2 (3.6, 60.7)
Sex
Female 3405 2.9 1
Male 3006 3.6 1.23 (0.907, 1.68)
Antibiotic taken*
No 6592 3.5 1 6150 3.3 1
Yes 261 0.8 0.197 (0.0323, 0.623) 261 0.8 0.169 (0.0271, 0.564)
Interaction term*
No sore throat, rainy 2643 3.3 1 2643 3.3 1
No sore throat, dry 3481 2.8 0.88 (0.651, 1.19) 3481 2.8 0.844 (0.617, 1.16)
Sore throat, rainy 123 2.4 0.906 (0.218, 2.52) 123 2.4 0.82 (0.192, 2.39)
Sore throat, dry 164 11 3.72 (2.09, 6.34) 164 11 3.67 (1.95, 6.65)
Sore throat*
No 6566 3.3 1
Yes 287 7.3 2.64 (1.58, 4.19)
Season
Rainy: June to December 1944 3.1 1
Dry: January to May 4467 3.3 1.07 (0.78, 1.47)
Meningitis vaccination
No 5743 3.7 1
Yes 1110 2 1.54 (0.899, 2.55)
Attendance at social event
No 3319 4.4 1
Yes 3534 2.5 0.851 (0.63, 1.14)
Travel greater than one hour
No 6055 3.6 1
Yes 798 2 0.955 (0.538, 1.58)
Cough
No 5163 3.6 1
Yes 1690 3 0.955 (0.682, 1.31)
Runny nose
No 4634 3.8 1
Yes 2219 2.6 0.961 (0.689, 1.32)
*P-value less than 0.1 in single risk factor analysis.
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MenAfriCar cross-sectional studies varied considerably
by country. Although laboratory methods were standard-
ised across centres, differences in laboratory techniques
could still have contributed to some of the differences
observed. As most meningococcal acquisitions were either
genogroup W or capsule-null and outside epidemics, it
cannot be assumed that risk factors for acquisition of
other genogroups or during epidemics would be the same
as those found in this study [23].
It was surprising that some risk factors such as
household crowding that have long been known to raise
the risk of carriage and disease [7, 13, 24, 25] were
not associated in this study with acquisition. Crowding
was measured here by numbers sharing a bedroom or
bedmat and by numbers of people per room in the
household. It is possible that crowded living conditions
are so prevalent across the meningitis belt countries that
any effect of crowding on acquisition is not
detectable. A study in rural Gambia did not find any
differences in crowding between compounds with and
without cases of meningococcal meningitis during an
epidemic [26].
Reported vaccination was clustered in particular time
periods and countries corresponding to the introduction
of group A conjugate vaccine. Vaccination was not found
to be protective against carriage acquisition. However,
we would not expect a group A conjugate vaccine to
have a significant impact on carriage in this study as very
few group A carriers were detected.
We were not able to draw any conclusions regarding
the relationship between carriage acquisition and disease
incidence because none of the study sites reported an out-
break of meningitis during the follow-up period.
This study involved multiple countries and examined
an exhaustive set of household and individual risk factors
for meningococcal acquisition. The importance of identi-
fying these risk factors is that acquisition is a necessary
prerequisite for invasive disease. Acquisition studies also
play a potential role in vaccine evaluation. Of particular
interest for countries of the African meningitis belt is the
finding that symptoms of upper respiratory tract infection
are linked to risk of acquisition, but only in the dry sea-
son. The evidence is mounting that such infections are an
important factor behind the risk of epidemics in the
meningitis belt.
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Background. After the re-emergence of serogroup C meningococcal meningitis (MM) in Nigeria and Niger, we aimed to 
re-evaluate the vaccination policy used to respond to outbreaks of MM in the African meningitis belt by investigating alternative 
strategies using a lower incidence threshold and information about neighboring districts.
Methods. We used data on suspected and laboratory-confirmed cases in Niger and Nigeria from 2013 to 2017. We calculated 
global and local Moran’s I-statistics to identify spatial clustering of districts with high MM incidence. We used a Pinner model to 
estimate the impact of vaccination campaigns occurring between 2015 and 2017 and to evaluate the impact of 3 alternative district-
level vaccination strategies, compared with that currently used.
Results. We found significant clustering of high incidence districts in every year, with local clusters around Tambuwal, Nigeria 
in 2013 and 2014, Niamey, Niger in 2016, and in Sokoto and Zamfara States in Nigeria in 2017. We estimate that the vaccination 
campaigns implemented in 2015, 2016, and 2017 prevented 6% of MM cases. Using the current strategy but with high coverage 
(85%) and timely distribution (4 weeks), these campaigns could have prevented 10% of cases. This strategy required the fewest doses 
of vaccine to prevent a case. None of the alternative strategies we evaluated were more efficient, but they would have prevented the 
occurrence of more cases overall.
Conclusions. Although we observed significant spatial clustering in MM in Nigeria and Niger between 2013 and 2017, there 
is no strong evidence to support a change in methods for epidemic response in terms of lowering the intervention threshold or 
targeting neighboring districts for reactive vaccination.
Keywords. epidemic response; meningitis; Niger; Nigeria; vaccine.
Since guidelines were first issued by the World Health 
Organization (WHO) in 1995, reactive vaccination policy in the 
African meningitis belt has evolved in response to changes in 
disease burden and continuing insights from research. The first 
set of guidelines proposed an incidence threshold indicating 
high epidemic risk at 15 or more suspected cases of meningitis 
per 100 000 population per week over a period of 2 weeks [1]. 
This was updated in 2000 to recommend a lower threshold of 10 
suspected cases per 100 000 per week for high-risk districts and 
to emphasize the importance of surveillance at a district level, 
because outbreaks of meningitis tend to occur at a fine spatial 
scale and can be missed when surveillance is carried out more 
coarsely [2]. A recommendation was also made for vaccination 
of districts in alert (exceeding incidence of 5 suspected cases per 
100 000 per week) and neighboring an epidemic district. With 
the introduction of group A meningococcal conjugate vaccine 
in the meningitis belt in 2010 and subsequent reduction in the 
burden of group A  meningococcal meningitis, these thresh-
olds were re-evaluated, focusing on Neisseria meningitidis (Nm) 
serogroup W outbreaks [3]. This research informed the next 
iteration of WHO guidelines, which maintained the epidemic 
threshold of 10 suspected cases per 100 000 per week but em-
phasized the importance of surveillance in populations smaller 
than 100 000 persons and minimizing delay between triggering 
of the incidence threshold and intervention. The guidelines also 
lowered the alert threshold to 3 suspected cases per 100  000 
per week and relaxed the recommendation for vaccination in 
neighboring districts to allow for more flexibility [4].
Prior studies of meningitis patterns in Niger have demon-
strated significant spatial heterogeneity and strong interannual 
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and intradistrict variation in meningitis incidence, and authors 
have suggested that surveillance on finer spatial scales may im-
prove the timeliness and targeting of epidemic response [5–7]. In 
particular, these studies find that performing outbreak detection 
on the subdistrict level and response on the district level is more 
efficient than traditional detection at the district level. In light 
of the recent emergence and continued epidemics of serogroup 
C meningococcal meningitis in Nigeria and Niger, we aimed to 
re-evaluate the reactive vaccination policy used to respond to 
seasonal outbreaks of meningococcal meningitis in the African 
meningitis belt and investigated alternative strategies. Although 
subdistrict-level data are not widely available, we wanted to in-
vestigate whether targeting neighbors at the district level might 
allow for more efficient use of vaccine. We also wanted to extend 
the scope of these earlier studies by including data from Nigeria 
in our analysis, and considering the full time period from the 
emergence of the outbreak strain in 2013 [8].
METHODS
Surveillance Data
We used surveillance data on suspected cases of meningitis 
from the enhanced district-level surveillance system estab-
lished in 2003 [9]. A  suspected case is defined as any person 
with sudden onset of fever (>38.5°C rectal or 38.0°C axillary) 
and any one of the following signs: neck stiffness, flaccid neck 
(infants), bulging fontanelle (infants), convulsion, or other me-
ningeal signs. Weekly district-level counts of suspected cases 
are collated nationally and then reported to the WHO Inter-
Country Support Team (WHO-IST) for West Africa. We used 
data from Niger and Nigeria during the period from 2013 to 
2017, when serogroup C was dominant. We used the district-
level population sizes reported by each country to WHO-IST, 
which are updated annually.
We used national-level annual data on confirmed cases of 
meningitis to estimate the overall proportion of cases due to sero-
group C and preventable by vaccination (Table 1). Cerebrospinal 
fluid (CSF) samples are tested by national reference laboratories 
using polymerase chain reaction, culture, or latex agglutination, 
and these results are collated by WHO-IST [10]. Because of the 
lack of microbiological data for Nigeria in 2016, we assumed the 
etiological proportions were the same as in Niger 2016 for the 
purposes of the model. We also used anonymized line list data, 
which includes the age of cases and more detailed laboratory 
confirmation data for Niger 2015 to 2017 and Nigeria 2017, to 
evaluate the accuracy of some of our model assumptions.
Maps
We matched districts to their locations on district-level maps 
obtained from WHO using place names. Where no match was 
found between the map names and a surveillance database place 
name, we used the GeoNames database to situate the unknown 
place name within a known district [11]. Large districts that di-
vided into 2 or more smaller districts during the study period 
(2013–2017) were kept as a single district to allow for tracking 
of vaccine coverage over time and to avoid introducing bias by 
sudden population changes (Supplementary Table S1). We de-
fined neighbors as those districts sharing a border with the focal 
district. This definition of neighboring districts included those 
across national borders.
Cluster Detection
We tested for nonrandom spatial distribution of annual cumu-
lative incidence using the Global Moran’s I statistic for each year 
from 2013 to 2017 [12]. Measures of spatial autocorrelation can 
be highly dependent on the imposed spatial structure, ie, what 
is considered a neighbor and how each neighbor is weighted 
[13]. For this reason, we calculated Moran’s global I statistic in R 
using the spdep package with 3 different weighting structures—
by simple contiguity, great circle distance (within 50 km of cen-
troid), and taking the 5 nearest neighbors, with distance again 
calculated by great circle centroid-to-centroid (Supplementary 
Table S2). For the distance-based weight, we evaluated distances 
between 20 and 100 kilometers. Fifty kilometers was chosen 
Table 1. Confirmed and Suspected Cases of Meningitis and Estimated Proportion of Suspected Cases That Could Have Been Prevented by C, ACW, and 
ACWY Vaccines Between 2013 and 2017 in Niger and Nigeriaa
Year Country Suspected Meningitis Cases Total Confirmed Nm A C X Y W Covered by C Covered by ACW Covered by ACWY
2013 Niger 311 11 0 0 0 0 11 0% 100% 100% 
 Nigeria 871 10 3 7 0 0 0 70% 100% 100% 
2014 Niger 315 24 0 8 0 0 16 33% 100% 100% 
 Nigeria 1175 38 0 38 0 0 0 100% 100% 100% 
2015 Niger 7978 1436 0 1183 1 0 206 82% 97% 97% 
 Nigeria 2655 20 0 20 0 0 0 100% 100% 100% 
2016 Niger 1976 357 0 312 15 0 25 87% 94% 94% 
 Nigeria 831 … … 22 … … … … … …
2017 Niger 3387 1073 0 848 220 0 4 79% 79% 79% 
 Nigeria 9918 18 1 14 0 0 1 78% 89% 89% 
Abbreviations: Nm, Neisseria meningitidis. 
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because it maximized spatial effects in most years. All districts 
meeting neighbor criterion were weighted equally. The signifi-
cance of these values was determined by rank within 999 Monte 
Carlo permutations.
Because all weighting methods detected significant positive 
spatial autocorrelation of similar magnitude in each year, we con-
tinued by using only contiguity weights for our analysis of local 
clusters. We calculated Anselin’s local Moran’s I to locate clusters 
of districts with high incidence or outlier districts with higher in-
cidence than neighbors [5, 14]. We used the spdep package in R 
and GeoDa software to calculate local Moran’s I statistics for each 
district in each year. In GeoDa, we used a permutation approach 
with 99 999 permutations to generate pseudo P values. We then 
compared these to the analytical results from the spdep packages. 
We used an overall alpha of 0.05 and a Bonferroni adjustment for 
repeated testing. Because the analytical P values and the pseudo P 
values gave inconsistent results, we reported only the clusters found 
significant by both methods (Supplementary Table S3, Figure 1).
Definitions
We refer to the raw data of weekly suspected cases as observed 
suspected cases (OSCs), and we refer to cases expected in the 
2013 2014 2015
2016 2017










Figure 1. Cumulative annual district-level incidence of suspected cases of meningitis in Niger and Nigeria 2013 to 2017. Centers of significant clusters of high incidence by 
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absence of the vaccination campaigns taking place in selected 
districts in 2015, 2016, and 2017 as modeled suspected cases. 
Epidemic and alert incidence thresholds are consistent with 
current WHO guidelines, with alert defined as more than 3 sus-
pected cases per 100 000 population per week or more than 2 
cases total per week for districts with less than 30 000 popula-
tion and epidemic with as more than 10 suspected cases per 
100  000 population per week or more than 5 cases total per 
week or a doubling of cases in a 2-week period for districts 
with less than 30 000 population [4]. We define a district-level 
meningitis outbreak period where Nm is the dominant cause of 
meningitis as the period in which incidence of OSCs exceeds 
the alert incidence threshold.
Estimating Cases in the Absence of Intervention
Reactive vaccination campaigns occurred in 2015, 2016, and 
2017 in 56 districts in response to NmC outbreaks using poly-
saccharide vaccine, monovalent C conjugate vaccine, and quad-
rivalent ACWY conjugate vaccine. To model suspected cases of 
meningitis in the absence of vaccination, we made the following 
assumptions: (1) 80% of suspected cases during the outbreak 
period are due to Nm; (2) 20% of cases outside the outbreak 
period are due to Nm; (3) the serogroup distribution is propor-
tional to national annual proportions; (4) there is a delay of 6 
weeks between triggering of the epidemic threshold and protec-
tion from vaccination (Table 2). Where no threshold was trig-
gered but vaccination still took place, we made a best guess for 
the timing of the intervention based on neighboring districts. 
For polysaccharide vaccine, we further assumed the following: 
(1) campaigns target 2- to 29-year-olds, who make up 70% of 
the population and 90% of cases [15, 16]; (2) 80% vaccine ef-
ficacy against serogroups A, C, and W [17]; and (3) protection 
lasts for 104 weeks (approximately 2 years) [18]. This type of 
model has been used by many authors in the past to estimate the 
impact of reactive vaccination for meningitis outbreaks [3, 19, 
20]. More importantly, it assumes no impact of the vaccine on 
carriage and thus transmission of meningococci.
For the monovalent C conjugate vaccine, we used output 
from a dynamic model to approximate herd effects, assuming 
85% vaccine efficacy against serogroup C meningitis, an average 
of 5 years duration of protection, and coverage levels calculated 
from reported population size and vaccine use [21, 22]. For the 
quadrivalent conjugate vaccine, we used output from the same 
dynamic model to approximate herd effects, assuming 98% 
coverage of 2- to 15-year-olds (reflecting the actual coverage in 
Ouallam), 85% vaccine efficacy against serogroups A, C, W, and 
Y, and an average 5 years duration of protection [23].
Vaccine coverage is calculated using the district-level pop-
ulation reported in surveillance data, assuming the targeted 
population is 2- to 29-year-olds, representing 70% of total pop-
ulation, and the number of doses of vaccine released by the 
International Coordinating Group on Vaccine Provision or pop-
ulation vaccinated as reported in the Weekly Epidemiological 
Record where available [24–26]. For all coverage calculations, 
we assumed 10% vaccine wastage.
Modeling New Vaccination Strategies
We then modeled uniform application of the current strategy 
and 3 alternative reactive vaccination strategies, making the 
same assumptions as described above (Table 2). Under the cur-
rent strategy, mass vaccination takes place on a district level 
where the weekly incidence of suspected cases exceeds the 
epidemic threshold and the causative serogroup can be iden-
tified. We drop this etiological confirmation requirement for 
modeling because weekly district-level laboratory data were not 
available. In alternative strategy A, vaccination takes place when 
the alert threshold is exceeded. In strategy B, all neighboring 
districts that have not received vaccine in the last 5 or 2 years for 
conjugate and polysaccharide vaccine, respectively, are targeted 
in addition to the district exceeding the epidemic threshold. In 
strategy C, only those neighboring districts in alert are targeted 
in addition to the focal district in epidemic. To compare these 
strategies, we modeled use of a trivalent polysaccharide vac-
cine, making the following assumptions: (1) campaigns target 
2- to 29-year-olds with 85% coverage, who make up 70% of the 
population and 90% of cases [15, 16]; (2) 80% vaccine efficacy 
against serogroups A, C, and W [17]; (3) protection lasts for 
104 weeks (approximately 2 years) [18]. We model delays be-
tween triggering a vaccine response and onset of vaccine pro-
tection as 4, 6, and 8 weeks, effectively giving 2, 4, and 6 weeks 










Polysaccharide vaccination (2015–2017) Calculated from ICG 
data
80% A, C, W 2 years 6 weeks No 2–29 years; 70% of 
population 
Monovalent conjugate C vaccination 
(2017)
Calculated from ICG 
data
85% C 5 years (average) 6 weeks Yes 1–19 years
Quadrivalent conjugate vaccination  
(2015)
Calculated from ICG 
data
85% A, C, W, Y 5 years (average) 6 weeks Yes 2–15 years
Theoretical polysaccharide vaccination 85% 80% A, C, W 2 years 4–8 weeks No 2–29 years; 70% of 
population
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for implementation and 2 weeks for vaccine protection to take 
effect after delivery [17].
Analysis of Model Results
We evaluated the performance of the different strategies and 
vaccine types by calculating the cases averted, doses of vaccine 
required to prevent a case (NNV), and the sensitivity, speci-
ficity, positive predictive value (PPV), and negative predictive 
value (NPV) of each strategy for predicting outbreaks defined 
by different cumulative annual incidences (from 100 cases per 
100 000 to 20 cases per 100 000).
RESULTS
Spatial and Temporal Characterization
Outbreak activity was first observed in northern Nigeria in 2013 
and continued in 2014 (Figures 1 and 2). In 2015, activity spread 
to the southwestern region of Niger, including the urban area of 
Niamey. Fewer outbreaks were observed in 2016, followed by 
relatively high case counts in Niger and the highest case counts 
in Nigeria thus far in 2017. We detected 20 district-years with 
high incidence and positive spatial autocorrelation (ie, centers 
of clusters of high incidence), 46 districts neighboring these 
clusters, and 1 district with high incidence and negative spatial 
autocorrelation, meaning it was an outlier from its neighbors). 
Tambuwal LGA in Sokoto State in Nigeria, where the group C 
outbreak strain was first identified, was detected as the center of 
high incidence clusters in 2013 and 2014, but it did not pass the 
weekly epidemic incidence threshold (WIT10) of 10 cases per 
100 000 in 2014 and did not exceed a cumulative annual inci-
dence of 100 suspected cases per 100 000 in either year (CAI100) 
[8]. Of the neighboring districts, 2 and 4 districts, respectively 
surpassed the WIT10 in 2013 and 2014 and none exceeded the 
CAI100. No significant clusters were detected in 2015. High 
incidence clustered around Niamey in Niger in 2016. Only 1 
district, Niamey I, exceeded the WIT10, and none exceeded 
the CAI100 (although Niamey I came close with 96 cases per 
100 000). There was also a spatial outlier of high incidence iden-
tified in Nguru LGA in Yobe State in north-central Nigeria. In 
2017, 2 large clusters were detected in Sokoto State and Zamfara 
State in Nigeria. All 15 of the center districts and 16 of the 21 
neighboring districts surpassed WIT10 between weeks 10 and 
18. Nine of the center districts in these clusters and 2 neigh-
boring districts exceeded the CAI100. Supplementary Table S3 
gives full details of all clusters detected.
Impact of Reactive Campaigns
Reactive vaccination campaigns were conducted in 2015, 2016, 
and 2017 in 60 districts in response to NmC outbreaks using 
polysaccharide vaccine, monovalent C conjugate vaccine, and 
quadrivalent ACWY conjugate vaccine (Supplementary Table 
S4). Our model estimates that these campaigns prevented 
1100 of 19 000 (6%) cases of meningococcal meningitis overall 
during the period 2015 to 2017 (270 of 10  000 [3%] cases in 
Nigeria and 830 of 9000 [9%] cases in Niger).
Modeling Alternative Reactive Vaccination Strategies
The current strategy required fewest interventions with 63 dis-
tricts requiring 11 million doses of polysaccharide vaccine be-
tween 2013 and 2017, followed by alternative strategy C, which 
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Figure 4. Sensitivity, specificity, positive predictive value, and negative predictive value of different targeting strategies for predicting cumulative annual incidence be-
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Figure 3. Number of interventions (individual districts vaccinated), doses, proportion of total cases averted, and number needed to vaccinate to prevent a case over the 
period 2013–2017 for different reactive vaccination strategies using polysaccharide ACW vaccine. Points show estimates for 4-week delays, lines show 2- and 6-week de-
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additional doses (Figure 3). Strategies A and B would have re-
quired targeting 73 and 82 additional districts, respectively, re-
quiring an additional 14 and 15 million doses of polysaccharide 
vaccine.
Strategy C had the greatest sensitivity in predicting small out-
breaks, whereas the current strategy had the least (Figure 4). 
Sensitivity was comparable across all strategies for large outbreaks. 
The current strategy had the highest PPV at any cumulative inci-
dence threshold, followed by strategy C. Specificity and NPV were 
similar across all strategies. Strategies A and B prevented the most 
cases, 19% and 18% of all meningococcal meningitis cases, fol-
lowed by strategy C (11%) and the current strategy (10%).
With shorter delays of 2 weeks, A prevented the most cases 
(25%); with longer delays of 6 weeks, B prevented the most 
cases (16%). Across all strategies, interventions with delays of 2 
weeks prevented between 1.4 and 1.8 times as many cases those 
with delays of 6 weeks. Shortening the delay by 2 weeks while 
maintaining the current strategy would have prevented 14% 
of cases, close to the proportion prevented by strategies A and 
B while requiring no additional vaccine. No strategy outper-
formed the current strategy in terms of NNV, but A  was the 
second most efficient use of vaccine, with an NNV of 6800 com-
pared with the current strategy at 5900.
DISCUSSION
We found significant clustering of high incidence districts in 
every year, with local clusters occurring around Tambuwal LGA 
in Nigeria in 2013 and 2014, around Niamey, Niger in 2016, 
and 2 around Sokoto and Zamfara States in Nigeria in 2017. 
The locations of these local clusters are consistent with areas of 
elevated incidence. No significant local cluster was identified 
in 2015 although incidence was high in Niamey and Tillaberi 
Regions, perhaps because the distribution of incidence was 
more even in space.
Our modeling analyses provide no strong evidence to sup-
port a change in the methods currently used for predicting and 
targeting outbreaks. The current weekly incidence threshold of 
10 suspected cases per 100 000 is highly specific and sensitive 
to large outbreaks. Shortening delays between outbreak detec-
tion and vaccination offers a substantial benefit. These 2 results 
are consistent with previous findings regarding group W out-
break response [3]. Although the absolute values in NNV may 
differ slightly between this and previous studies, adjustment for 
differing assumptions about coverage and vaccine efficacy can 
largely account for these differences [6, 27]. However, we note 
that the majority of districts were larger than 100  000 popu-
lation, which is not consistent with WHO recommendations. 
Previous studies have demonstrated that surveillance at finer 
spatial scales may allow for more efficient and earlier use of vac-
cine where it is needed [7, 28].
This study also highlights the substantial difference between 
the number of doses of vaccine required to intervene as per 
WHO policy (approximately 11 million) and the number of 
doses that were made available and used in reactive vaccination 
campaigns between 2013 and 2017 (approximately 4 million) 
[29]. Although some of this shortfall can be explained by the 
necessity of dropping the etiological confirmation requirement 
in our model, it is clear that vaccine scarcity had an impact on 
decisions about where to carry out reactive vaccination and for 
which age groups. Although data from Nigeria on laboratory-
confirmed cases of meningitis were lacking, one study con-
firmed our assumption that NmC was the predominant cause of 
meningitis in Nigeria, with 172 of 173 Nm isolates being from 
serogroup C [30].
Informed by expert opinion, our model assumes that 80% 
of suspected meningitis cases occurring during outbreaks are 
caused by Nm, with just 20% of suspected cases caused by Nm 
outside of outbreak periods. Line list data from Niger between 
2015 and 2017 and Nigeria in 2015 suggests that only 27% of 
suspected cases occurring during outbreaks are confirmed as 
meningococcal meningitis, with a similar proportion occurring 
outside of outbreak periods (Supplementary Table S5). A ma-
jority of CSFs test negative for common bacterial pathogens 
both during and outside of outbreak periods. It is possible that 
this is driven by antibiotic administration before taking CSF, 
sample degradation, and the low sensitivity of latex agglutina-
tion tests and culture methods compared with polymerase chain 
reaction-based methods [31–34]. However, we cannot exclude 
the possibility that there may be substantial clinical misclassifi-
cation of suspected meningitis cases.
CONCLUSIONS
The epidemiological behavior of meningococcal meningitis 
in the African meningitis belt is notoriously difficult to predict. 
Our results will only apply to future epidemiological situations 
insofar as the spatiotemporal distribution and magnitude of 
group C meningitis outbreaks remain approximately the same. 
There is a high degree of uncertainty about which epidemiolog-
ical characteristics may be considered typical given the strain’s 
recent emergence. In any case, it is important to maintain high-
quality surveillance throughout the meningitis belt, striving es-
pecially to improve laboratory diagnostics in outbreak settings.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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Table B.1 Age distribution of confirmed S. pneumoniae meningitis.
Publication Year Age group Confirmed cases Percent of total
Emele 2000 [112] 1987 to 1992 Under 1 year 6 14%
1 to 4 years 17 40%
5 to 9 years 14 33%
10 to 14 years 1 2%
15 to 19 years 1 2%
20 years plus 4 9%
Traore 2009 [62] 2002 to 2006 Under 1 year 57 23%
1 year 15 6%
2 to 4 years 21 8%
5 to 9 years 36 15%
10 to 14 years 23 9%
15 to 19 years 21 8%
20 to 29 years 18 7%
30 to 39 years 25 10%
40 to 49 years 18 8%
50 to 59 years 6 2%
60 years plus 6 2%
Gessner 2012 [111] 2007 to 2009 Under 1 year 47 17%
1 to 4 years 25 9%
5 to 14 years 93 33%
15 to 49 years 96 34%
50 years plus 19 7%
Karou 2012 [110] 2007 to 2010 Under 5 years 18 26%
6 to 12 years 22 32%
13 to 19 years 11 16%
20 to 39 years 8 12%
40 to 55 years 9 13%
Chaibou 2014 [108] 2007 to 2011 Under 1 year 103 23%
1 year 37 8%
2 to 5 years 35 8%
6 to 15 years 143 32%
16 to 30 years 69 15%
31 to 60 years 49 11%
61 plus years 12 3%
Kambire 2016 [32] 2011 to 2013 Under 1 year 276 18%
1 year 65 4%
2 to 4 years 137 9%
5 to 9 years 312 20%
10 to 14 years 287 19%
15 to 29 years 253 17%
30 plus years 198 13%
Kwambana-Adams 2016[21] 2015 to 2016 Under 1 year* 2 2%
1 to 4 years* 3 4%
5 to 14 years 30 35%
15 to 29 years 31 36%
30 to 59 years 16 19%
60 years plus 3 4%
Mihret 2016 [64] 2015 to 2016 Under 4 years § 6 33%
5 to 12 years 4 22%
13 to 19 years 1 6%
20 to 29 years 4 22%
30 to 39 years 0 0%
40 years plus 3 17%
*PCV13 used in routine EPI since 2012. §PCV10 used in routine EPI since 2011.
193
Table B.2 Case-fatality rates of confirmed S. pneumoniae meningitis.
Publication Year Age group Case-fatality rate
Campagne 1999 [59] 1981 to 1996 † Under 1 year 58%
1 to 4 years 57%
5 to 9 years 16%
10 to 14 years 35%
15 to 19 years 62%
20 to 29 years 58%
30 to 39 years 20%
40 plus years 60%
Overall 53% (n=340)
Campbell 2004 [60] 2002 to 2003 Under 1 year 26%
1 to 4 years 9%
5 to 15 years 31%
Overall 23% (n=47)
Leimkugel 2005 [61] 1998 to 2003 All ages 44% (n=117)
Traore 2009 [62] 2002 to 2006 Under 1 year 52% (n=79)
1 to 4 years 50% (n=58)
5 to 14 years 45% (n=80)
15 plus years 44% (n=145)
Overall 47% (n=363)
Mueller 2012 [63] 2007 to 2009 All ages 40% (n=155)
Kambire 2016 [32] ‡ 2011 to 2013 Under 2 years 32% (n=301)
2 to 4 years 18% (n=123)
5 to 9 years 25% (n=275)
10 to 14 years 23% (n=252)
15 to 29 years 23% (n=228)
30 to 64 years 31% (n=143)
65 years plus 54% (n=26)
Overall 26% (n=1348)
Kwambana-Adams 2016[21] ‡ 2015 to 2016 Under 2 years* 33% (n=3)
2 to 4 years* 0% (n=3)
5 to 9 years 33% (n=12)
10 to 14 years 36% (n=22)
15 to 29 years 20% (n=50)
30 to 64 years 38% (n=26)
65 years plus 0% (n=3)
Overall 28% (n=119)
Mihret 2016 [64] 2012 to 2013 All ages § 17% (n=18)
Moisi 2017 [65] 2010 to 2013 All ages 35% (n=78)
†Data from 11 non-meningococcal epidemic years. ‡Calculated from data. *PCV13 used in routine EPI since
2012. §PCV10 used in routine EPI since 2011.
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Table B.3 Serotype distribution of confirmed S. pneumoniae meningitis.
Publication Year Age group PCV13 vaccine-type isolates ST1 isolates
Campbell 2004 [60] 2002 to 2003 Under 16 years 30 of 38 (79%) 1 of 38 (3%)
Leimkugel 2005 [61] 1998 to 2003 Under 1 year 2 of 2 (100%) 0 of 2 (0%)
1 to 4 years 4 of 4 (100%) 2 of 4 (50%)
5 to 14 years 7 of 29 (24%) 4 of 29 (14%)
15 to 29 years 11 of 12 (92%) 11 of 12 (92%)
30 to 59 years 12 of 14 (86%) 11 of 14 (79%)
60 years plus 6 of 9 (67%) 5 of 9 (56%)
Traore 2009 [62] 2002 to 2006 Under 5 years 12 of 18 (67%) 3 of 18 (17%)
5 to 65 years 23 of 30 (77%) 18 of 30 (60%)
Gessner 2012 [111] 2007 to 2009 Under 5 years 32 of 60 (53%) 11 of 60 (18%)
5 to 9 years 26 of 32 (81%) 22 of 32 (69%)
10 to 14 years 24 of 27 (89%) 24 of 27 (89%)
15 to 19 years 18 of 24 (75%) 17 of 24 (71%)
20 to 24 years 6 of 7 (86%) 5 of 7 (71%)
25 to 29 years 9 of 12 (75%) 6 of 12 (50%)
30 to 34 years 7 of 8 (88%) 6 of 8 (75%)
35 to 39 years 3 of 6 (50%) 3 of 6 (50%)
40 to 44 years 4 of 7 (57%) 2 of 7 (29%)
45 to 49 years 7 of 10 (70%) 5 of 10 (50%)
50 years plus 7 of 11 (64%) 5 of 11 (45%)
Collard 2013 [109] 2003 to 2011 Under 2 years 147 of 244 (60%) 17 of 244 (7%)
2 years plus 449 of 633 (71%) 376 of 633 (59%)
Kambire 2016 [32] 2011 to 2013 Under 2 years 156 of 236 (66%) 28 of 236 (12%)
2 to 4 years 51 of 79 (65%) 22 of 79 (28%)
5 to 9 years 168 of 221 (76%) 127 of 221 (57%)
10 to 14 years 156 of 199 (78%) 121 of 199 (61%)
15 to 29 years 128 of 174 (74%) 109 of 174 (63%)
30 to 64 years 67 of 107 (63%) 51 of 107 (48%)
65 years plus 11 of 20 (55%) 6 of 20 (30%)
Kwambana-Adams 2016[21] 2015 to 2016 Under 1 year* 0 of 2 (0%) 0 of 2 (0%)
1 to 4 years* 1 of 2 (50%) 1 of 2 (50%)
5 to 14 years 9 of 10 (90%) 8 of 10 (80%)
15 to 29 years 12 of 14 (86%) 12 of 14 (86%)
30 to 59 years 6 of 10 (60%) 5 of 10 (50%)
60 years plus 1 of 1 (100%) 0 of 1 (0%)
Moisi 2017 [65] 2010 to 2013 Under 5 years 12 of 12 (100%) 1 of 12 (8%)
5 years plus 42 of 56 (75%) 32 of 56 (57%)
*PCV13 used in routine EPI since 2012.
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Table B.4 Annual incidence of confirmed S. pneumoniae meningitis per 100,000.
Publication Year Age group Annual incidence
Campagne 1999 [59] 1981 to 1996* Under 1 year 150
1 to 4 years 10
5 to 9 years 6
10 to 14 years 7
15 to 19 years 9
20 to 29 years 5
30 to 39 years 3
40 plus years 8
Campbell 2004 [60] 2002 to 2003 Under 1 year 43
1 to 4 years 6
5 to 15 years 3
Leimkugel 2005 [61] 1998 to 2003 Under 1 year 43
1 to 4 years 19
5 to 14 years 26
15 to 29 years 18
30 to 59 years 15
60 years plus 23
Traore 2009 [62] 2002 to 2006 Under 3 months 60
3 to 5 months 134
6 to 11 months 57
1 year 29
2 to 4 years 14
5 to 9 years 13
10 to 14 years 10
15 to 19 years 11
20 to 29 years 6
30 to 39 years 14
40 to 49 years 19
50 to 59 years 8
60 years plus 8
Mueller 2012 [63] 2007 to 2009 Under 6 months 58
6 to 11 months 43
1 to 4 years 5
5 to 9 years 11
10 to 14 years 9
15 to 19 years 15
20 to 29 years 6
30 to 39 years 6
40 years plus 4
Kambire 2016 [32] 2011 Under 1 year 31
1 to 4 years 7
5 to 9 years 9
10 to 14 years 10
15 plus years 4
2012 Under 1 year 33
1 to 4 years 7
5 to 9 years 8
10 to 14 years 7
15 plus years 3
2013 Under 1 year 17
1 to 4 years 3
5 to 9 years 4
10 to 14 years 5
15 plus years 2
*Data from 11 non-meningococcal epidemic years.
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Table C.1 Summary of studies of meningococcal carriage by age in the African meningitis belt included in meta-analysis. *Observations excluded in sensitivity
analysis climactic outlier sites.
Paper Location Study period Study design Study population Ages
Burian 1974[166] Bamako, Mali Jan to May 1970 Cross-sectional School children, children seen at
preventative care centers, contacts
of cases
All ages
Blakebrough 1980[181] Malumfashi, Nigeria Dec 1977 to Jun 1978 Cross-sectional School children 5 to 10
Blakebrough 1983[182] Malumfashi, Nigeria Jan to May 1978 Vaccine trial School children (boys), both con-
trols and polysaccharide vaccinees
11 to 20
Leimkugel 2007[169] Navrongo, Ghana Apr 1998 to Nov 2005 Longitudinal General All ages
Amadou 2006[177] Niamey, Niger Feb to May 2003 Longitudinal School children 7 to 16
Yaro 2007[178] Bobo-Dioulasso, Burkina Faso Feb to Jun 2003 Longitudinal General 4 to 29
Forgor 2005[167]* Kpalkpalgbeni, Ghana Apr 2003 to Apr 2004 Serial cross-sectional General All ages
Mueller 2011[170] Ouagadougou, Burkina Faso Mar 2006 Cross-sectional General 1 to 39
Trotter 2013[171] Bobo-Dioulasso, Burkina Faso Mar 2008 Cross-sectional General 0 to 59
Kristiansen 2011[41] Bogodogo, Dande, and Kaya, Burkina
Faso
Feb to Nov 2009 Serial cross-sectional General 1 to 29




MenAfriCar 2015[40] Bamako, Narena, and Siby, Mali Apr 2010 to Jul 2012 Serial cross-sectional General All ages
Butajira, Ethiopia*
Fatick and Niakkar, Senegal
Kassena-Nankana and Navrongo,
Ghana
Konduga and Maiduguri, Nigeria
Mandelia and N’Djamena, Chad
Say and Yantala, Niger
Kristiansen 2013[168] Bogodogo, Dande, and Kaya, Burkina
Faso
Oct 2010 to Nov 2011 Serial cross-sectional General 1 to 29
Kristiansen 2014[73] Bogodogo, Dande, and Kaya, Burkina
Faso
Oct to Nov 2012 Cross-sectional General 1 to 29
Manigart 2016[185] Fajikunda, the Gambia Jul 2013 Cross-sectional General 10 to 18
Barnes 2016[165]* Arba Minch, Ethiopia Mar to Sep 2014 Cross-sectional General 1 to 29
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Table C.2 Summary of carriage studies included in systematic review. *Climactic outlier observations excluded in sensitivity analysis.














No Culture All ages
Sanborn 1971 Northern Nigeria Feb to Mar
1971




No Culture 5 to 15
Etienne 1973 Bobo-Dioulasso, Burkina Faso Feb 1972 to
Feb 1973
Longitudinal General No Culture All ages




School children No Culture 4 to 16




School children No Culture 5 to 10
Blakebrough 1983[182] Malumfashi, Nigeria Jan to May
1978




Yes Culture 11 to 20




General No Culture 1 to 19
Leimkugel 2007[169] Navrongo, Ghana Apr 1998 to
Nov 2005
Longitudinal General Yes Culture with PCR
confirmation
All ages
MacLennan 2000 Senegal & the Gambia Vaccine trial Children receiving
conjugate vaccine
No Culture with PCR
confirmation
5
Raghunathan 2006[155] Dedougou & Yako, Burkina Faso May 2002 Cross-
sectional
General Yes Culture 5 to 25
Amadou 2006[177] Niamey, Niger Feb to May
2003
Longitudinal School children No Culture 7 to 16
Yaro 2007[178] Bobo-Dioulasso, Burkina Faso Feb to Jun
2003
Longitudinal General Yes Culture with PCR
confirmation
4 to 29




General No Culture with PCR
confirmation
All ages
Mueller 2011[170] Ouagadougou, Burkina Faso Mar 2006 Cross-
sectional
General Yes Culture with PCR
confirmation
1 to 39
Sie 2008[180] Nouna Health District, Burkina Faso May 2006 Cross-
sectional
General Yes Culture with PCR
confirmation
All ages
Trotter 2013[171] Bobo-Dioulasso, Burkina Faso Mar 2008 Cross-
sectional
General Yes Culture with PCR
confirmation
0 to 59




General Yes 1 to 29








School children No Culture with PCR
confirmation
5 to 15
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MenAfriCar 2015[40] Bamako, Narena & Siby, Mali
Butajira, Ethiopia*
Fatick & Niakkar, Senegal
Kassena-Nankana & Navrongo, Ghana
Konduga & Maiduguri, Nigeria
Mandelia & N’Djamena, Chad





General Yes Culture with PCR
confirmation
All ages




General Yes Culture with PCR
confirmation
1 to 29




General Yes Culture with PCR
confirmation
1 to 29
Manigart 2016[185] Fajikunda, the Gambia Jul 2013 Cross-
sectional
General No Culture with PCR
confirmation
10 to 18








Table C.3 Details of studies excluded from meta-analysis.
Paper Reason for
exclusion
Study population Location Time
period




Wide age range Polysaccharide
vaccinees and controls
Northern Nigeria Feb 1971 5 to 15 179 311 57.6
Etienne
1973[179]
Wide age range General Bobo-Dioulasso, Burkina
Faso










Wide age range School children Malumfashi, Nigeria Apr 1976
Aug 1976
Oct 1977














































Senegal & the Gambia 1997 5 43 510 8.4
Sie 2008[180] No sample size General Nouna Health District,
Burkina Faso





















Table C.4 Summary of model variants. * Akaike’s information criterion. §Leave-one-out cross-validation predictions and true observations correlation (Pearson’s
rho and 95% confidence interval). ‡Profile confidence intervals non-convergent.
Fixed effects odds ratios (95% CI)
Model type Natural cubic spline of age Season AIC* Log-
likelihood
LOOCV §




























































Table C.5 Carriage rates by study and age group. *Age group containing 10 years of age.




Lower prevalence than peak
(p-value < 0.0005)
Barnes 2016[165] 1-4 years 1575 4.7% ***
(n = 7479) 5-9 years 2766 6.7%
10-14 years* 1674 6.3%
15-19 years 490 9.8% Peak
20-24 years 332 8.4%
25-29 years 642 7.9%
Burian 1974[166] Under 1 year 60 6.7%
(n = 2569) 1-4 years 173 11.6%
5-9 years 1191 5.6%
10-14 years* 881 4.3%
15-19 years 136 5.9%
20-29 years 68 5.9%
30-39 years 38 5.3%
40-49 years 15 0%
Over 50 years 7 14.3% Peak
Emele 1999 1-4 years 95 8.4%
(n = 726) 5-9 years 270 8.5% Peak
10-14 years* 303 4.3%
15-19 years 58 1.7%
Etienne 1973 0-14 years* 63 20.6%
(n = 95) 15 plus years 32 34.4% Peak
Forgor 2005[167] Under 1 year 6 16.7%
(n = 299) 1-4 years 78 7.7%
5-9 years 44 15.9%
10-14 years* 37 29.7%
15-19 years 24 37.5% Peak
20-39 years 93 14.0%
40 plus years 17 5.9%
Kristiansen 2011[41] 1-4 years 4588 2.3% ***
(n = 20326) 5-9 years 5496 4.3%
10-14 years* 3732 5.1% Peak
15-19 years 2810 4.9%
20-24 years 2080 4.1%
25-29 years 1620 3.4%
Kristiansen 2013[168] 1-4 years 6258 4.4% ***
(n = 25520) 5-9 years 6987 8.7%
10-14 years* 4883 8.9% Peak
15-19 years 3159 6.3% ***
20-24 years 2369 3.3% ***
25-29 years 1864 2.7% ***
Kristiansen 2014[73] 1-4 years 1221 5.2% ***
(n = 4964) 5-9 years 1438 11.2% Peak
10-14 years* 896 9.7%
15-19 years 565 8.0%
20-24 years 455 5.1% ***
25-29 years 389 2.8% ***
Leimkugel 2007[169] Under 5 40 5.0%
(n = 300) 5-9 years 43 7.0%
10-14 years* 45 4.4%
15-19 years 34 2.9%
20-29 years 27 11.1% Peak
30-39 years 31 3.2%
40-49 years 33 3.0%
50 plus years 47 2.1%
Continued on next page
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Lower prevalence than peak
(p-value < 0.0005)
MenAfriCar 2015[40] Under 1 year 2195 1.2% ***
(n = 48404) 1-4 years 8817 1.4% ***
5-14 years* 13105 2.7% Peak
15-29 years 12407 1.9% ***
30-44 years 6575 1.3% ***
45 plus years 5305 1.5% ***
Mueller 2011[170] 1 year 30 16.7%
(n = 615) 2-4 years 124 9.7% ***
5-9 years 156 25.6%
10-19 years* 154 24.0%
20-29 years 82 31.7% Peak
30-39 years 69 13.0%
Trotter 2013[171] 0-0.5 years 56 0%
(n = 1037) 0.5-1 years 53 0%
1-4 years 120 0.8%
5-9 years 120 2.5%
10-14 years* 115 0%
15-19 years 118 0%
20-24 years 118 0.8%
25-29 years 115 2.6%
30-39 years 110 0.9%
40 plus years 112 2.7% Peak
Yaro 2007[178] 4-14 years* 224 4.5% Peak
(n = 456) 15-29 years 232 2.6%
1
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Table C.6 Random effects intercepts for location term.
Location Intercept
Bobo-Dioulasso, Burkina Faso -0.14
Bogodogo, Burkina Faso 0.13
Dande, Burkina Faso 0.81
Kaya, Burkina Faso 1.16
Secteur 15, Burkina Faso 0.34
Mandelia, Chad -0.8
N’Djamena, Chad -0.59
Arba Minch, Ethiopia 0.4
Butajira (rural), Ethiopia -0.02
Butajira (urban), Ethiopia -0.31
Kassena-Nankana (town), Ghana 0.34
Kassena-Nankana District, Ghana 0.28
Kpalkpalgbeni, Brong-Ahafo, Ghana 0.28
Navrongo, Ghana -0.32
Bamako, Mali -0.11
Bamako and Koulikoro, Mali 0.26






Malumfashi, Kaduna State, Nigeria -0.58
Fatick, Senegal 0.25
Niakkar, Senegal 0.45








Table C.7 Random effects intercepts for location-year interaction term.
Year
Location 1970 1977 1978 1998 2003 2006 2008 2009 2010 2011 2012 2013 2014
Bobo-Dioulasso, Burkina Faso ... ... ... ... 0.34 ... -0.60 ... ... ... ... ... ...
Bogodogo, Burkina Faso ... ... ... ... ... ... ... -0.22 0.47 -0.36 0.35 ... ...
Dande, Burkina Faso ... ... ... ... ... ... ... -0.11 0.07 -0.25 1.81 ... ...
Kaya, Burkina Faso ... ... ... ... ... ... ... 0.01 1.87 0.70 -0.40 ... ...
Secteur 15, Burkina Faso ... ... ... ... ... 0.63 ... ... ... ... ... ... ...
Mandelia, Chad ... ... ... ... ... ... ... ... 0.01 0.51 -2.01 ... ...
N’Djamena, Chad ... ... ... ... ... ... ... ... -0.18 -0.25 -0.67 ... ...
Arba Minch, Ethiopia ... ... ... ... ... ... ... ... ... ... ... ... 0.75
Butajira (rural), Ethiopia ... ... ... ... ... ... ... ... 0.42 0.45 -0.90 ... ...
Butajira (urban), Ethiopia ... ... ... ... ... ... ... 0.04 0.5 -0.23 -0.88 ... ...
Kassena-Nankana, Ghana ... ... ... ... ... ... ... ... -0.9 1.14 0.41 ... ...
Kassena-Nankana District, Ghana ... ... ... 0.52 ... ... ... ... ... ... ... ... ...
Kpalkpalgbeni, Brong-Ahafo, Ghana ... ... ... ... 0.52 ... ... ... ... ... ... ... ...
Navrongo, Ghana ... ... ... ... ... ... ... ... -1.49 -0.61 1.49 ... ...
Bamako, Mali ... ... ... ... ... ... ... 1.74 -1.32 -0.02 -0.60 ... ...
Bamako and Koulikoro, Mali 0.49 ... ... ... ... ... ... ... ... ... ... ... ...
Narena and Siby, Mali ... ... ... ... ... ... ... ... -0.94 -0.52 0.35 ... ...
Niamey, Niger ... ... ... ... 1.00 ... ... ... ... ... ... ... ...
Say, Niger ... ... ... ... ... ... ... -0.19 -0.18 0.70 -0.42 ... ...
Yantala, Niger ... ... ... ... ... ... ... ... 0.65 0.73 -0.76 ... ...
Konduga, Nigeria ... ... ... ... ... ... ... ... -1.08 -1.19 ... ... ...
Maiduguri, Nigeria ... ... ... ... ... ... ... ... -0.86 ... ... ... ...
Malumfashi, Kaduna State, Nigeria ... -0.20 -0.87 ... ... ... ... ... ... ... ... ... ...
Fatick, Senegal ... ... ... ... ... ... ... ... -0.33 -0.7 1.49 ... ...
Niakkar, Senegal ... ... ... ... ... ... ... -0.99 -0.27 -0.11 2.21 ... ...
Fajikunda, The Gambia ... ... ... ... ... ... ... ... ... ... ... 0.35 ...
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Fig. C.1 Carriage prevalence by age (circles), median bootstrap predictions including random effects (line) and
bias-corrected 95% confidence intervals (ribbon) by location and year. Dry season predictions shown in red;








Fig. C.2 Comparison of model fit (fixed effects) on the full data set (pink and black points) and excluding climactic outliers (pink points only). Carriage prevalence












Malumfashi, Kaduna State, Nigeria




















































Basta 2013 and MenAfriCar 2015
Djicoroni Para, Mali
Basta 2013 and MenAfriCar 2015
Dande, Burkina Faso
Kristiansen 2011, 2013, 2014
Bobo−Dioulasso, Burkina Faso
Trotter 2013 and Yaro 2007
Bogodogo, Burkina Faso
Kristiansen 2011, 2013, 2014
Ira Health Centre, Burkina Faso
Sie 2008
Kaya, Burkina Faso
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Fig. C.3 Rainfall and relative humidity monthly anomalies at study sites compared with model definition of rainy season (black shading). Climactic outliers at
bottom, marked with asterisk.
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Table D.1 District names in surveillance and map data sets.
Country Region District (surveillance) District (map) Year
Niger Agadez Aderbissanat Tchirozerine 2016-2017
Niger Agadez Iferouane Arlit 2017
Niger Agadez Ingall Tchirozerine 2017
Niger Diffa Bosso Diffa 2017
Niger Diffa Goudoumaria Maine Soroa 2017
Niger Diffa N’gourti N’guigmi 2017
Niger Dosso Dioundiou Gaya 2016-2017
Niger Dosso Falmeye Boboye 2017
Niger Dosso Tibiri Guidam-roumdji 2016-2017
Niger Maradi Bermo Dakoro 2017
Niger Maradi Gazaoua Tessaoua 2017
Niger Maradi Guidan-Roumdji Guidam-roumdji 2013-2017
Niger Niamey Niamey II Niamey I 2015-2017
Niger Niamey Niamey III Niamey II 2015-2017
Niger Niamey Niamey IV Niamey II 2015-2017
Niger Niamey Niamey V Niamey III 2015-2017
Niger Tahoua Bagaroua Illela 2017
Niger Tahoua Malbaza Birni N’konni 2016-2017
Niger Tahoua Tahoua Commune Tahoua 2017
Niger Tahoua Tahoua Dept Tahoua 2016-2017
Niger Tahoua Tassara Tchintabaraden 2017
Niger Tahoua Tillia Tchintabaraden 2017
Niger Tillaberi Abala Filingue 2017
Niger Tillaberi Ayorou Tera 2017
Niger Tillaberi Balleyara Filingue 2017
Niger Tillaberi Banibangou Ouallam 2016-2017
Niger Tillaberi Bankilare Tera 2017
Niger Tillaberi Gotheye Tillaberi 2017
Niger Tillaberi Torodi Say 2017
Niger Zinder Belbedji Tanout 2017
Niger Zinder Damagaram T Mirriah 2017
Niger Zinder Takeita Mirriah 2017
Nigeria Adamawa Lamurde Larmurde 2013-2015
Nigeria Adamawa Toungo Teungo 2013-2015
Nigeria Benue Buruku Bukuru 2013
Nigeria Benue Makurdi Markurdi 2013-2017
Nigeria Benue Ogbdibo Ogbadibo 2013
Nigeria Benue Otukpo Oturkpo 2013
Continued on next page
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Country Region District (surveillance) District (map) Year
Nigeria Gombe Shongom Shomgom 2013-2015
Nigeria Imo Ezinihitte Mbaise Ezinihitte 2013-2015
Nigeria Imo Mbaitoli Mbatoli 2013-2015
Nigeria Imo Onuimo Unuimo 2013-2015
Nigeria Jigawa Birniwa Biriniwa 2013-2015
Nigeria Jigawa Kiri-Kasamma Kiri Kasama 2013-2015
Nigeria Jigawa Sule-Tankarkar Sule Tankakar 2013-2015
Nigeria Kaduna Kubau Kuban 2013-2015
Nigeria Kano Ungogo Ungongo 2013-2015
Nigeria Katsina Jibya Jibia 2013-2015
Nigeria Katsina Maiaduwa Mai’Adua 2013-2015
Nigeria Katsina Malunfashi Malumfashi 2013
Nigeria Kebbi Aliero Aleiro 2013-2015
Nigeria Kebbi Arewa Arewa Dandi 2013-2015
Nigeria Kebbi Danko Wasagu Wasagu/Danko 2013-2015
Nigeria Kebbi Koko Bese Koko/Besse 2013-2015
Nigeria Kwara Patigi Pategi 2013-2015
Nigeria Nasarawa N/Eggon Nasarawa Egon 2013-2015
Nigeria Niger Minna Chanchaga 2013-2015
Nigeria Niger Munya Muya 2013-2015
Nigeria Oyo Ogbomoso North Ogbomosho North 2013-2015
Nigeria Oyo Ogbomoso South Ogbomosho South 2013-2015
Nigeria Oyo Oorelope Orelope 2013-2015
Nigeria Taraba K/Lamido Karim Lamido 2013
Nigeria Yobe Bade Barde 2013
Nigeria Yobe Bursari Borsari 2013-2015
Nigeria Yobe Tarmuwa Tarmua 2013-2015
Nigeria Zamfara Birnin Magaji Birnin Magaji/Kiyaw 2013-2015
Nigeria Zamfara Birnin Magaji/Kiyawa Birnin Magaji/Kiyaw 2016-2017
Table D.2 Significant clusters and outliers of high district-level incidence (per 100,000 population) detected
by Anselin’s local Moran’s I-statistic. Epidemic incidence threshold (ET) at 10 cases per 100,000 per week. *
indicates districts which also fall in the primary Kulldorff spatio-temporal cluster centred on Augie, Nigeria.









2013 Tambuwal Sokoto Nigeria Cluster centre 276637 8 87
2013 Kebbe Sokoto Nigeria Cluster 153314 0
2013 Shagari Sokoto Nigeria Cluster 192368 9 46
2013 Yabo Sokoto Nigeria Cluster 141449 1
2013 Aliero Kebbi Nigeria Cluster 81692 20
2013 Argungu Kebbi Nigeria Cluster 242059 2
2013 Augie Kebbi Nigeria Cluster 145231 0
2013 Gwandu Kebbi Nigeria Cluster 187000 9 35
2013 Jega Kebbi Nigeria Cluster 239419 0
2013 Gummi Zamfara Nigeria Cluster 254996 1
2014 Tambuwal Sokoto Nigeria Cluster centre 284936 15
2014 Kebbe Sokoto Nigeria Cluster 157913 0
2014 Shagari Sokoto Nigeria Cluster 198139 8 12
2014 Yabo Sokoto Nigeria Cluster 145692 2
2014 Aliero Kebbi Nigeria Cluster 84224 4 261
2014 Argungu Kebbi Nigeria Cluster 249563 8
2014 Augie Kebbi Nigeria Cluster 149734 12 55
2014 Gwandu Kebbi Nigeria Cluster 192797 12 73
Continued on next page
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2014 Jega Kebbi Nigeria Cluster 246841 22
2014 Gummi Zamfara Nigeria Cluster 263156 30
2016 Kollo Niger Cluster centre 511496 28
2016 Niamey I Niger Cluster centre 503655 8 96
2016 Niamey III Niger Cluster centre 145801 23
2016 Boboye Niger Cluster 385387 7
2016 Filingue Niger Cluster 613430 6
2016 Niamey II Niger Cluster 482426 50
2016 Ouallam Niger Cluster 431800 16
2016 Say Niger Cluster 393721 4
2016 Tera Niger Cluster 727727 11
2016 Tillaberi Niger Cluster 312550 10
2016 Nguru Yobe Nigeria Outlier 212481 51
2017 Bodinga Sokoto Nigeria Cluster centre* 242803 12 135
2017 Dange-Shuni Sokoto Nigeria Cluster centre* 269297 13 188
2017 Isa Sokoto Nigeria Cluster centre* 202241 14 35
2017 Kware Sokoto Nigeria Cluster centre* 185348 17 76
2017 Rabah Sokoto Nigeria Cluster centre* 206479 11 127
2017 Sokoto North Sokoto Nigeria Cluster centre* 322313 14 168
2017 Sokoto South Sokoto Nigeria Cluster centre* 269807 14 144
2017 Tureta Sokoto Nigeria Cluster centre* 94640 12 192
2017 Wamako Sokoto Nigeria Cluster centre* 248635 14 146
2017 Anka Zamfara Nigeria Cluster centre* 201197 12 65
2017 Bakura Zamfara Nigeria Cluster centre* 264300 12 108
2017 Kaura Namoda Zamfara Nigeria Cluster centre* 397878 13 97
2017 Maradun Zamfara Nigeria Cluster centre* 298163 13 116
2017 Talata Mafara Zamfara Nigeria Cluster centre* 304281 13 99
2017 Zurmi Zamfara Nigeria Cluster centre* 415512 13 89
2017 Binji Sokoto Nigeria Cluster* 145382 16 27
2017 Goronyo Sokoto Nigeria Cluster* 252340 14 58
2017 Gwadabawa Sokoto Nigeria Cluster* 320254 14 76
2017 Sabon Birni Sokoto Nigeria Cluster* 287366 11
2017 Shagari Sokoto Nigeria Cluster* 216512 7
2017 Silame Sokoto Nigeria Cluster* 144484 14 27
2017 Tangaza Sokoto Nigeria Cluster* 157599 18 26
2017 Wurno Sokoto Nigeria Cluster* 224671 16 81
2017 Yabo Sokoto Nigeria Cluster* 159202 15 46
2017 Birnin
Magaji/Kiyaw
Zamfara Nigeria Cluster* 252583 13 95
2017 Bukkuyum Zamfara Nigeria Cluster* 299268 17 33
2017 Bungudu Zamfara Nigeria Cluster* 364718 15 37
2017 Gummi Zamfara Nigeria Cluster* 289236 14 45
2017 Gusau Zamfara Nigeria Cluster* 541825 13 93
2017 Maru Zamfara Nigeria Cluster* 412773 13 99
2017 Shinkafi Zamfara Nigeria Cluster* 191820 12 236
2017 Batsari Katsina Nigeria Cluster 289274 29
2017 Jibia Katsina Nigeria Cluster 234971 10 43
2017 Sandamu Katsina Nigeria Cluster 190037 2
2017 Guidam-
Roumdji
Niger Cluster* 966372 31
2017 Madarounfa Niger Cluster* 548890 16 115
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Table D.3 Vaccine use in reactive vaccination campaigns. Coverage data used in modelling cases in the absence
of intervention. No data indicates districts where no specific coverage data were found other than a description
of “full” or “partial” coverage.
District Country Year Population Vaccine type Doses Coverage No data
Dogon-Doutchi Niger 2015 385897 ACW PS 256622 95% *
Dosso Niger 2015 519638 ACW PS 345559 95% *
Filingue Niger 2015 594689 ACW PS 208141 50% *
Illela Niger 2015 468833 ACW PS 311774 95% *
Kollo Niger 2015 495869 ACW PS 329753 95% *
Niamey I Niger 2015 224212 ACW PS 149101 95% *
Niamey II Niger 2015 263583 ACW PS 175283 95% *
Niamey III Niger 2015 174202 ACW PS 115844 95% *
Niamey IV Niger 2015 293033 ACW PS 194867 95% *
Niamey V Niger 2015 141209 ACW PS 93904 95% *
Ouallam Niger 2015 419980 ACYW conjugate 279287 90%
Aliero Nigeria 2015 86835 ACW PS 30392 50% *
Bunza Nigeria 2015 159869 ACW PS 66222 59%
Gudu Nigeria 2015 124663 ACW PS 82901 95% *
Jega Nigeria 2015 254493 ACW PS 81975 46%
Maiyama Nigeria 2015 231241 ACW PS 21316 13%
Shagari Nigeria 2015 204083 ACW PS 51700 36%
Zuru Nigeria 2015 217896 ACW PS 144901 95% *
Niamey II Niger 2016 272153 ACW PS 180982 95% *
Goronyo Nigeria 2016 244991 ACW PS 162919 95% *
Birni N’Konni Niger 2017 374442 ACW PS 131055 50% *
Dioundiou Niger 2017 132321 ACW PS 87993 95% *
Tibiri Niger 2017 325948 ACW PS 114082 50% *
Kollo Niger 2017 560762 ACW PS 196267 50% *
Madarounfa Niger 2017 548890 ACW PS 365012 95% *
Niamey II Niger 2017 289437 ACW PS 192476 95% *
Niamey III Niger 2017 191289 ACW PS 66951 50% *
Niamey IV Niger 2017 321775 ACW PS 112621 50% *
Anka Nigeria 2017 201197 ACW PS 29172 21%
Bakura Nigeria 2017 264300 ACW PS 19210 10%
Batagarawa Nigeria 2017 255495 ACW PS 6775 4%
Batsari Nigeria 2017 289274 ACW PS 12177 6%
Birnin Magaji/Kiyawa Nigeria 2017 252583 ACW PS 55254 31%
Bukkuyum Nigeria 2017 299268 ACW PS 199013 95% *
Bungudu Nigeria 2017 364718 ACW PS 22165 9%
Damaturu Nigeria 2017 128498 ACW PS 38802 43%
Faskari Nigeria 2017 271358 ACW PS 6876 4%
Fika Nigeria 2017 199863 ACW PS 58811 42%
Fune Nigeria 2017 439100 ACW PS 14509 5%
Funtua Nigeria 2017 312243 ACW PS 5535 3%
Gada Nigeria 2017 343660 ACW PS 18786 8%
Gujba Nigeria 2017 189925 ACW PS 24676 19%
Gummi Nigeria 2017 289236 ACW PS 19070 9%
Gusau Nigeria 2017 541825 ACW PS 89030 23%
Jibia Nigeria 2017 234971 ACW PS 12545 8%
Katsina Nigeria 2017 440822 ACW PS 164 0%
Kaura Namoda Nigeria 2017 397878 ACW PS 125123 45%
Malumfashi Nigeria 2017 253204 ACW PS 1991 1%
Maradun Nigeria 2017 298163 ACW PS 14121 7%
Maru Nigeria 2017 412773 ACW PS 59443 21%
Shinkafi Nigeria 2017 191820 ACW PS 37904 28%
Talata Mafara Nigeria 2017 304281 ACW PS 42096 20%
Tsafe Nigeria 2017 376159 ACW PS 60874 23%
Continued on next page
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Zurmi Nigeria 2017 415512 ACW PS 23591 8%
Bodinga Nigeria 2017 242803 C conjugate 124450 73%
Dange-Shuni Nigeria 2017 269297 C conjugate 125037 66%
Goronyo Nigeria 2017 252340 C conjugate 36414 21%
Gwadabawa Nigeria 2017 320254 C conjugate 31485 14%
Isa Nigeria 2017 202241 C conjugate 42708 30%
Rabah Nigeria 2017 206479 C conjugate 97388 67%
Sokoto North Nigeria 2017 322313 C conjugate 154669 69%
Sokoto South Nigeria 2017 269807 C conjugate 133854 71%
Tureta Nigeria 2017 94640 C conjugate 47625 72%
